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ABSTRACT 
 
The Notch signalling pathway is important in development and differentiation of a 
diverse range of both embryonic and adult tissues. There is now strong evidence 
implicating aberrant Notch signalling in the pathogenesis of T-cell acute 
lymphoblastic leukaemia (T-ALL), with over 50% of paediatric patients having 
activating mutations in NOTCH-1. This thesis aims to explore several aspects of the 
Notch pathway in both T-ALL and acute myeloid leukaemia (AML). Chapter one 
includes an overview of the clinical and biological characteristics of AML and T-
ALL, and summarises the published data on the Notch signalling pathway, addressing 
the basic understanding of Notch activation through cell-to-cell interaction, as well as 
the mechanisms through which it is normally regulated. The role that Notch signalling 
plays in normal haematopoiesis is also discussed. Chapter two gives details of the 
reagents and methods used, and detailed methods are also given in the appropriate 
results chapters. Chapter three addresses the incidence and characteristics of NOTCH-
1 mutations in a cohort of adult patients with T-ALL in comparison to the published 
study of paediatric T-ALL, as well as in a cohort of patients with infantile leukaemia 
and AML. Secondly, the prognostic significance of NOTCH-1 and FBXW7 mutation 
status of adult T-ALL patients treated on the UKALLXII was investigated. Thirdly, a 
novel mutation affecting the LNR domain of NOTCH-1 is reported. Chapter four 
includes data quantifying NOTCH-1 mutation level in T-ALL patients, as well as the 
stability of NOTCH-1 mutations at presentation and relapse, and attempts to interpret 
these findings in relation to the timing of acquisition of the mutation and clonal 
heterogeneity of T-ALL. Chapter five explores the functional and prognostic 
significance of a novel alternatively spliced isoform of the CSL transcription factor in 
AML, which was termed CSL-TREX (for TRuncates Exon X). The functional 
consequences of expressing CSL-TREX in CD34+ cells, in luciferase reporter assays 
and co-immunoprecipitation experiments with NOTCH-1 is reported. Chapter six 
summarises the overall implications of these findings to T-ALL and AML, and the 
future directions of research in this area. 
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CHAPTER 1. INTRODUCTION 
 
1.1 Haematopoiesis 
The blood system is comprised of a hierarchical organisation of different cellular 
lineages arising from pluripotent haematopoietic stem cells (HSCs) (Orkin and Zon, 
2008). Because mature blood cells are short-lived, HSCs need to indefinitely self-
renew throughout life, as well as dynamically respond to physiological stressors such 
as infection, hypoxia or haemorrhage. The mechanisms by which HSCs determine 
whether to self-renew or generate daughter cells that terminally differentiate toward a 
particular cell fate are highly complex, and involve multiple different extracellular 
cues such as cell-to-cell interaction with bone marrow (BM) stroma and stimulation 
by cytokines such as erythropoietin (EPO), thrombopoietin (TPO), granulocyte 
colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating 
factor (GM-CSF) (Orkin and Zon, 2008).  
 
HSCs are capable of committing daughter cells to all components of the blood system, 
including the development of red blood cells (erythropoiesis), myeloid cells 
(myelopoiesis), platelets (megakaryopoiesis), and lymphocytes (lymphopoeisis). 
Long-term HSCs reside in a BM niche in close proximity to osteoblasts, and give rise 
to short-term HSCs that have multi-lineage potential and can differentiate into either 
common myeloid progenitors (CMPs) or common lymphoid progenitors (CLPs) 
(Akashi et al., 2000). CMPs thence differentiate into either granulocyte/macrophage 
progenitors (GMPs) (which give rise to neutrophils, monocytes/macrophages, 
eosinophils and mast cells), or megakaryocyte/erythroid progenitor (MEPs) (which 
give rise to red blood cells and megakaryocytes). Although a wide range of 
transcription factors are involved in lineage determination, the level of signalling 
imparted by NOTCH-1 is one of the most important determinants of whether CLPs 
commit to either the B- or T-cell lineage, and also plays an important role in early 
definitive haematopoiesis, self-renewal of HSCs and interaction of HSCs with the 
stem cell niche (see section 1.6). 
 
1.2 Acute leukaemia and its clinical presentation 
Acute leukaemias are malignant clonal disorders resulting from chromosomal, genetic 
and epigenetic alterations arising in haematopoietic progenitors that lead to 
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unregulated cellular proliferation, a block in differentiation and enhanced self-renewal 
properties. The principal feature of leukaemia is the accumulation of malignant blast 
cells in the BM and often peripheral blood (PB), resulting in a failure of normal 
haematopoiesis and resultant PB cytopenias. Clinical symptoms can be broadly 
divided into those resulting from BM failure and those relating to the leukaemic cell 
burden. Typical clinical features occurring from BM failure include easy bruising or 
bleeding from thrombocytopenia, acute or chronic infection as a consequence of 
neutropenia, and pallor, fatigue and exertional dyspnoea from anaemia. The 
accumulation of leukaemic blasts often results in bone pain, a common presenting 
symptom. Extreme hyperleucocytosis can impair blood flow and oxygen transfer in 
the lung leading to respiratory failure. Other signs and symptoms include 
lymphadenopathy and hepatosplenomegaly, skin infiltration from malignant blasts 
(chloromas), widespread bleeding or thrombosis from disseminated intravascular 
coagulation (typically associated with acute promyelocytic leukaemia), features of 
superior vena cava obstruction from a mediastinal mass (typically associated with T-
cell acute lymphoblastic leukaemia/lymphoma) and neurological symptoms from 
leukaemic infiltration of the central nervous system.  
 
Accurate classification of acute leukaemia is essential in directing the correct 
treatment modality and in determining prognosis. Acute leukaemias are categorised 
according to the putative progenitor cell of origin and level of differentiation arrest, 
which is determined by a combination of morphological assessment of the BM or PB, 
blast cell immunophenotype, and the presence of particular cytogenetic abnormalities. 
At the broadest level of classification, acute leukaemias are divided into acute 
myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL), depending on 
whether the malignant blast cells are of myeloid or lymphoid origin respectively. 
Further subclassification is discussed below.   
 
This thesis attempts to address the role of the Notch signalling pathway in both AML 
and ALL, with a particular focus on activating mutations in the NOTCH-1 gene in T-
cell ALL (T-ALL) and alternative splicing of the Notch pathway transcription factor 
CSL in AML. The introductory chapter offers a brief overview of both the clinical, 
molecular and prognostic features of AML and ALL, and discusses the role of Notch 
signalling in normal haematopoiesis. More detailed review of Notch signalling in 
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malignant haematopoiesis is discussed in the introduction of the relevant results 
chapters.  
 
1.3 AML 
1.3.1 Incidence of AML  
AML has an annual incidence of 3.4 cases per 100,000 adults in the UK and occurs at 
higher frequency with increasing age, with two-thirds of cases occurring in people 
aged greater than 60 years of age (Milligan et al., 2006). Compared to ALL, 
childhood AML is relatively rare, with an annual incidence of 0.6 cases per 100,000 
children between 1-14 years, although it is considerably more common in infants (<1 
year of age), affecting 1.6 per 100,000 per year, where it is predominantly associated 
with translocations of the mixed lineage leukaemia gene (MLL) (data from the Cancer 
Research Website, www.cancerresearchuk.org, based on statistics from the National 
Registry of Childhood Tumours).  
 
1.3.2 Causative/predisposing factors in AML 
In the majority of cases, the cause of AML is idiopathic, although it has been 
associated with the following disorders (reviewed in Jabbour et al., 2006): 
1. Transformation from acquired syndromes such as myelodysplasia (MDS), 
essential thrombocythaemia (ET), myelofibrosis (MF), chronic myeloid 
leukaemia (CML), polycythaemia vera (PRV), or paroxysmal nocturnal 
haemoglobinuria. 
2. Genetic disorders: 
a. Chromosomal disorders: Kleinfelter’s syndrome (XXY), Down’s 
syndrome (trisomy 21), Patau syndrome (trisomy 13), familial 
monosomy 7 syndrome. 
b. Inherited/congenital genetic defects – ataxia telangiectasia, severe 
congenital neutropenia, Fanconi syndrome, Wiskott-Aldrich 
syndrome, Shwachman-Diamond syndrome, familial platelet 
disorder with predisposition to myeloid malignancy (associated 
with inherited mutations of the runt-related transcription factor 1 
gene RUNX1), and inherited mutations of the CCAAT enhancer 
binding factor alpha (CEBPA) gene. 
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3. Radiation exposure – either from therapeutic radiotherapy, such as for a 
separate malignancy, or as seen with those exposed to ionising radiation, 
such as after the Chernobyl disaster or survivors of the atomic bombs in 
Japan. 
4. Prior therapy with either alkylating agents, such as cyclophosphamide and 
melphalan, where the resultant AML is often associated with abnormalities 
of chromosomes 5 and 7, or topoisomerase II inhibitors such as etoposide 
and anthracyclines, where the AML is often associated with MLL gene 
rearrangements on chromosome 11q23 or with t(15;17), and has a short 
latency period of 1 to 3 years.  
5. Exposure to other agents such as benzene, printing dyes and smoking. 
 
 
Table 1.1. French-American-British (FAB) classification of AML 
 
• AML M0: acute myeloblastic leukaemia without differentiation, with absent 
expression of myeloperoxidase (MPO) 
• AML M1: acute myeloblastic leukaemia with minimal differentiation but with 
the expression of MPO that is detected by immunohistochemistry or flow 
cytometry 
• AML M2: acute myeloblastic leukaemia with differentiation 
• AML M3: acute promyelocytic leukaemia (APML)  
o AML M3v: APML, microgranular variant 
• AML M4: acute myelomonocytic leukaemia  
o AML M4Eo: with eosinophilia.  
• AML M5: acute monocytic leukaemia  
o AML M5a: without differentiation (monoblastic) 
o AML M5b: with differentiation 
• AML M6: acute erythroid leukaemia  
o AML M6a: erythroleukaemia 
o AML M6b: pure erythroid leukaemia 
•  AML M7: acute megakaryocytic leukaemia  
(According to Bennett et al., 1976; Bennett et al., 1985)
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1.3.3 French-American-British (FAB) classification of AML 
In 1976, the French-American-British (FAB) group was the first to comprehensively 
classify AML, based on morphological and histochemical staining patterns (Bennett 
et al., 1976). The classification system, including subsequent modifications (Bennett 
et al., 1985), is shown in Table 1.1. 
 
1.3.4 World Health Organisation classification of AML 
Although the FAB classification system is still used, its lack of prognostic power and 
the poor concordance between haemato-pathologists in assigning a FAB type has 
limited its clinical utility. Furthermore, it has now been superseded by improvements 
in immunophenotypic, cytogenetic and genetic characterisation of leukaemias, which 
can be standardised across laboratories and give a greater wealth of prognostic 
information. Such factors have been incorporated into the latest 2008 World Health 
Organisation (WHO) classification of AML (Arber DA, 2008; Falini et al., 2010; 
Vardiman et al., 2009) (Table 1.2). For instance, there is now the provisional 
inclusion of a subcategory for ‘AML with mutated nucleophosmin’ and ‘AML with 
mutated CEBPA’, because such patients have a superior prognosis. The presence of 
20% or more blasts in PB or BM is required for the diagnosis of AML, except for 
cases harbouring t(8;21)(q22;q22), inv(16)(p13.1q22), or t(15;17)(q22;q12), which 
are now considered AML irrespective of the blast cell count. Additional changes 
include subcategories for ‘AML with t(6;9)(p23;q34)’ and ‘AML with 
inv(3)(q21q26.2) or t(3;3)(q21;q26.2)’, because patients with these translocations 
have a particularly poor outcome.  
 
1.3.5 Molecular basis of AML 
In a hypothesis explaining the malignant transformation to acute leukaemia it has 
been suggested that two molecular events or ‘hits’ are required – one leading to an 
increase in proliferation (so called class I mutation), and the other blocking 
differentiation (class II mutation) (Gilliland et al., 2004). For example, in a study by 
Kelly et al (2002), transgenic mice expressing the PML-RARα fusion transcript 
produced by the t(15;17) translocation only developed a low penetrance of leukaemia 
(approximately 20%) after 6 months or more, suggesting that a second mutational 
event was required for transformation. Similarly, when murine BM was transduced 
with a fms-like tyrosine kinase receptor gene (FLT3) internal tandem duplication  
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(ITD), a myeloproliferative disease developed, but not a transplantable leukaemia. 
However, when both PML-RARα and FLT3-ITD were expressed in murine marrow, 
AML developed with 100% penetrance, showing co-operativity between these two 
events. Furthermore, it has been argued that mutations in AML rarely affect more 
than one gene involved in differentiation or proliferation; for instance, RAS and FLT3-
ITD mutations rarely occur together in the same leukaemic cell (Kelly and Gilliland, 
2002).  
 
Hanahan and Weinberg have described six hallmarks of cancer: sustaining 
proliferative signalling, evading growth suppressors, resisting cell death, enabling 
replicative immortality, inducing angiogenesis, and activating invasion and metastasis 
(Hanahan and Weinberg, 2011). The two-hit model of leukaemogenesis does not take 
into account many of these features, and it is becoming apparent from whole genome 
sequencing data that there are a large number of somatically acquired genetic 
alterations in AML cases (Ding et al., 2012; Ley et al., 2010; Ley et al., 2008; Mardis 
et al., 2009). Many of these mutations are likely to be ‘passenger’ mutations that do 
not confer a selective advantage to cells, and may have been present by chance in the 
cell of origin or acquired as a result of genetic instability during tumour progression 
(Stratton et al., 2009; Welch et al., 2012). Determining which of the somatic 
mutations are so-called ‘driver’ mutations (those providing a survival or growth 
advantage to cells) is an area of on-going study, but is crucial in identifying 
dysregulated pathways that may serve as drug targets. Further details regarding the 
multi-hit model of tumourigenesis and clonal heterogeneity in leukaemia are 
discussed in the introduction of Chapter 4.  
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Table 1.2 World Health Organisation classification of AML 
 
• AML with recurrent genetic abnormalities 
o AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 
o AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-
MYH11 
o Acute promyelocytic leukaemia (APML) with 
t(15;17)(q22;q12); PML-RARA (note that fusion partners of 
RARA other than PML are no longer considered together as the 
same entity) 
o AML with t(9;11)(p22;q23); MLLT3-MLL 
o AML with t(6;9)(p23;q34); DEK-NUP214 
o AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
o AML with mutated NPM1 (provisional entity) 
o AML with mutated CEBPA (provisional entity) 
• AML with myelodysplasia-related changes 
• Therapy-related myeloid neoplasms 
• Myeloid sarcoma 
• Myeloid proliferations related to Down syndrome 
o Transient abnormal myelopoiesis 
o Myeloid leukaemia associated with Down syndrome (usually 
megakaryocytic) 
• Blastic plasmacytoid dendritic cell neoplasm (previously ‘agranular 
CD4+/CD56+ hematodermic neoplasm’ and ‘blastic NK-cell 
lymphoma’) 
• AML Not Otherwise Specified (NOS) 
o AML with minimal differentiation 
o AML without maturation 
o AML with maturation 
o Acute myelomonocytic leukaemia 
o Acute monoblastic and monocytic leukaemia 
o Acute erythroid leukaemia 
o Acute megakaryoblastic leukaemia 
o Acute basophilic leukaemia 
o Acute panmyelosis with myelofibrosis 
(According to Arber DA, 2008; Vardiman et al., 2009)
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1.3.6 Prognostication in AML 
Although there are a multitude of international published studies that have reported on 
prognosis in AML, the following section focuses on data from the UK Medical 
Research Council (MRC) trials, which are broadly in line with other trials and 
generally consist of large patient cohorts. In the first AML MRC trial conducted 
between 1970-1979, there was a 5-year overall survival (OS) of approximately 5% for 
young adult patients (<60 years old). There has been an incremental improvement in 
OS with each consecutive MRC trial, relating partly from changes in therapy, but also 
to improvements in supportive care, and current 5-year OS approaches 50% (Burnett 
et al., 2011; Burnett et al., 2010; Grimwade et al., 1998). However, there is marked 
heterogeneity in outcome in particular patient subsets according to clinical, 
cytogenetic and molecular criteria. Thus, attempts have been made to develop 
prognostic models that can predict outcome, which would enable the development of 
a risk-adapted approach to patient therapy. In this way, low-risk patients could benefit 
by avoiding highly toxic therapies such as allogeneic stem cell transplantation, which 
could be reserved for high-risk patient subgroups.  
 
 
1.3.7 Clinical prognostic factors 
Clinical attributes have been shown to have a significant impact on patient outcome in 
multiple UK AML MRC trials (Burnett et al., 2011; Burnett et al., 2010; Wheatley et 
al., 1999). These include: 
 
1. Age and performance status – advanced age has been associated with a poor 
prognosis in all adult UK MRC AML trials. Despite the advances in outcome 
with therapy for young adult patients (age 18 to 60 years), outcome for older 
patients (>60 years) remains dismal and has changed little. This partly relates 
to the higher proportion of patients in this category with poor performance 
status and co-morbidities who are unfit for intensive treatment with curative 
intent, experience higher treatment-related mortality and are not candidates for 
allogeneic transplantation. However, the biology of disease is somewhat 
different than younger patients, with a higher incidence of resistant disease in 
this age group, many with preceding MDS. 
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2. Blast cell count – a high PB blast cell count at presentation is associated with 
poor prognosis (Kottaridis et al., 2001; Wheatley et al., 1999).  
 
3. Response to therapy - patients with resistant disease have a poorer OS. In the 
MRC AML10 trial, patients with greater than 15% blasts after their first 
course of induction had a 5 year OS of 22% compared to 53% in patients with 
less than 5% blasts (Wheatley et al., 1999). This does not hold true for acute 
promyelocytic leukaemia (APML), where the presence of greater than 5% 
blasts after induction is relatively common and does not convey an adverse 
prognosis. Minimal residual disease (MRD) analysis using flow cytometry or 
molecular abnormalities specific to the leukaemic blast population allows a 
more sensitive indication of response than is possible by morphological 
analysis (limit 1%) (Al-Mawali et al., 2009). Recent data using quantitative 
PCR (qPCR) directed at mutant nucleophosmin-1 (NPM1) as a means of 
assessing MRD, has shown that patients who are MRD-positive (>1 blast cell 
in 105 normal cells) at the end of double induction therapy have higher rates of 
relapse compared with MRD-negative patients (4-year cumulative incidence 
of relapse 6.5% for MRD-negative versus 53% for MRD-positive patients) 
(Kronke et al., 2011).  
 
1.3.8 Cytogenetic abnormalities as prognostic factors 
Data from over 1600 patients treated on the MRC AML10 trial and published 15 
years ago showed that cytogenetic analysis has important prognostic implications for 
patient outcome (Grimwade et al., 1998). According to the particular cytogenetic 
abnormality, patients were divided into three risk groups, favourable, adverse, or 
intermediate:  
• The favourable cytogenetic group (24% of patients) included patients with 
APML with the t(15;17) translocation, or core binding factor (CBF) 
leukaemias with inv(16) or t(8;21). The 5 year OS for this group was 72%, 
although patients with t(15;17) fared significantly better than those with 
CBF leukaemias. 
• In the adverse cytogenetic group (16% of patients), abnormalities included 
a complex karyotype (five or more abnormalities), monosomy 5,  
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monosomy 7, del(5q), abn (3q), or t(9;22), and this group had a 17% 5 
year OS. Of note, Lowenberg’s group have more recently reported that 
patients with two or more distinct chromosome monosomies have a 
particularly poor prognosis with a 4-year OS of 3% (Breems et al., 2008).  
• The intermediate group (60% of patients) included those without either 
favourable or adverse risk cytogenetics, or those with 11q23 abnormalities, 
trisomy 8, trisomy 21, trisomy 22, del(9q), or del(7q). This group had a 
44% 5 year OS. 
 
This data has now been updated with nearly 6000 patients from the AML10, AML12 
and AML15 MRC trials (Grimwade et al., 2010). The expanded dataset confirms the 
original findings, and adds a further level of refinement to some of the rarer 
cytogenetic aberrations. For instance, prognosis related to chromosome 11q23 
abnormalities (previously grouped in the intermediate risk group) involving the mixed 
lineage leukemia (MLL) gene depends on the fusion partner. Poor prognosis was 
associated with t(6;11)(q27;q23) and t(10;11)(p12;q23), involving the MLLT4 (AF6) 
and MLLT10 (AF10) genes respectively, while t(9;11)(p21-22;q23), resulting in the 
MLLT3-MLL fusion, or t(11;19)(q23;p13), leading to the ELL-MLL fusion remained 
in the intermediate risk group.  
 
For non-APML patients, the current UK MRC AML17 trial includes a risk scoring 
system based on outcomes of the AML12 and AML15 trials, that takes into 
consideration these cytogenetic criteria (www.aml17.cardiff.ac.uk/aml17/), with the 
highest score indicating the worst prognosis (Table 1.3). This system divides patients 
into three risk groups with OS of 63%, 47% and 24% for scores of <1.85, 1.85-2.62 
and high >2.63 respectively (Burnett, 2006).  
 
Risk stratifying the large group of intermediate-risk patients, which includes over half 
of all patients, has been challenging and the focus of research for many groups, 
particularly with regards to molecular markers in this disease. 
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Table 1.3 Scoring system used on the UK MRC AML17 trial for risk 
stratification to determine prognosis 
0.01325 x age (in years) 
+ 
0.16994 x sex (1=male, 0=female)   
+ 
0.22131 x diagnosis (0=de novo, 1 secondary)  
+ 
0.65082 x cytogenetics (1=favourable, 2=intermediate, 3 adverse) 
+ 
0.19529 x status post course 1 (1=complete remission, 2=partial remission, 3=no 
response) 
+ 
0.00169 x WBC (x109/l) 
Patients are divided into three risk groups with OS of 63%, 47% and 24% for scores of <1.85, 
1.85-2.62 and high >2.63 (Burnett, 2006). 
 
 
1.3.9 Molecular markers as prognostic factors 
Some of the somatic mutations identified in the presenting AML samples have proven 
to be important prognostic markers in multiple different AML trials (Lowenberg, 
2008). Such markers have the potential to be particularly useful in patients with 
cytogenetically normal AML, who have a highly heterogenous outcome. One of the 
earliest prognostic molecular markers identified, associated with an increased relapse 
rate and poor outcome in AML was a FLT3-ITD, found in about one quarter of 
patients (Kottaridis et al., 2001). The discovery of NPM1 mutations in approximately 
30% of AML cases (Falini et al., 2005) added considerably to risk stratification and 
helped further stratify the FLT3-ITD positive group. For example, data from the MRC 
AML10 and 12 trials identified three prognostic groups – good risk (FLT3-ITD 
negative/NPM1 positive), intermediate risk (FLT3-ITD negative/NPM1 negative or 
FLT3-ITD positive/NPM1 positive), and poor risk (FLT3-ITD positive/NPM1 
negative), with 5 year OS of 61%, 38% and 9% respectively (Gale et al., 2008).  
 
Analysis of somatic mutations and aberrant expression of a number of other genes has 
also been useful in prognostication and some are summarised in Table 1.4. In recent 
years, whole genome sequencing (WGS) has been integral in identifying a number of 
recurrent mutations in AML that would have been hard to predict using a hypothesis-
driven candidate gene approach. Interestingly, the first AML genome sequenced  
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identified a FLT3-ITD and an NPM1 mutation, but no other recurrent mutations (Ley 
et al., 2008). The importance of depth of sequence coverage and appropriate 
bioinformatic analysis of WGS is best highlighted by the fact that repeat analysis 
from the same patient identified a DNA (cytosine-5)-methyltransferase 3A 
(DNMT3A) mutation, which is highly recurrent in AML (approximately 20% of 
patients) and associated with a poor prognosis (Ley et al., 2010; Ribeiro et al., 2012; 
Thol et al., 2011). WGS was also used to identify mutations in isocitrate 
dehydrogenase IDH1, which occur in 7% of patients and are strongly associated with 
NPM1 mutations and can be associated with a poor prognosis (Mardis et al., 2009; 
Schnittger et al., 2010). On the MRC trials, IDH1 mutation status was an independent 
adverse factor for relapse in FLT3-ITD negative patients and a favourable factor in 
FLT3-ITD positive patients. Recurrent mutations have also been found in IDH2 in 
approximately 10% of AML patients (Gross et al., 2010). The R140 mutation in IDH2 
was associated with an improved prognosis, while IDH2 R172 mutations were 
associated with a poor prognosis and relapse rate of 72% (Green et al., 2011). Other 
recurrent mutations with potential prognostic significance include ten-eleven 
translocation-2 (TET-2) and BCL-6 co-repressor (BCOR), both of which have been 
associated with a poor prognosis (Chou et al., 2011; Grossmann et al., 2011; 
Weissmann et al., 2012).  
 
With the ongoing sequencing effort in AML, it is likely that more genetic mutations 
will be identified, many of which are likely to be of low frequency and uncertain 
prognostic significance. Their clinical utility will have to be taken into account in the 
context of the other known prognostically significant molecular markers. For instance, 
one group recently reported that the favorable effect of NPM1 mutations was 
restricted to patients with co-occurring NPM1 and IDH1 or IDH2 mutations (Patel et 
al., 2012). How molecular stratification should influence treatment choice remains an 
area of controversy, and will need to be tested prospectively in large national trials.   
 29 
 
 
Table 1.4 Selected gene mutations and aberrantly expressed genes shown to be 
associated with prognosis in AML 
Gene mutations associated with poor prognosis 
 FLT3-ITD positive in NPM1 WT patients (Gale et al., 2008; 
Rockova et al., 2011) 
 WT1 mutation (Paschka et al., 2008; Virappane et al., 2008)  
 MLL-PTD (Dohner et al., 2002; Patel et al., 2012) 
 IDH1 mutation in FLT3-ITD negative patients (Green et al., 
2010a) 
 IDH2 (R172 mutation) (Green et al., 2011) 
 DNMT3A mutation (Ribeiro et al., 2012; Thol et al., 2011) 
 BCOR (Grossmann et al., 2011) 
 TET2 (Chou et al., 2011; Weissmann et al., 2012) 
Gene mutations associated with good prognosis 
 CEBPA biallelic mutations (Green et al., 2010b; Wouters et 
al., 2009) 
 NPM1 mutation in FLT3-ITD WT patients (Gale et al, 
2008) 
 IDH1 mutation in FLT3-ITD positive patients (Green et al., 
2010a) 
 IDH2 (R140 mutation) (Green et al., 2011; Patel et al., 
2012) 
Gene overexpression associated with poor prognosis 
 ERG (Marcucci et al., 2007) 
 MN1 (Langer et al., 2009) 
 BAALC (Langer et al., 2008) 
BAALC, Brain and leukaemia cytoplasmic gene. CEBPA, CCAAT enhancer binding factor gene. 
ERG, Ets-related gene. IDH, isocitrate dehydrogenase gene. MN1, Meningioma 1 gene. NPM1, 
Nucleophosmin 1 gene. PTD, Partial tandem duplication. WT, Wild type. WT1, Wilm’s tumour-1 
gene.
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1.3.10 Current chemotherapeutic approaches in non-APML AML 
Detailed guidelines for the treatment of AML in the UK have been published 
(Milligan et al., 2006). Treatment is broadly divided into induction and consolidation 
therapy. The standard approach in the UK has been to give two induction courses 
consisting of daunorubicin together with cytarabine (Ara-C), so called ‘3+7’ due to 
the respective number of days given of each drug. If patients achieve remission after 
two courses of induction therapy, they require further consolidation therapy to prevent 
relapse from residual leukaemic blasts. Consolidation therapy typically consists of a 
course of MACE (amsacrine, cytarabine, etoposide) followed by MidAC 
(mitoxantrone, cytarabine). 
 
Some of the areas of clinical uncertainty, which are currently under investigation, 
include: 
1. Number of required consolidation cycles:  this remains controversial. Both the 
MRC AML12 and AML15 trials found no benefit of a third consolidation 
course, with the reduction in relapse rate nullified by the toxicity of additional 
treatment. Patients on the AML12 and AML15 trial who were only able to 
receive three total courses of therapy had an outcome that was not statistically 
worse than those who received four. Thus, AML17 is prospectively 
randomising patients to a total of three versus four courses of therapy 
(www.aml17.cardiff.ac.uk/aml17/).  
2. Optimal drug dosage: there is data to suggest that both elderly and young adult 
patients may benefit from higher dose daunorubicin (90mg/m2 as opposed to 
standard dose 45mg/m2) at induction (Lee et al., 2011; Lowenberg et al., 
2009). Of note, high-dose daunorubicin was shown to have a survival benefit 
only among patients with DNMT3A, NPM1 mutations or MLL translocations, 
but not among patients wild-type for these genes. High dose daunorubicin is 
currently being tested in the UK MRC AML17 trial. 
3. Monoclonal antibody therapy: Gemtuzumab ozogamicin (Mylotarg), an anti-
CD33 monoclonal antibody conjugated to the calicheamicin toxin, has 
recently received significant publicity. Although the drug has significant anti-
leukaemic properties, it was associated with an increased risk of veno-
occlusive disease and was withdrawn from the US market in 2010 following 
an increased risk of death in the Mylotarg arm at induction on the SWOG 
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S0106 trial (16 of 283 [5.7%] died at induction on the 
Mylotarg/cytarabine/daunorubicin arm vs. 4 of 281 [1.4%] on the 
cytarabine/daunorubicin alone arm, P=0.01) (Petersdorf 2009). However, on 
the UK MRC AML15 trial, there was a survival benefit for patients receiving 
Mylotarg in those with favourable cytogenetics and a trend towards improved 
survival without significant additional toxicity (Burnett et al., 2011). The 
French ALFA Group also showed an OS benefit for the addition of Mylotarg 
in patients aged 50-70 years (Castaigne et al., 2011). The differences in 
toxicity between the US and European trials likely relates to drug dosage and 
scheduling.   
4. Alternative chemotherapeutic agents: cytarabine and daunorubicin have been 
the mainstay of induction therapy for over 20 years, and attempts to improve 
upon this combination have in general shown negative results. Large French 
and Japanese studies have shown no benefit in using idarubicin instead of 
daunorubicin at induction (Ohtake et al., 2011; Pautas et al., 2010). The UK 
MRC AML15 trial showed no difference in OS for FLAG-Ida 
(fludarabine/cytarabine/G-CSF/idarubicin) versus daunorubicin/cytarabine 
(Burnett et al., 2011).  
5. Novel agents: a large number of novel agents are currently being tested in 
AML, and deciding on which should be included in national trials is 
challenging. A ‘Pick-a-winner’ approach has been adopted by the AML MRC 
trials (Hills and Burnett, 2011). This is a modification of the “Multi Arm Multi 
Stage” (MAMS) design of Royston et al (2003) (Royston et al., 2003) where, 
rather than sequentially testing agents against a control arm in a randomised 
fashion, multiple novel agents are tested in parallel against a single control 
arm or historical data. If an agent reaches a pre-specified outcome, it is 
selected for further study, while inferior drugs are dropped. This strategy has 
the potential to expedite early phase trial results and maximises the number of 
patients recruited into the investigational treatment arms. Such a strategy is 
underpowered to identify drugs that offer minor incremental benefits, and best 
reserved for patients whose outcome remains extremely poor and where the 
need for drugs with meaningful efficacy is greatest, such as for elderly AML 
patients or those at relapse (Hills and Burnett, 2011). 
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1.3.11 Use of transplantation in AML 
The use of autologous transplantation (high dose chemotherapy with autologous stem 
cell rescue) instead of a course of consolidation chemotherapy was tested in the UK 
MRC AML10 trial. Although there was a modest improvement in OS in the first 
analysis, this was not substantiated in recruitment of 330 additional patients, and is no 
longer standard practice in the UK (Burnett et al., 1998). Furthermore, it had proven 
particularly difficult to obtain adequate stem cell harvest from patients following prior 
intensive chemotherapy. 
 
It is universally accepted that patients with favourable cytogenetics, particularly 
APML, should not receive allogeneic transplantation in first remission. Deciding on 
which patients are most likely to benefit from allogeneic transplantation has been an 
area of interest and controversy worldwide (reviewed in Koreth et al., 2009). 
Myeloablative transplantation has consistently shown a reduction in relapse risk due 
to a graft-versus-leukaemia effect (GvL). However, in terms of OS, the reduction in 
relapse is offset by significant transplant-related mortality (TRM), which can be in 
excess of 40% in older patients groups treated with myeloablative non-sibling 
allografts (Alyea et al., 2005). Although it is less effective than myeloblative 
transplantation in reducing relapse risk, reduced intensity (non-myeloablative) 
transplantation significantly reduces TRM and is being increasingly used in patients 
more than 45 years of age (Alyea et al., 2005; Sorror et al., 2011; Storb, 2007). The 
use of prognostic markers that can identify patients at high-risk of relapse who may 
benefit most from such procedures is an area of ongoing study, and large prospective 
randomised studies taking into account the increasing number of markers are likely to 
be required to address this question comprehensively.  
 
1.4 Acute lymphoblastic leukaemia (ALL) 
ALL arises from lymphoid progenitor cells, and is subclassified as B-ALL or T-ALL 
depending on the expression of B-cell markers (cytoplasmic CD79a, CD19, HLA-
DR) or T-cell markers (cytoplasmic CD3, with CD7 plus CD2 or CD5) (Swerdlow, 
2008).  Further subclassification of ALL is given below.  
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1.4.1 Incidence of ALL 
ALL has a bimodal pattern of onset, with a major peak in early childhood (around 3 
years of age), and an increase in incidence after middle age. Childhood ALL is the 
commonest childhood malignancy, accounting for 24% of all malignancies, with an 
annual incidence of 3-4 cases per 100,000 (Dores et al., 2012), whilst adult ALL has 
an incidence of 1.3 cases per 100,000 (Bassan et al., 2004).  
 
1.4.2 Causative/predisposing factors in ALL 
Similar to AML, the majority of cases of ALL are idiopathic. In both children and 
adults, there is a slight male preponderance, at a ratio of 1.4:1. For reasons that are not 
clear, the incidence is highest in higher socio-economic groups and in the most 
developed countries (Switzerland has the highest worldwide incidence), and there has 
been a moderate but steady increase in both childhood and adult ALL worldwide over 
the last 20 years (Dores et al., 2012). Hispanic groups are also at significantly higher 
risk of developing ALL than other ethnic groups. Other risk factors for ALL 
development (as reviewed in the National Institute of Health website: 
http://www.cancer.gov/cancertopics/pdq/treatment/childALL/) include: 
 
1. Genetic disorders: 
a. Chromosomal disorders: Down’s syndrome (trisomy 21), where 
there is a 20 fold increased risk for the development of ALL 
b. Inherited/congenital genetic defects – ataxia telangiectasia, Bloom 
syndrome, neurofibromatosis, and Shwachman-Diamond syndrome 
2. X-ray exposure: 
a. Foetal exposure to X-rays 
b.  Postnatal X-ray exposure. The classic example here being the so-
called ‘ringworm affair’, in which over 200,000 children were 
treated with X-ray therapy in the 1940-1950s, predominantly to the 
scalp, for the treatment of tinea capitis (ringworm) (Crossland, 
1956), resulting in brain tumours, skin cancers and ALL (Shore et 
al., 2003).1 
                                                
1 A selected abstract of the original Crossland paper (Crossland 1956) is worth noting here. ‘Roentgen ray epilation [X-ray], 
which is at present the most important single weapon against M. audouini infection of the scalp, should not be withheld except in 
special circumstances, from a child who has the disease. It can quickly cure the disease and halt spread from one child to another. 
Harmful sequelae and medicolegal complications can be averted by competent use of the method…The Keinbock-Adamson 
technique of epilation can be recommended without hesitancy’ 
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3. Single nucleotide polymorphisms (SNP). Genome-wide association studies 
have shown an association of specific SNPs at the ARID5B and CEBPE 
loci with an increased risk of B-ALL (Papaemmanuil et al., 2009).  
  
1.4.3 WHO classification of ALL  
Despite the FAB system categorising ALL according to morphological criteria (L1, 
L2 or L3 morphology) (Bennett et al., 1981), the majority of patients with L3 
morphology (typically associated with the presence of numerous cytoplasmic 
vacuoles) have Burkitt’s lymphoma and should be treated on appropriate protocols. 
Distinguishing between the L1 and L2 subgroups does not provide robust prognostic 
information or influence therapy, and for that reason is no longer used in routine 
practice. The 2008 WHO classification of ALL takes into account cellular 
immunophenotype and cytogenetic abnormalities, and is shown in Table 1.5 
(Swerdlow, 2008). 
 
 
 
Table 1.5 World Health Organisation classification of ALL 
 
• B-lymphoblastic leukaemia/lymphoma not otherwise specified 
• B-lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities: 
o t(9;22) BCR-ABL 
o t(v;11q23) 11q23 MLL rearrangement 
o t(12;21) ETV6-RUNX1 
o hyperdiploidy (>50 chromosomes) 
o hypodiploidy (<45 chromosomes) 
o t(5;14) IL3/IGH 
o t(1;19) E2A/PBX1 
• T-lymphoblastic leukaemia/lymphoma 
(According to Swerdlow, 2008) 
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1.4.4 European Group for the Immunological Characterization of Leukaemias 
(EGIL) classification of ALL 
The EGIL classification relies purely on a flow cytometric assessment of blast 
immunophenotype to characterise ALL (Table 1.6), and the descriptive terminology 
used is still common in current practice. The advantages of this approach are that it 
assesses the extent of cellular differentiation, can be standardised between 
laboratories, has prognostic value in some categories, and predicts the presence or 
absence of particular underlying genetic/cytogenetic lesions (for instance, MLL gene 
rearrangements are common in CD10 negative B-ALL). The disadvantages are that, 
on occasion, some leukaemias do not display a characteristic immunophenotype 
despite being clearly of a particular lineage by cytochemical or morphological 
analysis, and it does not take into account cytogenetic abnormalities.  
 
 
Table 1.6 Flow cytometric markers used to distinguish subtypes of ALL 
according to the EGIL classification  
 Positive markers Negative 
markers 
Approximate 
percentage of 
ALL cases 
B-ALL    
     Pro B-ALL HLA-DR+ TdT+ CD19+ CD10-, CyIg- 10% 
     Common ALL CD10+ TdT+ CyIg- 50% 
     Pre-B-ALL CyIg+  CD10+ TdT+  10% 
     Mature B-ALL* SmIg+ TdT-, CD34- 4% 
T-ALL    
    Pro-T-ALL TdT+ CD7+ CyCD3+ CD2-, CD4-, 
CD8- 
7% 
    Pre-T-ALL TdT+ CD7+ CyCD3+ CD2+ CD4-, CD8- 1% 
    Cortical/thymic  
     T-ALL 
TdT+ CD7+ CyCD3+ CD1a+ 
CD2+ CD5+ CD4+ CD8+ 
 17% 
     Mature T-ALL CD7+ SmCD3+ CD2+  
CD4 or CD8+ 
TdT-, CD1a- 1% 
B-ALLs can be CD79a±, and/or CD22±, and/or CD34±. T-ALLs can be CD33±, and/or CD34±, and/or 
CD13±. Cy, cytoplasmic. Ig, immunoglobulin; Sm surface. *Majority are Burkitt’s lymphomas. Table 
according to (Bene et al., 1995). 
 
 
1.4.5 EGIL classification of biphenotypic leukaemia 
Biphenotypic leukaemias constitute a rare subgroup of leukaemias with a poor 
prognosis where the blast population co-expresses antigens of different cell lineages. 
This is distinct from the presence of two separate blast populations of different 
lineages, which should be termed ‘bilineage leukaemia’. Using the EGIL 
classification points system, a score of greater than 2 for myeloid markers plus greater 
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than 1 for lymphoid markers is considered to meet the criteria for biphenotypic 
leukaemia (Table 1.7) (Bene et al., 1995). 
 
The use of such scoring systems is important because it distinguishes these select 
subgroups from leukaemias that express a single marker of an alternate lineage, which 
is a common occurrence in both AML and ALL. For instance, approximately 20-25% 
of AML patients co-express T-cell markers such as CD7 and CD5 (Casasnovas et al., 
2003). Since the 1980s it has been debated whether these aberrantly expressed 
markers relate to ‘lineage promiscuity’ or ‘lineage infidelity’. Greaves proposed the 
lineage promiscuity argument as ‘the existence of a transient phase of limited 
promiscuity of gene expression occurring in normal bipotential or multipotential 
progenitors and able to be preserved as a relic in leukaemic blast cell populations that 
are in maturation arrest’ (Greaves et al., 1986), whilst McCulloch hypothesised that 
the aberrant expression of markers of different lineages related to lineage infidelity, 
explained as the ‘misprogramming of differentiation in leukaemia’ (McCulloch, 
1983). It is very possible that both arguments hold true in particular settings. Such 
aberrant markers, whatever their origin, have proved useful in differentiating 
malignant clonal populations from normal cells when analysing samples for MRD by 
flow cytometry, as discussed below. 
 
 
Table 1.7 EGIL classification for the diagnosis of biphenotypic leukaemia 
 B-lineage T-lineage Myeloid lineage 
2 points CD79+ IgM+ CD22+ CD3+ Anti TCR+ MPO+ 
CD19+ CD13+ 
CD10+ CD33+ 1 point 
CD20+ 
CD2+ CD5+ CD8+ 
CD10+ 
CD65+ 
TdT+ 
0.5 point 
 
TdT+ CD17+ CD10+ 
CD14+ 
CD15+ 
CD64+  
CD117+ 
MPO, myeloperoxidase. A score of >2 points for myeloid markers plus >1 point for lymphoid markers 
is considered to meet criteria for biphenotypic leukaemia. Table according to (Bene et al., 1995)
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1.5 T-ALL 
1.5.1 Clinical characteristics of T-ALL 
T-ALL accounts for 10-15% of paediatric and approximately 25% of adult ALL cases 
(Pui and Evans, 1998). It has a male preponderance, at a ratio of 3:1, and is associated 
with very high circulating blast cell counts, the presence of a mediastinal mass, and 
increased risk of leukaemic infiltration of the central nervous system (CNS) at the 
time of diagnosis (Marks et al., 2009; Pui and Evans, 1998).  
 
1.5.2 Cytogenetic aberrations in T-ALL 
The most common cytogenetic abnormality (>70% of patients) in T-ALL is deletion 
of chromosome 9p. The deletions are usually large and occasionally homozygous, and 
involve the CDKN2A locus that encodes the cell cycle regulatory tumour suppressor 
genes p16INK4A and p14ARF, that are encoded from alternate reading frames of the 
same locus (Marks et al., 2009). Most of the important discoveries of the molecular 
anatomy of T-ALL have come from the study of rare, specific chromosomal 
translocations and intrachromosomal rearrangements. These typically juxtapose 
promoter elements or enhancers of the T-cell receptor (TCR) beta and alpha/delta 
genes (on chromosomes 7q34 and 14q11 respectively) to transcription factors that 
have roles in normal T-cell differentiation (Armstrong and Look, 2005; Ferrando et 
al., 2002; Look, 1997; Van Vlierberghe and Ferrando, 2012). Typical translocation 
partners of the TCR loci include basic helix-loop-helix (bHLH) transcription factors 
such as TAL1 and LYL1, LIM-only domain (LMO) genes such as LMO1 and LMO2, 
and the orphan homeobox genes HOX11 and HOX11L2 (Table 1.8) (Van Vlierberghe 
and Ferrando, 2012). Several transgenic mouse models have been developed where T-
ALL is induced by overexpression of one of these transcription factors, including 
Tal1, Lmo1/2, and Tlx1 (De Keersmaecker et al., 2010; Larson et al., 1996; Tremblay 
et al., 2010). Translocations have also been identified juxtaposing TCR enhancer 
elements to oncogenes including intracellular NOTCH-1 (ICN-1) and c-MYB (Table 
1.8), and although the translocations themselves are extremely rare, study of these 
genes has led to the identification of highly recurrent genetic abnormalities, including 
activating mutations of NOTCH-1 in over 50% of patients and duplication of the MYB 
locus in 10% of patients (O'Neil et al., 2007b; Weng et al., 2004).  
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Table 1.8 Frequency of cytogenetic translocations identified in T-ALL 
Gene family Gene name Cytogenetic   
aberration 
Prognostic 
implication 
Frequency 
in T-ALL 
bHLH family 
members  
 
TAL1  
 
 
t(1;14)(p32;q11) 
t(1;7)(p32;q34)  
1p32 deletion  
Good1-3 
Good1-3 
Good1-3 
3% 
3% 
16%–30% 
 TAL2 
  
t(7;9)(q34;q32)  1% 
 LYL1 
 
t(7;19)(q34;p13)  1% 
 BHLHB1 t(14;21)(q11.2;q22)  1% 
LMO family 
members  
 
LMO1 t(11;14)(p15;q11) 
t(7;11)(q34;p15)  
 1% 
1% 
 LMO2  
 
t(11;14)(p13;q11) 
t(7;11)(q34;p13) 
11p13 deletion  
 
 6% 
6% 
3% 
 LMO3  t(7;12)(q34;p12)  <1% 
Homeobox  
family  
TLX1(HOX11) t(10;14)(q24;q11) Good3 5-10% 
members TLX3(HOX11L2) t(5;14)(q35;q32)  5-20% 
 HOXA inv(7)(p15q34)  
t(7;7)(p15;q34)  
 
 3% 
3% 
 HOXA (CALM-AF10)* t(10;11)(p13;q21)  5-10% 
 HOXA (MLL-ENL)* t(11;19)(q23;p13)  1% 
 HOXA (SET-NUP214)* 
 
9q34 deletion 
inv(14)(q11.2q13)  
 
 3% 
 NKX2.1 inv(14)(q13q32.33) 
t(7;14)(q34;q13)  
 
 5% 
 NKX2.2  t(14;20)(q11;p11)  1% 
Oncogene NOTCH-1 t(7;9)(q34;q34)  <1% 
 MYB t(6;7)(q23;q34)  3% 
 C-MYC t(8;14)(q24;q11)  2% 
Cell cycle CDKN2A/B 
CCND2 
 
RB1 
Deletion 9p21 t(7;12)(q34;p13)	  t(12;14)(p13;q11)	  
Deletion 13q14 
 >70% 
1% 
 
4% 
Signal 
transduction 
NUP214-ABL1 Episomal 
amplification of 
9q34 
Poor4 4% 
The 7q34 lesions involve the TCR beta enhancer/promoter and 14q11 lesions involve TCR alpha/delta 
enhancer/promoter. Other translocation partners are shown in brackets. *These translocations have 
been show to directly upregulate the HOXA cluster and so are included in the HOXA category here. 
Absent data in the prognosis column signifies no comprehensive outcome data available or have no 
prognostic significance. (Table modified from Van Vlierberghe and Ferrando, 2012), including 
additional data from http://atlasgeneticsoncology.org. 1(Kikuchi et al., 1993); 2(Bash et al., 1993); 
3(Cave et al., 2004); 4(Graux et al., 2004). ABL1 c-abl1 oncogene; BHLHB1 Beta helix-loop-helix B1 
gene; C-MYC myelocytomatosis viral oncogene homolog; CCND2 Cyclin D2 gene; CDKN2A cyclin-
dependent kinase inhibitor 2A; HOXA homeobox; LMO Lim domain only gene; LYL1 lymphoblastic 
leukemia derived sequence-1 gene; MYB myeloblastosis viral oncogene homolog gene; NKX NK 
homeobox gene; NUP214 nucleoporin 214kDa gene; TAL T-cell acute lymphoblastic leukemia gene; 
RB1 retinoblastoma-1 gene; TLX T-cell leukemia homeobox gene. 
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1.5.3 Somatic mutations in T-ALL 
Driven by technological advances such as copy number analysis by array comparative 
genomic hybridisation (aCGH) and SNP arrays, exome capture and whole genome 
sequencing, a wealth of somatic mutations have now been identified in T-ALL (Table 
1.9). Many of these have been discovered since the work for this thesis was 
undertaken.  
 
Table 1.9 Frequency of somatic mutations identified in T-ALL 
Type of mutation Mutated gene (approximate incidence in T-ALL) 
Activating 
mutations 
(oncogenes) 
 
• NOTCH-1 (60%) (Weng et al., 2004) 
• IL7R (10%) (Zhang et al., 2012) 
• JAK1 (1% children; 18% adults) (Flex et al., 2008) 
• JAK3 (5%) (Zhang et al., 2012) 
• NRAS (5-10%) (Zhang et al., 2012) 
• FLT3 (2%) (Zhang et al., 2012) 
Inactivating 
mutations  
(tumour 
suppressor genes) 
 
Transcription factors: 
• RUNX1 (10-20%) (De Keersmaecker et al., 2010) 
• LEF1 (10-15%) (Gutierrez et al., 2010b) 
• ETV6 (13%) (Van Vlierberghe et al., 2011; Zhang et al., 2012) 
• WT1 (10%) (Tosello et al., 2009) 
• BCL11B (10%) (Gutierrez et al., 2011; Zhang et al., 2012) 
• GATA3 (5%) (Zhang et al., 2012) 
Chromatin regulators: 
• PHF6 (20-40%) (Van Vlierberghe et al., 2010; Zhang et al., 
2012) 
• EZH2 (10-15%) (Ntziachristos et al., 2012; Simon et al., 2012; 
Zhang et al., 2012) 
• SUZ12 (10%) (Ntziachristos et al., 2012; Zhang et al., 2012) 
• EED (10%) (Zhang et al., 2012) 
Signal transduction: 
• PTEN (10%) (Palomero et al., 2007; Zhang et al., 2012) 
• NF1 (3%) (Zhang et al., 2012) 
Ubiquitin ligase: 
• FBXW7 (20%) (Maser et al., 2007; O'Neil et al., 2007a; 
Thompson et al., 2007; Zhang et al., 2012) 
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1.5.4 Prognostication in T-ALL 
Approximately 85-95% of paediatric patients and 35-50% of adult patients achieve 
long-term remission with ALL, depending on the treatment protocol (Goldstone et al., 
2008; Hann et al., 2000; Larson, 2005). Historically, T-ALL had a particularly poor 
prognosis in comparison to B-ALL (Clavell et al., 1986; Steinherz et al., 1991) and, 
given the lack of effective agents, even led to an unsuccessful trial of thymectomy in 
these patients (Sallan, 1981). However, the introduction in recent years of intensified 
combination chemotherapy, particularly the inclusion of high dose methotrexate, has 
resulted in a remarkable improvement in the prognosis for this disease in children, 
with 5-year relapse-free survival rates now exceeding 80%, equivalent to B-ALL 
(Goldberg et al., 2003; Schrappe et al., 2000). In adult patients, the use of more 
aggressive combination chemotherapies has improved the OS rates to approximately 
50%, which is a better prognosis than in adults diagnosed with B-lineage ALL 
(Goldstone et al., 2008; Hunault et al., 2004; Marks et al., 2009; Rowe et al., 2005).  
 
Nonetheless, T-ALL patients with similar clinical features often respond quite 
differently to the same multi-drug regimen, creating a major obstacle to the 
development of risk-directed treatment strategies. Listed below are some of the 
variables that impact on patient outcome in ALL: 
1) Age. Age remains one of the most important prognostic variables in terms of 
patient outcome for both B- and T-ALL. Excluding patients with infant ALL, who 
often harbour rearrangements of the MLL gene and fare particularly badly 
(Chessells et al., 1994), paediatric patients less than 10 years old tend to fare 
significantly better than those 10 years of age or more (Hann et al., 2000). Current 
paediatric treatment protocols in the UK (the UKALL 2003 protocol) offer 
reduced intensity therapy to those patients less than 10 years of age if they do not 
have other poor prognostic markers. In adults, age is a continuous variable 
inversely correlated with outcome, with lower complete remission (CR) rates, 
higher infective complications and less than 20% OS for patients greater than 60 
years of age in the majority of studies (Larson, 2005; Sive et al., 2012). In B-ALL, 
a significant contribution can be attributed to a higher incidence in older patients 
of Philadelphia positive (Ph+) disease with the t(9;22) chromosomal translocation 
resulting in the BCR-ABL fusion transcript, which is associated with 
chemoresistance, and a lower incidence of the t(12;21) chromosomal translocation 
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resulting in the ETV6-RUNX1 fusion transcript (known previously as TEL-AML1), 
which is associated with a better response to therapy.  
 
Several studies have shown that adolescent patients and those in their early 20s 
have an inferior outcome when treated on adult ALL protocols compared to 
paediatric protocols (Boissel et al., 2003; de Bont et al., 2005; Hallbook et al., 
2006; Ramanujachar et al., 2007; Usvasalo et al., 2008), and current amendments 
to protocols in the UK have attempted to address this. Although there are several 
other possible reasons for the disparate outcomes between paediatric and adult 
patients, such as higher cumulative doses of steroids and L-asparaginase, better 
tolerance to chemotherapy, and a lower incidence of protocol delays for paediatric 
patients, there appears to be an inherent difference in chemosensitivity between 
adult and paediatric ALL that as yet remains unexplained. For example, at the end 
of induction therapy, which consists of similar drug regimens in both children and 
adults, the incidence of MRD positivity is significantly higher in adults, 
suggesting that they have increased levels of inherent chemoresistance 
(Bruggemann et al., 2006; Patel et al., 2010). A comparison of the incidence of 
recently identified molecular abnormalities in these different age groups has the 
potential to elucidate mechanisms that may be associated with treatment response, 
which could add value both in terms of prognostication and, possibly, targeted 
therapy. 
 
2) Presenting white cell count (WCC). WCC remains one of the most robust 
prognostic markers in both B- and T-ALL (Goldstone et al., 2008; Hoelzer et al., 
1988; Rowe et al., 2005). For B-ALL a presenting WCC <30x109/l, and for T-
ALL, a presenting WCC <100x109/l have been associated with improved OS. 
 
3) Early treatment response. In the UK, it has become standard practice to perform 
BM aspirates on paediatric patients after one, two and four weeks of therapy to 
assess early treatment response. On the UK ALL2003 protocol, patients are 
classified by their marrow status at these time points as M1 (<5% blasts), M2 (5-
25% blasts) and M3 (>25% blasts). This classification has significant prognostic 
value, with patients with M2 or M3 marrows faring significantly worse.  
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4) Minimal residual disease (MRD). In paediatric ALL, almost 60% of relapses 
occur from patients who have had a rapid treatment response by morphological 
criteria, which highlights the limited sensitivity of this technique for identifying 
residual leukaemia within the marrow. This has led to the development of MRD 
analysis, which aims to identify those patients with significant marrow disease 
that is below the limit of morphological sensitivity (1-5%), but which can be 
indicative of treatment failure. Ideally, MRD should be specific (able to 
distinguish malignant cells from normal cells), sensitive (able to detect at the very 
least one abnormal cell in 104 normal cells) and be amenable to standardisation so 
that results can be interpreted from different laboratories worldwide. There are 
two main approaches to MRD:  
a. Flow cytometry. Flow cytometric MRD requires the identification of an 
aberrant immunophenotype on the leukaemic clone that enables it to be 
distinguished from normal haematopoietic cells. For T-ALL, co-
expression of T-cell markers such as CD2, CD7 and CD3 with markers of 
other lineages such the myeloid antigens CD13 or CD33, or the B-cell 
antigen CD19, can be used to identify an abnormal clone that is not present 
on normal cells (Campana and Coustan-Smith, 1999). The major 
limitations are the requirement for fresh samples, aberrant phenotypes are 
not always present on leukaemic cells, changes in immunophenotype can 
occur at relapse, and the sensitivity is inferior to qPCR techniques (limited 
to 1 leukaemic cell in 104-105 normal cells) (Coustan-Smith and Campana, 
2010).  
b. Quantitative PCR (qPCR). Evaluation of rearrangements of the 
immunoglobulin genes to assess the levels of MRD at a variety of time 
points during therapy has proven to be highly predictive of relapse and 
outcome in B-ALL (Bruggemann et al., 2006). During normal T-cell 
development, lymphocytes first rearrange the Variable Diversity Joining 
(VDJ) segments of the T-cell receptor delta (TCRδ) and gamma (TCRγ) 
genes to form a γδTCR, and then the TCRβ and finally the alpha (TCRα) 
loci are rearranged to form a functional αβ TCR (Dadi et al., 2009; 
Krangel, 2009). VDJ recombination is mediated by the RAG recombinase-
1 and-2 genes (RAG-1 and RAG-2), and in order to produce a T-cell 
repertoire with extensive diversity, additional random DNA insertions and 
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deletions are introduced by the activity of terminal deoxynucleotidyl 
transferase (TdT). The cells then undergo a process of positive and 
negative selection that results in a polyclonal population of mature T-cells 
that are released from the thymus and are able to both recognise foreign 
antigens and tolerate self antigens. Consequently, PCR across the VDJ 
region of isolated T-cells in normal individuals produces a smear due to 
the extensive variation in DNA sequence length produced during VDJ 
recombination. However, in T-ALL, the clonal dominance of a T-cell 
clone can be identified by the presence of a specific intense band at PCR. 
The VDJ sequence is usually unique to the individual clone, therefore a 
primer designed to the specific sequence can be used for the sensitive 
detection of the clone by qPCR, which can then be expressed as a copy 
number or sensitivity, with a sensitivity as low as 1 abnormal cell in 106 
normal cells (van Dongen et al., 2003). Monitoring of MRD by qPCR has 
proven highly predictive of outcome in large studies of T-ALL (Schrappe 
et al., 2011). Alternative methods, such as qPCR quantification of SIL-
TAL1 transcripts in patients harbouring the 1p32 microdeletion, have also 
been used successfully to monitor MRD in T-ALL (Breit et al., 1993). 
 
5) Chromosomal aberrations. In B-ALL, there are well-defined cytogenetic groups 
that have robust associations with prognosis, such as improved outcome for 
patients with ETV6-RUNX1 translocations and hyperdiploidy (>51 chromosomes), 
or poor outcome associated with hypodiploidy (<45 chromosomes), the BCR-ABL 
translocation, iAMP21 (RUNX1 amplification) and rearrangements involving the 
MLL gene on 11q23 (Moorman et al., 2010). However, due to the rarity of 
recurrent translocations in T-ALL (Table 1.8), there are few cohort studies of 
adequate size to robustly address the impact of cytogenetics on outcome. The 
largest trial to date to assess this in adults is the UKALLXII/ECOG2993 trial, 
which identified complex karyotype (defined as 5 or more chromosomal 
abnormalities) as an adverse prognostic marker (Marks et al., 2009; Moorman et 
al., 2007). Deletions of the CDKN2A locus had no prognostic significance on this 
trial. Although it remains controversial, the majority of studies have shown 
improved outcome associated with translocations involving the HOX11 or TAL1 
loci, and poorer prognosis associated with NUP214-ABL1 episomal amplification 
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(Table 1.8) (Bash et al., 1993; Cave et al., 2004; Graux et al., 2004; Kikuchi et al., 
1993). Apart from the latter, that may respond to treatment with tyrosine kinase 
inhibitors such as imatinib, these cytogenetic aberrations do not currently impact 
the choice of therapy in T-ALL.  
 
6) Immunophenotype. Both adult and paediatric T-ALL with an immunophenotype 
similar to that of early cortical thymocytes (expressing CD1a) seem to respond 
particularly well to therapy (Marks et al., 2009). Whether chemosensitivity relates 
in some way to expression of HOX11, which is normally expressed during the 
early cortical stage and highly expressed in blasts with this immunophenotype, is 
unclear. It is possible that the association of HOX11 translocation with improved 
prognosis reflects the differentiation arrest at the cortical stage, which is 
characteristic of such translocations (Asnafi et al., 2009; Cave et al., 2004).  
 
7) Early T-cell progenitor (ETP) ALL. Patients with T-ALL and aberrant expression 
of CD13 and/or CD33 myeloid antigens have a poor prognosis (Marks et al., 
2009), which raises the possibility that these cases originated from very early 
multipotent haematopoietic cells that are inherently more chemoresistant to ALL-
directed therapy. Analysis of microarray data from 139 T-ALL patients identified 
a subgroup (12%) of T-ALL patients that had a gene expression signature highly 
similar to normal ETP cell subsets, and also overexpressed many myeloid-related 
genes including CEBPA, GATA2, KIT and CD34 (Coustan-Smith et al., 2009). 
These patients had a characteristic flow cytometric immunophenotype with absent 
CD1a and CD8 expression, weak CD5 expression, and one or more of the 
following myeloid/stem cell antigens: CD117, CD34, CD13, CD33, CD11b or 
CD65. It should be noted that approximately half of the ETP-ALL patients would 
fulfil EGIL criteria for biphenotypic AML/T-ALL. In this study patients with 
ETP-ALL had a particularly dire outcome with a 10-year OS of 19% compared to 
84% for their non-ETP counterparts. ETP leukaemias arise from early stem cells 
that have not undergone complete TCRγ rearrangement. An independent study 
used array comparative genomic hybridisation (aCGH) and qPCR to identify a 
subset of T-ALL patients with an absence of biallelic TCRγ deletion (so called 
‘ABD’ patients) that were enriched in patients with the ETP phenotype and 
associated with a particularly poor prognosis (Gutierrez et al., 2010a).  
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8) Other factors. Historically, boys have tended to fare slightly worse than girls, 
partly, but not solely, due to the risk of testicular relapse, and this is addressed in 
current paediatric trials where maintenance therapy is extended by one year for 
boys. However, no difference in outcome according to sex was seen for adults 
with T-ALL entered onto the UKALLXII/ECOG2993 (Marks et al., 2009). 
Contrary to what one might expect, the presence of CNS disease at the 
presentation of T-ALL was not associated with a poorer prognosis on this trial 
(Marks et al., 2009).  
 
1.5.5 Current chemotherapeutic approaches in ALL 
A brief overview of the treatment approach for ALL in the UK is given below. Due to 
the differences in drug tolerability, adult and paediatric ALL treatment algorithms 
vary considerably between these two age groups. Paediatric regimens have also 
become increasingly risk-adapted (guided by age, cytogenetics, MRD, and marrow 
response), to enable treatment reduction in children at low risk of relapse and 
intensification for those at high risk. In adults, there is an increasing use of allogeneic 
transplantation, particularly non-myeloablative transplantation in older patients. 
Patients less than 25 years of age now receive a modified paediatric regimen in the 
UK.  
 
On the paediatric UKALL2003 trial, the treatment regimen involves a sequential 
phase of induction, consolidation, intensification and maintenance therapy 
(www.ctsu.ox.ac.uk/research/mega-trials/leukaemia-trials/ukall-2003). This is given 
together with intrathecal CNS-directed therapy to treat and/or prevent CNS relapse. 
The treatment protocols are divided into regimens A, B and C depending on whether 
patients are standard-risk (children <10 years old with WCC<50x109/l), intermediate 
(children ≥10 years old or WCC >50x109/l) or high-risk (slow early response, high 
MRD at day 29, hypodiploid with less than 44 chromosomes), BCR-ABL positive, 
RUNX1 amplification positive or MLL gene rearranged) respectively. Induction 
therapy using a three-drug regimen with steroids, vincristine, and asparaginase leads 
to remission in 95% of patients with standard-risk ALL (children <10 years old with 
WCC<50x109/l) (Pui and Evans, 2006). Intermediate and high-risk patients also 
receive daunorubicin at induction. Regimen A consists of two courses of interim 
maintenance (steroids, vincristine, 6-mercaptopurine and oral methotrexate), and two 
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courses of delayed intensification (steroids, vincristine, asparaginase, 
cyclophosphamide, cytarabine, 6-mercaptopurine), followed by maintenance therapy 
of steroids, vincristine, 6-mercaptopurine and oral methotrexate (2 years for girls, 3 
years for boys). On the UKALLVIII trial, half of the patients were cured despite the 
lack of an intensification block (Eden et al., 1991), thus the UKALL2003 trial has 
randomised patients with low risk MRD between one and two intensification arms. 
Regimen B is similar but includes a consolidation phase after induction, consisting of 
cyclophosphamide, cytarabine, vincristine, asparaginase and 6-mercaptopurine 
(known as standard BFM consolidation). Regimen C is as for regimen B but the 
interim maintenance phases are replaced with the more intense escalating Capizzi 
regimen based on IV methotrexate.  
 
Adult protocols tend to use the same drugs as for paediatric ALL but at differing 
doses and scheduling. On the adult ECOG2993/UKALLXII trial protocol 
(www.ctsu.ox.ac.uk/research/mega-trials/leukaemia-trials/adult-all/ukall-xii-ph-
positive-patients/ukall-xii-archive/protocol/view), treatment consists of two courses of 
induction therapy (Phase I consists of steroids, vincristine, asparaginase, 
daunorubicin; phase II consists of cyclophosphamide, cytarabine and 6-
mercaptopurine) and three courses of high dose methotrexate, followed by 
consolidation with further chemotherapy, autologous transplantation or allogeneic 
transplantation (as discussed below). Several centres worldwide have adopted the MD 
Anderson Hyper-CVAD regimen, which consists of courses of cyclophosphamide, 
vincristine, doxorubicin and dexamethasone, alternating with high dose 
methotrexate/cytarabine, with similar outcomes to the UKALLXII trial (Thomas et 
al., 2004). The addition of monoclonal antibodies against CD20 and CD22 for B-ALL 
and the use of the purine nucleoside analog nelarabine for T-ALL are currently being 
tested on the UKALL 14 trial. 
 
Despite the similarity of the drugs used, the outcome between adult and paediatric 
ALL is markedly different. This, at least in part, relates to the high induction death 
rate in adults, which is 5-10%, as compared to less than 1% on most paediatric trials 
(Fielding, 2008). While a proportion of the mortality is related to higher risk of 
infective complications, there is a general poorer drug tolerance in adults (for 
instance, liver toxicity from asparaginase, cardiac toxicity from anthracyclines), and 
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significantly higher TRM. There was also a significant incidence of death in 
remission reported for patients on the UKALLXII protocol that may relate to drug 
and/or age-related complications (Goldstone et al., 2008).  
 
1.5.6 Role of transplantation in adult and paediatric ALL 
For adults entered on the UKALLXII/ECOG2993 trial, those less than 50 years old 
with an HLA-matched sibling donor received an allograft, whilst patients older than 
50 years or lacking an HLA-matched donor were randomised to either consolidation 
therapy or an autologous transplant (Goldstone et al., 2008). This is the largest trial 
conducted to date in adult ALL and showed that patients who received autologous 
transplantation fared worse than those who received standard consolidation therapy (5 
year OS 37% versus 46%, respectively). In a donor versus no-donor analysis, patients 
with a donor had a lower rate of relapse and the best outcome (5 year OS 53% versus 
45%, respectively). As it is clear that patients who fail therapy have a very poor 
salvage rate, with only 7% of adult patients alive 5 years after relapse (Fielding et al., 
2007), this would suggest that intensive therapy, including the use of allogeneic 
transplantation, should be given upfront to such patients, rather than being reserved 
for relapse. Unfortunately, the one group that did not benefit from allogeneic 
transplantation in terms of OS were those in the high-risk group (Goldstone et al., 
2008). However, there was a higher TRM in these patients, relating, at least in part, 
from the older age of this subgroup. This has prompted the use of reduced intensity 
transplantation in older patients in the current UKALL14 trial.  
 
In paediatric patients, allogeneic transplantation is generally reserved for patients at 
relapse. On the UKALL2003 trial, there are clear criteria for those at particularly high 
risk of relapse who should receive allogeneic transplant in first remission:  
1. MLL rearrangement or hypodiploid (< 44 chromosomes) with day 28 M2 
marrow (>5% blasts).  
2. M3 marrow at day 28.  
3. BCR-ABL positive ALL 
4. t(17;19) (E2A-HLF) positive ALL 
5. iAMP21 (amplification of RUNX1) with slow early response 
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1.6 The Notch signalling pathway  
In 1917, the American geneticist and Nobel laureate Thomas Hunt Morgan first 
described a strain of the fruit fly, Drosophila melanogaster, with a notch in its wing 
margin that exhibited X-linked inheritance of the notch defect (Morgan, 1917). It was 
later discovered this was due to haploinsufficiency in a gene that earned its name from 
the defect - notch. In 1983, Spyros Artavanis-Tsakonas was the first to clone the 
Drosophila notch gene, which opened the way to many important discoveries relating 
to the mechanism of Notch signalling and its role in normal biology, embryology, and 
now cancer (Wharton et al., 1985). Because of the distinct phenotypes associated with 
either gain-of-function or loss-of-function of the Notch signalling pathway during 
development in D.melanogaster and C.elegans, many members of the Notch pathway 
were identified through forward genetic screens in these organisms. The gene 
terminology used for members of the Notch pathway in these species together with 
their human orthologues are given in Table 1.10 (modified from Bray, 2006). Whilst 
D.melanogaster have only one Notch gene, the number of Notch genes, ligands and 
members of the regulatory pathway increases with higher order species, reflecting the 
degree of tissue complexity.  
 
1.6.1 Notch and embryonic development 
Notch forms part of an ancient highly conserved evolutionary signalling pathway, 
with vital roles in the embryonic development of both invertebrates and vertebrates. 
The important developmental role of Notch was evident in Thomas Hunt Morgan’s 
original 1917 publication (Morgan, 1917): ‘A female with notch wings carries the 
gene in one of her X-chromosomes and the normal allelomorph in the other X-
chromosome. Half of her sons get the former and die, the other half get the latter X-
chromosome and live.’  
 
Consistent with this finding, homozygous Notch-1 knockout mice die at E10.5 due to 
gross developmental abnormalities affecting multiple organs, many related to 
disorders in vascular development (Swiatek et al., 1994). Notch signalling has now 
been show to govern cell-fate specification of a wide number of different tissues, 
including the intestine, skin, retina, neuronal tissue, vasculature including cardiac 
tissue and valves, exocrine pancreatic tissue, mammary glands, and haematopoietic 
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tissue (Blaumueller and Artavanis-Tsakonas, 1997; Iso et al., 2003; Murtaugh et al., 
2003; Sandy and Maillard, 2009; Uyttendaele et al., 1998; Wharton et al., 1985).  
 
 
Table 1.10 Terminology used for members of the Notch pathway in different 
species 
 Drosophila 
melanogaster 
Caenorhabditis 
elegans 
Homo sapiens 
Notch receptors Notch lin-12 NOTCH-1 
  glp-1 NOTCH-2 
   NOTCH-3 
   NOTCH-4 
Notch ligands Delta lag-2 Delta-like-1 (DLL-1) 
  apx-1 Delta-like-3 (DLL-3) 
  arg-1 Delta-like-4 (DLL-4) 
 Serrate dsl-1 Jagged-1 (JAG-1) 
   Jagged-2 (JAG-2) 
CSL transcription factor Suppressor of 
hairless (Su(H)) 
lag-1 CBF1/RBPJ-Κ  
F-box E3 ubiquitin ligase Archipelago sel-10 FBXW7/FBW7 
Co-activator Mastermind lag-3 Mastermind-like-1 
(MAML-1) 
   Mastermind-like-2 
(MAML-2) 
   Mastermind-like-3 
(MAML-3) 
Glycosyltransferase Fringe  Lunatic fringe (LFNG) 
   Manic fringe (MFNG) 
   Radical fringe (RFNG) 
 (Modified from Bray, 2006) 
 
 
1.6.2 The Notch pathway 
The Notch signalling pathway is one of the most studied and best characterised in 
biology, and is outlined below (reviewed in Bray, 2006; Fortini, 2009; Kopan and 
Ilagan, 2009). 
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1.6.2.1 Notch receptors are activated by three cleavage steps 
                  The Notch receptors are large single-pass type I transmembrane receptors of 
approximately 300kD. In humans there are four Notch receptors, NOTCH-1, -2, -3 
and -4, that share the same basic structure, exhibit approximately 70% sequence 
homology, and differ predominantly in the size of their extracellular domain. In the 
extracellular region they have a large epidermal growth factor (EGF)-like repeat 
domain responsible for binding to ligand (Figure 1.1). The extracellular LIN12-
Notch-repeat (LNR) domain, comprised of 3 LNR regions (LNR-A, -B and -C) each 
coupled to a single calcium atom, was the first negative regulatory region (NRR) 
described in C.elegans, and associates with the heterodimerisation (HD) domain 
(Greenwald and Seydoux, 1990). Intracellular Notch (ICN) is comprised of an RBP-
JΚ-associated module (RAM) domain, ankyrin repeat (ANK) domain, and C-terminal 
transactivation (TAD) and proline-glutamate-serine-threonine (PEST) domains 
(Figure 1.1), the functions of which are described below. 
 
 
 
 
 
Figure 1.1 Structure of Notch receptors. ICN, intracellular Notch. EGF, Epidermal like 
growth factor repeats. LNR, Lin12-Notch repeats. HD, Heterodimerisation domain. RAM, 
RBP-Jkappa-associated module. ANK, Ankyrin repeat domain. PEST, proline (P) glutamic 
acid (E) serine (S) threonine (T) rich domain. Modified from Weng et al 2004.
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When full-length Notch is en route to the cell membrane, it is first cleaved in the 
Golgi by a furin-like convertase at a site termed S1 in the HD domain at a position 
approximately 70 amino acids external to the transmembrane domain (Figure 1.2) 
(Logeat et al., 1998). The resulting two subunits of the Notch receptor, commonly 
referred to as the Notch extracellular [N(EC)] and Notch transmembrane [N(TM)] 
subunits, are held together by a non-covalent bond maintained by interaction between 
the LNR and HD domain. Crystallography data has shown that the LNR forms a tight 
protective packaging interface over the HD domain, preventing access of tumour 
necrosis factor-α converting enzyme (TACE/ADAM17) to the S2 cleavage site 
(Gordon et al., 2009; Gordon et al., 2007; Sanchez-Irizarry et al., 2004). Tight control 
of S2 cleavage is one of the key regulatory steps maintaining Notch in its quiescent 
state, and Notch alleles with a deletion of the LNR domain are constitutively active 
(Greenwald and Seydoux, 1990). The physical pulling force generated by endocytosis 
on the Notch extracellular region after ligand binding is thought to uncouple the LNR 
from its protective interaction with the HD, exposing the S2 site to cleavage by 
TACE, the so-called ‘lift-and-cut’ mechanism (Figure 1.3) (Gordon et al., 2008; 
Gordon et al., 2007).  
 
Critical to stability of the LNR-HD interface are three disulphide bonds formed across 
cysteine residues in the LNR. In D.melanogaster, disruption of these bonds actually 
inactivates Notch signalling by activation of the unfolded protein response after 
protein misfolding in the endoplasmic reticulum (ER), such that membrane-bound 
Notch is not expressed (Tien et al., 2008). Interestingly, chelation of calcium by 
EDTA in vitro, which depletes calcium ions from the LNR, disrupts its stability 
leading to S2 cleavage and activation, a tool that has proved useful for in vitro Notch 
activation experiments without the requirement for ligand activation (Krejci et al., 
2009; Rand et al., 2000).  
 
Once Notch has undergone S2 cleavage, S3 cleavage is triggered at a site just 
intracellular to the transmembrane portion of N(TM) by γ-secretase (GS) (Figure 1.2). 
This consists of a four enzyme complex comprised of presenilin, nicastrin, PEN2 and 
APH1 (Okochi et al., 2002). ICN is then free to translocate to the nucleus to bind the 
transcription factor CSL. 
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Figure 1.2 Notch is activated by three cleavage steps. In the Golgi, Notch is first 
cleaved in the HD domain by a furin-like convertase (S1 cleavage) and the HD domain held 
together by a non-covalent bond. On activation by ligand, the LNR domain is pulled from the 
HD, exposing the S2 cleavage site to proteolytic cleavage by TNFα-converting enzyme 
(TACE). This triggers S3 cleavage by the γ-secretase complex in the transmembrane domain, 
releasing ICN to translocate to the nucleus to bind CSL and activate a multitude of target 
genes, some of which are shown.      
 
 
1.6.2.2 Notch ligand binding affinity is regulated by glycosylation of Notch 
receptors 
Humans have five Notch ligands, JAGGED-1 and -2, and DLL-1, DLL-3 and DLL-4. 
These are single-pass type I proteins with a large extracellular domain containing up 
to 36 EGF-like tandem repeats. Receptor-ligand binding primarily involves the ligand 
EGF repeat interacting with EGF repeats 11-12 of NOTCH, with auxillary binding 
augmented by NOTCH EGF repeats 5-9 and 25-36 (Rebay et al., 1991; Xu et al., 
2005). The receptor-ligand interaction has been shown, through atomic microscopy 
studies and cell-bead optical tweezer assay, to be of remarkably high affinity, 
presumably to withstand the high physical forces produced during endocytosis, a 
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mechanism that is dependent on dynamin, epsins, and actin (Ahimou et al., 2004; 
Meloty-Kapella et al., 2012; Musse et al., 2012; Shergill et al., 2012).  
 
The affinity of the NOTCH-ligand interaction is regulated by modification of 
NOTCH by fucosylation (Stahl et al., 2008). O-fucosylation of EGF repeat 12 of 
NOTCH, the site of ligand binding, is first mediated by protein O-fucosyltransferase 
(POFUT-1) and then further fucose groups are added and extended by the Fringe 
family of fucosyltransferases, of which there are three family members in mammals: 
manic (MNFG), lunatic (LNFG) and radical (RNFG) fringe. D.melanogaster with 
mutant inactive O-fut (the orthologue of POFUT-1) have the classic phenotype seen 
with Notch haploinsufficiency and Pofut1 -/- mouse ES cells have absent downstream 
Notch activity, highlighting the importance of fucosylation to physiological Notch 
signalling (Stahl et al., 2008).  
 
As each of the different Notch ligands are individually capable of activating all four 
NOTCH receptors, O-fucosylation is thought to confer specificity through alterations 
in receptor-ligand affinity (Fitzgerald and Greenwald, 1995). This has been best 
established in the wing of D.melanogaster, where fringe-mediated O-fucosylation of 
Notch increases its affinity to Delta and decreases its affinity to Serrate (Haines and 
Irvine, 2003). Considering that humans have five ligands rather than the two seen in 
flies, and four Notch receptors rather than one, the role fucosylation plays in human 
Notch ligand-receptor affinity and specificity is likely to be more complex, especially 
as there are multiple other potential fucosylation sites in the EGF regions of both 
Notch and the ligands themselves that remain to be functionally tested.  
 
On ligand binding to one of the four Notch receptors with cell-to-cell contact, 
endocytosis is activated from the so-called ‘sending cell’ (the cell expressing ligand), 
followed by internalisation of the Notch-ligand complex into a clathrin-coated pit and 
degradation in the lysosome (Figure 1.3) (Emery and Knoblich, 2006). 
 54 
 
 
 
 
Figure 1.3 Notch is activated by ligand-binding and endocytosis. The ‘sending cell’ 
expresses a Notch ligand that binds to the EGF region of a Notch receptor of a neighbouring 
cell. Endocytosis mechanically pulls the LNR domain from the HD domain exposing the S2 
site to cleavage, resulting in release of intracellular Notch (ICN), which translocates to the 
nucleus. The ligand-Notch extracellular domain is then degraded by the lysosome in the 
sending cell (Emery and Knoblich, 2006). 
    
 
1.6.2.3 Structure/function of ICN 
The RAM and ANK domains of ICN (Figure 1.1) are directly involved in binding 
both CSL and the co-activator Mastermind-like-1 (MAML-1). The PEST domain is 
the negative-regulatory domain and contains a threonine at position 2512, which is the 
target of the E3 ubiquitin ligase F-Box WD40 repeat-7 (FBXW7). Once T2512 is 
phosphorylated by cyclin dependent kinase-8 (CDK8), FBXW7 is capable of binding 
to and degrading ICN by ubiquitination (Fryer et al., 2004). ICN constructs containing 
a deletion of either the TAD or ANK domains lose transactivation potential in vitro 
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and their oncogenic potential in vivo, but the RAM domain is dispensable for these 
functions (Aster et al., 2000). ANK repeat numbers 2-7 govern the transactivation 
potential of ICN; the difference in the amino acids of this domain in ICN-4, which are 
conserved in the other three NOTCH family members, is thought to explain its 
inability to transform murine HSCs to T-ALL (Aster et al., 2011). 
    
1.6.2.4 The ICN-CSL-MAML activation complex 
The transcription factor CSL binds motifs with the sequence (C/T)GTGGGAA in 
both promoter and enhancer regions. In the absence of Notch activation, it acts as a 
repressor of its target genes (Tun et al., 1994) and is bound by co-repressors that 
include nuclear receptor co-repressor-2 (NCOR2, also known as SMRT), MSX2 
interacting nuclear target (MINT) and corepressor interacting with RBPJ-1 (CIR-1). 
Rather than statically occupying target sites, as was originally thought, it is now 
believed to have a dynamic on-off interaction with DNA (Krejci and Bray, 2007).  On 
entering the nucleus, ICN binds CSL, dislocating co-repressors and recruiting 
MAML, to form an activation complex that, with the assistance of acetyltransferases 
such as p300, leads to transcription of target genes. Although the basic-helix-loop-
helix (bHLH) family of genes, such as hairy/enhancer of split (HES) and 
hairy/enhancer-of-split related with YRPW motif (HEY), are probably the best-
characterised of the Notch targets, over 150 direct target genes have been identified, 
the regulation of which are cell context dependent (Palomero et al., 2006; Wang et al., 
2011). In T-ALL, important direct targets of Notch signalling include c-Myc, the IL7 
receptor (IL7R), insulin-like growth factor receptor-1 (IGF1R), and cyclin D3 
(CCND3) (Figure 1.2) (Medyouf et al., 2011; Palomero et al., 2006; Wang et al., 
2011; Weng et al., 2006). How Notch target genes are regulated in a cell context 
specific manner is not well understood, but may relate to promoter methylation, 
occupancy of promoter regions and enhancers by other transcription factor 
complexes, and chromatin state.  
 
1.6.2.5 CSL structure 
CSL is highly conserved amongst species; human CSL has over 80% protein 
homology with D.melanogaster Su(H) and is highly homologous to the Rel family of 
transcription factors. CSL consists of three integrated domains – the N-terminal 
domain (NTD), a central β-trephoil domain (BTD) and a C-terminal domain (CTD) 
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(Figure 1.4). The association of CSL with MAML, ICN and DNA has been 
characterised by crystallography of the CSL-ICN-MAML activation complex (Nam et 
al., 2006; Wilson and Kovall, 2006). The RAM domain of ICN binds to a loop of the 
BTD of CSL, whilst the C-terminal portion of CSL forms a groove with the ICN 
ankyrin repeats (ANK), in which MAML sits. The CSL-ANK interaction is thought to 
be a weaker bond than the CSL-RAM interaction. DNA binding occurs through an 
electropositive domain formed by the NTD and BTD of CSL, which bind the major 
and minor grooves of DNA respectively. Paired CSL-binding sites in the Hes 
promoter that are separated by 15–22 base pairs and oriented in a head-to-head 
fashion are required for Notch-mediated transcriptional activity (Bailey and 
Posakony, 1995; Cave et al., 2005). Such head-to-head dimerisation of the CSL 
complex on promoters is also required for its oncogenic potential, since an ICN-1 
construct containing an R1985 mutation that inhibits CSL dimerisation cannot 
activate c-Myc or transform murine marrow (Liu et al., 2010).  
 
 
 
 
Figure 1.4 Structure of the CSL transcription factor. The N-terminal domain (NTD) 
of CSL and β-trephoil domain (BTD) bind the major and minor grooves of DNA respectively. 
The C-terminal domain (CTD) binds MAML and the RAM domain of ICN (Nam, et al 2006, 
Wilson and Kovall 2006). For details of the crystal structure, please see Figure 5.6 Page 
175. 
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1.6.2.6 Lateral inhibition and binary cell fate decisions 
In embryogenesis, binary cell fate decisions are regulated by Notch through lateral 
inhibition (Cabrera, 1990; Sternberg, 1988). This is the mechanism by which two 
equivalent neighbouring cells are prevented from adopting the same cell fate; one cell 
develops an active Notch signal (the so-called ‘receiving cell’) whilst the other down-
regulates its Notch activity but increases expression of ligand (the so-called ‘sending 
cell’). Initially, the two cells express equal amounts of Notch and ligand and, probably 
through a stochastic mechanism, one develops slightly higher Notch signal than the 
other. Notch activation increases the transcription of Hes, which in turn feeds back to 
increase Notch expression and decrease ligand expression, mediated by suppression 
of the acheate-scute complex (ASCL1 in humans), creating an amplification loop 
within the cell. Meanwhile, the sending cell receives little ligand stimulation from its 
neighbour, which decreases Hes, and leads to increased ligand expression and 
decreased Notch expression. The increased ligand expression in turn activates Notch 
in the receiving cell, and thus a feedback amplification loop is established in trans. 
This sequence has been demonstrated, for example, in invertebrate neurogenesis, 
where the cell with the highest Notch activity is destined to become epidermal, whilst 
its neighbour with low Notch activity becomes a neuroblast. If the latter cell is laser 
ablated at an early time point, the neighbouring cell destined to an epidermal fate, no 
longer receiving ligand stimulation, instead becomes a neuroblast itself (Doe and 
Goodman, 1985). 
 
Whilst binary cell fate decisions of this sort may suggest a cell is destined to only two 
potential outcomes, increasing and decreasing Notch expression iteratively as cells 
differentiate can lead to multiple outcomes (Figure 1.5)	  (Pourquie, 2003). Such 
iterative signalling has been well-described for the Notch pathway during somite 
formation in D.rerio and D.melanogaster, and a similar mechanism may be relevant 
to haematopoietic cell fate determinations (Jiang et al., 2000; Pourquie, 2003). For 
example, NOTCH-1 inhibits B-cell commitment at the common lymphoid progenitor 
stage, but is required for terminal differentiation of B-cells into antibody-secreting 
cells (Allman et al., 2002; Santos et al., 2007). The Notch pathway also displays 
oscillatory signalling during somitogenesis and neural stem cells development, with 
Hes-1 expression dynamically cycling between high and low levels over a period of 
hours before reaching levels critical for cell fate determination (Kageyama et al., 
2009; Shimojo et al., 2008).  
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Figure 1.5 Mechanism through which a temporal expression of a single gene can 
result in multiple different outcomes. Notch is involved in binary cell fate decisions 
in embryogenesis and haematopoietic differentiation. The example here shows 4 
different cellular outcomes (A1, A2, B1, B2) depending on the timing of Notch 
activation. Iterative signalling of this type is involved in somite formation and also 
likely to play a role in haematopoietic cell differentiation (Allman et al., 2002; Jiang 
et al., 2000; Pourquie, 2003). 
 
 
1.6.3 Germ-line mutations in the Notch pathway in humans 
In humans, germ-line mutations in the Notch pathway, either inherited or sporadically 
acquired, that lead to loss-of-function of Notch signalling cause a variety of 
syndromic diseases depending on the gene affected. These include: 
 
i)  Alagille syndrome 
  The autosomal dominant Alagille syndrome, caused by germ-line mutations 
(usually truncating) in the NOTCH ligand JAGGED-1, highlights the importance 
of Notch signalling in human embryonic development, with patients having a 
constellation of defects involving the heart, liver, vertebrae, eye and characteristic 
facial appearance (Krantz et al., 1997). Typical mutations described in JAGGED-1 
include P163L, R184H, and C714Y, which lead to abnormal folding of JAGGED-
1 protein in the ER, and absent expression on the cell surface (Tada et al., 2012). 
Although the stem cell compartment has not been tested in detail in these patients, 
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haematopoiesis is not affected as determined by measurement of normal blood 
parameters (Krantz et al., 1997).  
 
ii)  CADASIL syndrome 
  CADASIL syndrome (cerebral autosomal dominant arteriopathy with subcortical 
infarcts and leukoencephalopathy) is a disease affecting the small vessels of the 
brain characterised by early onset dementia, migraine, and transient ischaemic 
attacks or stroke, usually in the 4th/5th decade of life, and arises from mutations in 
the NOTCH-3 gene. The arteriopathy is in fact systemic and results from an 
accumulation of NOTCH-3 in the vascular smooth muscle, and thus can be 
diagnosed from NOTCH-3 immunostaining on a skin biopsy (Joutel et al., 2001). 
The majority of mutations described result in either the gain, or less frequently 
loss, of a cysteine residue in the NOTCH-3 EGF region, leading to an odd number 
of cysteines (Joutel et al., 1996). Recent evidence suggests this results in unpaired 
disulphide bonding between mutant and wild type (WT) NOTCH-3, leading to 
protein multimerisation and a dominant-negative affect on Notch signalling 
(Monet-Lepretre et al., 2009; Opherk et al., 2009).  
 
iii) Bicuspid aortic valve disease 
Heterozygous inactivating mutations in the EGF region of NOTCH-1 have been 
linked to bicuspid aortic valve disease in several kindreds, and the propensity to 
valve calcification in these families is thought to be due to loss of the osteogenic 
inhibitory signal normally conferred by NOTCH-1 in cardiac valves (Garg et al., 
2005; Nigam and Srivastava, 2009).  
 
iv) Spondylocostal dysostosis 
Loss-of-function mutations of a variety of genes in the Notch signalling pathway, 
delta-like-3 (DLL-3), mesoderm posterior-2 (MESP2), lunatic fringe (LFNG) and 
hairy enhancer of split-7 (HES-7), lead to spondylocostal dysostosis types 1 to 4 
respectively. These are inherited autosomal dominant disorders that are 
characterised by the presence of scoliosis, extensive hemivertebrae, truncal 
shortening and abnormally aligned ribs, with multiple bone fusions, and highlight 
the role of tightly regulated Notch signalling in normal bone development 
(Bulman et al., 2000; Sparrow et al., 2006; Sparrow et al., 2008).  
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1.7 The role of Notch in normal haematopoiesis 
Whilst much of the embryonic lethality of homozygous Notch-1 knockout mice can 
be explained by the widespread vascular defects, there is also an absence of definitive 
haematopoiesis, independent of the vascular abnormalities (Kumano et al., 2003; 
Kumano et al., 2001). Several groups have shown that the Notch pathway is required 
for the establishment of early embryonic haematopoietic stem cells and maintenance 
of haematopoietic stem cell self-renewal (Clements et al., 2011; Kumano et al., 2003; 
Kumano et al., 2001). 
 
1.7.1 Expression of Notch and its ligands in haematopoietic tissue 
All four NOTCH receptors are expressed in haematopoietic cells, although their 
expression pattern is dependent on the specific haematopoietic lineage and stage of 
differentiation (Kojika and Griffin, 2001). For instance, NOTCH-1 and NOTCH-2 are 
not expressed in erythroid precursors and have relatively low level expression in 
CD34+ cells, but are highly expressed in early myeloid cells and monocytes (Ohishi 
et al., 2003; Ohishi et al., 2000). Mast cells express NOTCH-2 and -3, and monocytes 
also express NOTCH-4 (Jonsson et al., 2001).  
 
Activation of the Notch pathway in haematopoietic cells is thought to be mediated by 
direct contact with bone marrow or thymic stroma, or through cell-to-cell contact with 
neighbouring haematopoietic cells that express ligand. Bone marrow stromal cells 
predominantly express JAGGED-1, whilst thymic stromal cells also express 
JAGGED-2 and DLL-1, with the latter thought to be most important in determining 
T-lymphocyte lineage commitment (see below) (Anderson et al., 2001). Notch ligands 
are also expressed on haematopoietic cells, although, similar to the Notch receptors, 
expression patterns are dependent on cell type. JAGGED-1 is expressed on human 
CD34+ cells, megakaryocytes, and mast cells, JAGGED-2 on CD34+ cells. Thus 
there is a complex bidirectional cell-to-cell interplay between the various Notch 
receptors and their ligands in haematopoietic tissue, the subtleties of which are not yet 
fully understood. The density and ratio of Notch ligands and their receptors is likely 
to play an important role in cell fate specification and self-renewal signals imparted 
through Notch signalling (Delaney et al., 2005; Varnum-Finney et al., 2003).  
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1.7.2 Notch and haematopoietic lineage commitment 
Just as it plays a vital role in cell fate determination of a wide variety of developing 
embryonic tissue, Notch is also a key regulator of haematopoietic cell fate 
commitment. In mice, Notch-1 has a non-redundant role in committing early 
lymphoid progenitors towards a T-cell fate, and conditional Notch-1 knockout mice 
have thymic hypoplasia and a complete absence of T-cells (Radtke et al., 2004). ETP 
cells originate from CLPs, and in the thymus differentiate through the double-negative 
(DN) stage (in mice, DN stages 1-4 are characterised by the expression of CD44 and 
CD25) to become double positive (DP) cells expressing both CD4 and CD8, before 
their release into the circulation as single positive (SP) CD4+ or CD8+ T-cells (Dadi 
et al., 2009; Krangel, 2009). Progression of T-cell committed lymphoid progenitors 
through to the double-negative (DN3) stage of lymphocyte development is Notch-1 
dependent (De et al., 2002; Pui et al., 1999). In early T-cells, the Notch-CSL 
activation complex directly activates pre-T-cell receptor-alpha (pTα) through binding 
to its promoter region, which leads to formation of the pre-T-cell receptor complex. 
However, once through the β selection checkpoint at the DN3b stage, there is 
downregulation of Notch-1 and terminal T-cell differentiation can occur in the 
absence of Notch-1 (Taghon et al., 2006; Witt et al., 2003). When Notch-1 was 
constitutively over-expressed by reconstituting lethally-irradiated mice with CD34+ 
cells transduced with a vector expressing ICN-1, there was a reduction in B-cells 
numbers, a marked increase in T-cells, thymic hyperplasia, and eventual development 
of an aggressive fatal T-cell leukaemia (Pear et al., 1996). Enforced expression of 
Notch-1 at and after the time of VDJ recombination, when signalling is normally on 
the decline, is thought to be when Notch confers its leukaemogenicity (Roy et al., 
2007). The oncogenic role of Notch-1 in T-cells is discussed in more detail in Chapter 
3.  
 
NOTCH-2 enhances mast cell differentiation from CD34+ cells and also regulates 
marginal zone B-cell development, such that Notch-2 haploinsufficient mice have a 
severe deficiency in marginal zone B-cell development in the spleen (Sakata-
Yanagimoto et al., 2008; Witt et al., 2003). NOTCH-4 has recently been shown, both 
in vitro and in vivo, to be an important positive regulator of megakaryocyte lineage 
commitment, in part through an interaction with DLL-1 (Mercher et al., 2008). 
Umbilical cord blood-derived CD34+ cells undergo erythroid differentiation when co-
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cultured with a stromal cell line expressing DLL-4 (Sugimoto et al., 2006). DLL-1, 
but not JAGGED-1, completely inhibits the differentiation of human CD34+ cells into 
B-cells, while promoting their development into T/NK precursor cells (Jaleco et al., 
2001).  
 
1.7.3 Notch and myeloid differentiation 
There is still much controversy as to the role Notch signalling plays in myeloid 
differentiation. Conditional knock-out of Notch-1 or CSL in bone marrow cells in vivo 
has been shown to have no effect on the myeloid lineage (Han et al., 2002). 
Additionally, overexpression of ICN-1 in bone marrow only affected lymphoid 
lineage commitment in vivo, with no apparent effect on myelopoiesis (Pui et al., 
1999). In vitro experiments have shown conflicting results, with much of the 
published data using the murine 32D cell line. Two groups have shown that 32D cells, 
when either transduced with ICN-1 or cultured on JAGGED-1 expressing stroma, 
have accelerated and increased granulocytic differentiation in response to G-CSF 
resulting from the up-regulation of Pu.1 by ICN-1 (Schroeder and Just, 2000; Tan-
Pertel et al., 2000). Conversely, several independent groups have found that 
expression of ICN-1 in 32D cells markedly inhibited myeloid differentiation, and was 
associated with sustained levels of GATA-2 (Bigas et al., 1998; Kumano et al., 2001; 
Milner et al., 1996; Tan-Pertel et al., 2000). This latter data is supported by the 
finding that umbilical cord blood-derived CD34+ cells exhibited a significant delay 
and inhibition in myeloid differentiation when cultured on JAGGED-2 expressing 
stroma, or when transduced with ICN-1 (Carlesso et al., 1999). Whilst one possibility 
for the conflicting data may relate to the propensity for 32D cell subclones to become 
aneuploid, altering their phenotype, it is likely that even small changes in the 
expression levels of ICN between experiments can have a significant impact on 
cellular phenotype. An elegant example of this was reported by Bernstein’s group 
where they showed that human CD34+CD38- cord blood progenitors co-cultured with 
stroma expressing low densities of DLL-1 generated higher numbers of CD34+ cells 
and promoted early myeloid and lymphoid differentiation, but high density DLL-1 
expression on stroma impaired myeloid differentiation and induced apoptosis of 
CD34+ cells (Delaney et al., 2005).  
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A further complexity is the possibility that NOTCH-1 may affect myeloid 
differentiation in a non-cell-autonomous manner. For example, Kawamata and 
colleagues noticed that when mice were transplanted with ICN-1-transduced 
haematopoietic cells, the neighbouring non-transduced population of marrow cells 
had increased numbers of terminally differentiated myeloid cells (Kawamata et al., 
2002). This was not a result of direct cell-to-cell interaction, since conditioned 
medium from ex vivo cultures of ICN-1-transduced bone marrow significantly 
promoted myeloid maturation of normal marrow cultures. 
 
Post-translational modifications of Notch may also be important to myelopoiesis. 
Fucosylation of the EGF repeats of Notch receptors markedly enhances their affinity 
for ligand binding. The FX–/– mouse, which is deficient in the FX protein that converts 
GDP-mannose to GDP-fucose in the de novo fucose synthesis pathway, develops a 
marked neutrophilia (Zhou et al., 2008). Whereas activation of Notch signalling of 
wild-type murine marrow by co-culture with OP9 stromal cells expressing either Dll-
1, Dll-4, Jagged-1, or Jagged-2 receptors impaired terminal myeloid differentiation, 
ligand activation of FX–/– marrow exhibited no inhibition on myelopoiesis, suggesting 
that suppression of myelopoiesis by Notch is fucosylation-dependent (Zhou et al., 
2008). The authors therefore hypothesised that the marked neutrophilia and marrow 
myeloid hypoplasia seen in FX–/– mice is mediated through loss of Notch-mediated 
repression on myeloid differentiation. 
 
1.7.4 Notch and the stem cell niche  
As long as ago as the 1970s, it was appreciated that higher numbers of HSCs reside 
nearest the bony surface of the marrow architecture and that as haematopoietic cells 
undergo differentiation, they move further from the endosteal surface of bone (Lord et 
al., 1975). In fact, the number of cells with colony forming potential obeys a negative 
linear relationship with the square of the distance from the endosteal surface (Lord et 
al., 1975). It has also been hypothesised for some time that HSC numbers are 
integrally related to signals received through direct cell-to-cell contact of HSCs and 
osteoblasts (Gong, 1978). More recently, using a mouse transgenic for a constitutively 
activated parathyroid hormone receptor (PTHr), David Scadden’s group have 
elegantly shown that osteoblasts directly interact with and regulate HSCs (Calvi et al., 
2003). These transgenic mice had an increased density of trabecular bone, higher 
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numbers of osteoblasts and more HSCs. The authors showed that this relationship was 
mediated by the interaction of Jagged-1 expressed on osteoblasts binding to and 
activating Notch-1 on HSCs; inhibiting this interaction abrogated the increased 
numbers of HSCs seen in the transgenic mice. As a consequence of this work, trials 
are underway using synthetic PTH in humans to enhance HSC numbers prior to 
collection of stem cells for autologous transplantation (Ballen et al., 2007).   
 
1.7.5 Notch and self-renewal of HSCs  
Stem cells are characterised by their ability to self-renew whilst maintaining multi-
lineage potential, and it has been shown through a variety of approaches that up-
regulation of Notch signalling can expand HSC numbers without leading to lineage 
commitment and differentiation. For instance, co-culture of HSCs with a stromal layer 
expressing Jagged-1 increased the number of primitive CD34+ CD38- cells and 
enhanced their repopulating capacity when transplanted into lethally irradiated 
NOD/SCID mice (Karanu et al., 2000; Varnum-Finney et al., 1998; Varnum-Finney 
et al., 2000). Similar data was obtained when HSCs were co-cultured with a stromal 
layer expressing Dll-1, although as discussed above, ligand density was a critical 
factor in determining self-renewal capacity, with low density expression promoting an 
increase in HSC numbers, and high density expression diminishing their numbers 
through the induction of apoptosis (Delaney et al., 2005; Varnum-Finney et al., 2003).  
 
The utilisation of umbilical cord blood stem cells for bone marrow transplantation is 
often limited by inadequate numbers of HSCs, particularly for adult recipients. Thus, 
co-culture techniques capable of expanding HSC numbers without initiating a 
differentiation programme have genuine therapeutic potential. To this end, the 
Bernstein group, that have pioneered much of the initial work, established a Phase I 
trial whereby one unmanipulated cord blood unit and one cord blood unit expanded 
on stroma expressing DLL-1 were infused concurrently into a myeloablated patient 
(Dahlberg et al., 2011; Delaney et al., 2010). After co-culture with the stroma, there 
was an average 40-fold increase (range 4 to 140) in the number of CD34+ cells. For 
the thirty-two patients that have thus far been recruited, there has been rapid 
engraftment of the manipulated cord blood unit, with a median time to neutrophil and 
platelet engraftment of 15 days (range 9-42) and 40 (range 13-62) days respectively. 
Such an approach could thus potentially significantly shorten the dangerous 
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neutropenic period seen with cord blood transplantation and enable the inclusion of 
patients previously deemed unsuitable on the basis of inadequate numbers of donor 
cells for their body weight. Whether this affects long-term outcome and rates of graft-
versus-host disease (a potential issue from increased T-cell numbers), awaits to be 
determined.  
 
1.8 Aims of this thesis 
At the time the work presented in this thesis was started, NOTCH-1 mutations had not 
been described in adult T-ALL and could potentially account for the difference in 
prognosis between adult and paediatric patients. The incidence and characteristics of 
NOTCH-1 mutations were therefore investigated in a cohort of adult T-ALL patients 
and these results are presented in Chapter 3. To address the prognostic implications of 
NOTCH-1 and FBXW7 mutations in adult T-ALL, the clinical outcome of patients 
treated on the E2993/UKALLXII trial was evaluated according to mutation status 
(Chapter 3). Alternative mechanisms of Notch pathway activation in T-ALL were 
explored through mutational screening of NOTCH-3 as well as the LNR domain of 
NOTCH-1. Because AML patients often co-express T-cell antigens and the role of 
NOTCH-1 signalling in myeloid cells is unclear, NOTCH-1 mutational status was also 
investigated in this disease (Chapter 3). The timing at which NOTCH-1 mutations 
occur in T-ALL was studied, specifically addressing whether they occur as disease 
initiators or as secondary events (Chapter 4). Finally, as NOTCH-1 mutations were 
not detected in AML, expression of the downstream transcription factor CSL was 
investigated and the prognostic and functional significance of an alternatively spliced 
isoform, identified in a significant proportion of AML patients, were studied (Chapter 
5). 
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CHAPTER 2. MATERIALS AND METHODS 
 
Specific materials and methods are described in the relevant results chapters.  
 
2.1 Cell culture 
Unless otherwise specified, suspension cells were grown in RPMI-1640 medium with L-
glutamine supplemented with 10% foetal calf serum (FCS) and penicillin-streptomycin 
(used at 100 units/ml and 100 µg/ml respectively) in a humidified incubator with 5% 
CO2 at 37°C. Adherent cells were grown in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% FCS and penicillin-streptomycin under the same 
conditions. All cell lines used were growth factor independent. Specific techniques used 
for the isolation and culture of primary CD34+ cells is given in the methods of chapter 5. 
 
2.1.1 Cell lines 
• ALL-SIL - human T-cell acute lymphoblastic leukaemia, non-adherent 
• HEK-293T - human embryonal kidney line, adherent 
• HeLa – human cervical carcinoma, adherent 
• HL-60 - human acute myelocytic leukaemia, non-adherent 
• Jurkat - human T-cell acute lymphoblastic leukaemia, non-adherent 
• KG-1 - human erythroleukaemia, non-adherent 
• Monomacs-6 - human mature monocytic cell line, non-adherent 
• NALM-6 - human B-cell acute lymphoblastic leukaemia, non-adherent 
• NB-4 - human acute promyelocytic leukaemia, non-adherent 
• RAJI - human Burkitt’s lymphoma, non-adherent  
• SEM - human B-cell acute lymphoblastic leukaemia, non-adherent 
• THP-1 - human acute monocytic leukaemia, non-adherent 
• U2OS - human osteosarcoma, adherent 
• U937 - human histiocytic lymphoma, non-adherent 
 
2.1.2 General cell culture reagents 
• Dimethyl sulfoxide (DMSO) (Sigma Aldrich, Poole, UK) 
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• Dulbecco’s Modified Eagle Medium (DMEM) – high glucose 4.5g/l with L-
glutamine (Invitrogen, Paisley, UK) 
• Ficoll-Paque™ gradient (Amersham Biosciences, Bucks, UK) 
• Flow Check Fluorospheres (Beckman Coulter, High Wycombe, UK) 
• Foetal calf serum (FCS) (Sigma Aldrich, Poole, UK), heat inactivated for 30 minutes 
at 56°C and filtered through 0.44micron filter (PAA Laboratories, Pasching, Austria) 
• Intracellular flow kit (BD Bisocience Ltd.) 
• MACS® Cell Separation Columns and Reagents (Miltenyi Biotec, Germany) 
• Methocult™ (Stem Cell Technologies, Vancouver, Canada) 
• Penicillin-Streptomycin containing 10,000 units/ml penicillin and 10,000 µg/ml 
streptomycin, used at 100 units/ml and 100 µg/ml respectively (Sigma Aldrich, 
Poole, UK) 
• Phosphate buffered solution (PBS) (Invitrogen, Paisley, UK) 
• Polyethylenimine (PEI) (Sigma Aldrich, Poole, UK) 
• Polybrene (Sigma Aldrich, Poole, UK) 
• RPMI-1640 medium with L-glutamine (Invitrogen, Paisley, UK) 
• StemPro-34 with nutrients (Invitrogen, Paisley, UK) 
• Trypsin-EDTA (0.25%) (Invitrogen, Paisley, UK) 
 
2.1.3 Cell culture plastics 
• T25, T75 and T175 flasks (VWR International, Merck, UK) 
• 100mm and 145mm tissue culture dishes (Greiner Bio-One Ltd, Stonehouse, UK) 
• 6, 12, 24 and 48 well tissue culture plates (Nalge Nunc, Rochester, NY, USA) 
• 1.8ml cryovials (VWR International, Merck, UK) 
 
2.1.4 Active compounds used in cell culture 
• L-685,458  Potent selective gamma secretase inhibitor (GSI) (Sigma Aldrich, Poole, 
UK) 
 
2.1.5 Antibodies 
• Mouse anti-human CD11b antibody conjugated to allophycocyanin (APC) (Miltenyi 
Biotec, Germany)  
• Mouse anti-human CD34 antibody conjugated to APC (BD Biosciences) 
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• CD34 microbead kit for isolation of human CD34+ haematopoietic cells (Miltenyi 
Biotec, Germany) 
• Rat anti-human RBP-JK antibody (polyclonal clone SIM-2ZRBP3, T6719) 
(Cosmobio, Japan)   
• Mouse anti-human Notch-1 antibody, specific to cleaved Notch-1 (monoclonal clone 
mN1A, N-6786) (Sigma Aldrich, Poole, UK)  
• Mouse anti-FLAG M2 antibody, monoclonal (Sigma Aldrich, Poole, UK) 
• Goat anti-rabbit IgG antibody conjugated to horseradish peroxidase (HRP) (Cell 
Signaling Technology, Hitchin, UK)  
• Goat anti-mouse IgG antibody conjugated to HRP (Cell Signaling Technology, 
Hitchin, UK) 
• Goat anti-rat IgG antibody conjugated to HRP (Cell Signaling Technology, Hitchin, 
UK) 
 
2.1.6 Recombinant growth factors 
• Human FLT3-ligand (PeproTech, London, UK) 
• Human granulocyte colony-stimulating factor (G-CSF) (PeproTech, London, 
UK)  
• Human granulocyte macrophage colony-stimulating factor (GM-CSF) 
(PeproTech, London, UK)  
• Human erythropoietin (PeproTech, London, UK) 
• Human interleukin-3 (IL-3) (PeproTech, London, UK)  
• Human stem cell factor (SCF) (PeproTech, London, UK)  
• Human thrombopoietin (TPO) (PeproTech, London, UK) 
 
2.1.7 Cell cryopreservation 
A total of 2x106 cells were frozen slowly in 1ml freeze mix consisting of 10% DMSO, 
50% FCS and 40% RPMI-1640 medium, and stored in liquid nitrogen. When required, 
cells were thawed in a 37°C waterbath, then 10mls pre-warmed medium added dropwise 
to completely resuspend them. They were then centrifuged at 300g for 5 minutes at room 
temperature, the supernatant removed and replaced with fresh medium.  
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2.2 Lentivirus production 
 
2.2.1 Production of lentivirus 
A total of 1x107 HEK-293T cells were suspended in 20mls DMEM/10% FCS in a 
14.5cm plate, and transfected the following day when the cells were 70-80% confluent. 
For each plate, 40µg of the vector plasmid was added to 5mls serum-free DMEM, 
together with 10µg envelope plasmid VSVG-pMD.G2 and 30µg pCMV-deltaRp8.91, 
which codes for the helper and packaging plasmids, and filtered through a 0.2µm filter. 
One µl of 10 mM polyethylenimine (PEI, Sigma 40, 872-7) was added to 5mls serum-
free DMEM per plate and filtered through a 0.2µm filter. The DNA and PEI solutions 
were mixed and left at room temperature for 20 minutes. After the cells were checked for 
confluence, the medium was removed and the cells were washed with PBS to remove 
FCS, and then 10mls of the DNA and PEI mixture was carefully added. The cells were 
incubated at 37oC in 5% CO2 for 4 hours, then the medium was replaced with 
DMEM/10% FCS. Incubation was continued for a further 48 hours, then the supernatant 
was harvested. The supernatant was filtered through a 0.4µm filter to remove cell debris, 
transferred to polyallomer centrifuge tubes and centrifuged at 50,000g for 90 minutes at 
4oC. The supernatant was decanted off and 50µl Stempro medium (Invitrogen) added to 
the viral pellet, which was resuspended by pipetting up and down, and left on ice for 1 
hour. The mix was transferred to an Eppendorf tube and centrifuged for 10 minutes at 
600g at 4oC to remove cell debris. The viral supernatant was aliquoted into cryovials and 
stored at -80oC until required. 
 
2.2.2 Biological titre of lentiviral supernatants 
HeLa cells were plated at a concentration of 5 x 104 cells per well in 1.5mls DMEM/10% 
FCS in a 12 well plate. The cells were incubated at 37oC in 5% CO2 for 4 hours, 
allowing time for them to adhere to the plate but not divide, thus keeping cell numbers 
constant. To create dilutions of the viral supernatant prepared above, 30ml supernatant 
was added to 1.47mls serum-free DMEM to make a starting dilution of 1:50. A total of 
0.15mls was taken from this dilution and added to 1.35mls serum-free DMEM. This was 
repeated to prepare serial 1 in 10 dilutions of the supernatant to create six dilutions 
between 1:50 and 1:500,000. Cells were incubated for 48 hours at 37oC in 5% CO2 
before the percentage of GFP positive cells was measured by flow cytometry.  
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The estimated titre of the virus was determined as below: 
 
Viral titre = % GFP positive cells x 50,000 (cell number) x virus dilution factor  
 
 
 
2.3 Molecular biology 
 
2.3.1 Reagents for molecular biology, cloning and plasmid generation 
• Acetonitrile (VWR International Ltd, Lutterworth, UK) 
• Agar (Calbiochem, UK) 
• Agarose (Bioline, London, UK) 
• BIOTAQ DNA polymerase (Bioline, London, UK) 
• Bioline buffer and magnesium chloride (Bioline, London, UK) 
• Carbenicillin (Invitrogen, Paisley, UK) 
• Chloroform (VWR International Ltd, Lutterworth, UK) 
• Diethylpyrocarbonate (DEPC) treated water (Invitrogen, Paisley, UK) 
• DH5α competent bacteria (Invitrogen, Paisley, UK) 
• DNA size standard kit – 400bp or 600bp (Beckman Coulter UK Ltd., 
Buckinghamshire, UK) 
• dNTPs (Bioline, London, UK) 
• DTAB (dodecyl-trimethyl ammonium bromide) (Sigma Aldrich, Poole, UK) 
• DTCS Quick Start kit (Beckman Coulter UK Ltd., Buckinghamshire, UK) 
• EDTA (ethylenediaminetetraacetic acid, disodium salt) (Sigma Aldrich, Poole, 
UK) 
• Ethanol 100% (VWR International Ltd, Lutterworth, UK) 
• Ethidium Bromide (Invitrogen, Paisley, UK) 
• Glycerol (VWR International Ltd, Lutterworth, UK) 
• HEPES (Sigma Aldrich, Poole, UK) 
• Isopropanol (VWR International Ltd, Lutterworth, UK) 
• Isopropyl β-D-1-thiogalactopyranoside (IPTG) (Sigma Aldrich, Poole, UK) 
• Luria-Bertani (LB) broth (Anachem, Luton, UK) 
• Optimase proof-reading Taq polymerase (Transgenomic, Glasgow, UK) 
• Optimase buffer and magnesium sulphate (Transgenomic, Glasgow, UK) 
• Orthoboric acid (VWR International Ltd, Lutterworth, UK) 
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• Plasmid Mini and Mega prep kits (Qiagen, Crawley, UK) 
• Oligonucleotide primers (Sigma Aldrich, Poole, UK) 
• Promega Dual Luciferase Kit (Promega, Southampton, UK) 
• QIAquick Gel Extraction Kit (Qiagen, Crawley, West Sussex, UK) 
• QIAquick PCR Purification kit (Qiagen, Crawley, UK) 
• Quick Ligase kit (New England Biolabs, Hitchin, UK)     
• Restriction enzymes (New England Biolabs, Hitchin, UK) 
• Reverse transcriptase Superscript III kit (Invitrogen, Paisley, UK) 
• Sodium dodecyl sulfate (SDS) (Sigma Aldrich, Poole, UK) 
• S.O.C. media (Super Optimal broth with Catabolite repression) (Invitrogen, Paisley, 
UK) 
• Sodium acetate (VWR International Ltd, Lutterworth, UK) 
• TOPO cloning kit (Invitrogen, Paisley, UK) 
• TOP10F competent bacteria (Invitrogen, Paisley, UK) 
• Triethylammonium acetate (TEAA) (Transgenomic, Glasgow, UK) 
• Trizol reagent (Invitrogen, Paisley, UK) 
• X-gal (Invitrogen, Paisley, UK) 
 
2.3.2 DNA extraction 
Cells were resuspended at 10x106/ml in PBS and 2 volumes of DTAB solution (8% 
DTAB, 1.5M NaCl, 100mM Tris pH 8.0, 50mM EDTA pH 8.0) were added. The sample 
was thoroughly mixed and incubated at 68°C for 5 minutes. An equal volume of 
chloroform was added and the sample was mixed by end-over-end inversion for several 
minutes then centrifuged at 2000g for 10 minutes. To precipitate the DNA, the upper 
DNA-containing layer was removed and mixed with an equal volume of 100% ethanol. 
The precipitated DNA was then either removed with a pipette tip, if visible in solution, 
or centrifuged at 2000g for 10 minutes to form a pellet. The supernatant was removed 
and the precipitated DNA washed twice with 500µl 70% ethanol, resuspended in double 
distilled water (DDW) and stored at 4oC.  
 
2.3.3 RNA extraction 
RNA extraction was carried out using the Trizol reagent. Between 1x106 and 5x106 cells 
were pelleted by centrifugation at 300g for 5 minutes, mixed with 1ml Trizol, vortexed 
to completely lyse the cells and then left at room temperature for 10 minutes. The sample 
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was then frozen at -20°C and further processing carried out in batches. After thawing, 
200µl chloroform was added, the sample mixed thoroughly and centrifuged at 12,000g 
for 15 minutes at 4°C. The upper aqueous layer containing RNA was decanted off into a 
fresh tube and 500µl isopropanol added. The tube was incubated at room temperature for 
10 minutes then centrifuged at 12,000g for 10 minutes at 4°C. The RNA pellet was then 
washed in 1ml 75% ethanol, centrifuged at 7,500g for 5 minutes, air dried and 
resuspended in DEPC-treated water. 
 
2.3.4 Reverse transcription of RNA 
Reverse transcription of RNA was performed using the Superscript III kit according to 
the manufacturer’s recommendations (Invitrogen). A reaction mix containing 10µl 
reverse transcriptase reaction mix (which includes 2.5µM oligo(dT), 2.5ng/µl random 
hexamers, 10mM MgCl2, and 2.5µM dNTPs), 2µl reverse transcription enzyme and 
500ng RNA, 1µl RNAse inhibitor, made up to 20µl with DEPC-treated water. On a PCR 
thermocycler, the sample was incubated at 25ºC for 10 minutes, 50ºC for 30 minutes and 
85ºC for 5 minutes, and then kept at 4ºC for 5 minutes. To remove residual RNA 
template, 1µl (2U) E.coli RNase H was added and the sample incubated at 37ºC for 20 
minutes. The cDNA was stored at -20ºC until use. 
 
2.3.5 Polymerase chain reaction (PCR) 
For general PCR reactions, the non-proof reading enzyme BIOTAQ DNA polymerase 
(Bioline) was used. BIOTAQ DNA polymerase, Bioline buffer and magnesium chloride 
were used according to the manufacturer’s recommendations. In order to amplify PCR 
products for DHPLC analysis, the proofreading Taq polymerase Optimase 
(Transgenomic) was used. This reagent has a low base substitution error rate due its 3’ to 
5’ exonuclease activity and in general creates DHPLC chromatograms of superior quality 
to non-proof reading Taq polymerase. Optimase Taq polymerase, Optimase buffer and 
magnesium sulphate was used according to the manufacturer’s recommendations. On the 
occasion when PCR products of adequate quality could not be obtained for DHPLC with 
Optimase, BIOTAQ DNA polymerase (Bioline) was used and is stated in the appropriate 
methods section. For both reagents, forward and reverse primers were used at 500nM, 
each dNTP at 200µM and a total of 100ng DNA template in a 20µl PCR reaction. For 
PCR reactions from cDNA, 2µl of cDNA (diluted 1 in 5 from the original 20µl RT 
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reaction) was used in the reaction. PCR conditions included an initial denaturation step at 
95oC (1 minute for BIOTAQ and 5 minutes for Optimase Taq) followed by successive 
cycles of denaturation (95oC, 45 seconds), primer annealing (30 seconds) and extension 
(72oC, time calculated according to PCR product size at 1kb per minute) for a total of 35 
cycles, followed by a final 5 minute extension at 72oC. Specific annealing temperatures 
are stated in the appropriate methods section. 
 
2.3.6 Agarose gel electrophoresis 
TBE (10x):108g Tris base, 55g Boric acid, 9.3g EDTA, made up to 1l with DDW.  
Gel loading buffer: 3.9mls glycerol, 500µl 10% SDS, 25mg bromophenol blue, made up 
to 10mls with DDW.   
 
Agarose gel electrophoresis was used to separate and visualise PCR products or plasmid 
DNA according to size. Agarose gel was made up to between 1%-2.5% weight/volume 
(depending on the anticipated size of the PCR products) in 35mls 1xTBE, melted in a 
microwave oven, then cooled before the addition of ethidium bromide (100ng/ml final 
concentration). PCR products were mixed with loading buffer and then run out in a 
horizontal submarine gel electrophoresis tank in 1xTBE at 70mA for 20-30 minutes. 
Products were visualised and photographed under UV light.  
 
2.3.7 DNA Sequencing protocol 
When screening for mutations, PCR products were sequenced from both the forward and 
reverse primers. PCR products were generated using BioTaq PCR, analysed by gel 
electrophoresis to ensure the correct size band was present, and then purified using the 
QIAquick PCR purification kit (Qiagen). The DNA concentration was determined using 
a Nanodrop spectrophotometer. The sequencing reaction was then performed using the 
CEQ™ DTCS Quick Start kit (Beckman Coulter) with 4µl mastermix, 20ng PCR 
product, and 3.2pmols oligonucleotide primer, made up to 10µl with DDW. The cycling 
parameters were 96°C for 20 seconds, 50°C for 20 seconds and 60°C for 4 minutes, 
repeated for 25 cycles. In order to adequately remove secondary structure of the 
template, an initial 2 minute denaturation step at 95oC was performed when sequencing 
plasmids, and either 200ng plasmid DNA or 1µl of a bacterial culture was used in each 
10µl reaction. The reaction products were precipitated by mixing with 0.4µl 500mM 
EDTA, 2µl 3M sodium acetate pH 5.2, 1µl 20ng/µl glycogen and 60µl 95% ethanol, and 
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then pelleted by centrifugation at 14,000g for 15 minutes. The pellet was washed twice 
in 200µl 75% ethanol, centrifuged at 12,000g, the supernatant removed, and allowed to 
air dry prior to resuspension in 38µl sample loading solution.  The sample was then run 
on a CEQ™8000 Beckman Coulter DNA Genetic Analysis System. 
 
2.3.8 TOPO cloning  
PCR products prepared using BIOTAQ DNA polymerase were cloned using a TOPO kit 
(Invitrogen). The principle of this technique is that the A overhangs of the PCR product 
that are added by non-proof reading DNA polymerases are ligated into the T overhang of 
the TOPO vector. The ligation was performed according to the manufacturer’s 
instructions and then used to transform TOP10F competent bacteria (Invitrogen). Here, 
2µl TOPO reaction mix was incubated with 50µl TOP10F competent bacteria 
(Invitrogen) on ice for 30 minutes and then the bacteria were heat-shocked at 42°C for 30 
seconds. SOC media (200µl) was then added, and the sample left on a shaker at 37°C for 
1 hour. Agar plates containing 100µg/ml ampicillin and spread prior to use with 40µl 
100mM IPTG and 40µl 40mg/ml X-gal were pre-warmed at 37°C for 30 minutes, spread 
with 100µl of the SOC/ bacterial culture, and left at 37°C overnight in a bacterial 
incubator. Blue colonies contain no insert, but white colonies, containing the PCR 
product, were then picked with a sterile pipette tip and inoculated into 200µl LB medium 
containing ampicillin and left at 37°C for 12-24 hours in a bacterial incubator. For 
sequencing, 1µl of the culture was added directly to the sequencing reaction (see section 
2.3.7).  
 
2.3.9 Plasmid preparation 
Cloning reactions into retroviral and lentiviral vectors are described in the methods 
section of chapter 5. For bacterial transformations, 5-20ng plasmid DNA was incubated 
with 25µl DH5α competent bacteria (Invitrogen), left on ice for 30 minutes and then 
heat-shocked at 42°C for 30 seconds. SOC media (200µl) was then added, and the 
sample left on a shaker for 1 hour at 37°C. Agar plates containing 100µg/ml ampicillin 
were pre-warmed at 37°C for 30 minutes, spread with 100µl of the SOC/ bacterial 
culture, and left at 37°C overnight in a bacterial incubator. One colony was then picked 
with a sterile pipette tip, inoculated into 7ml LB medium containing 100µg/ml ampicillin 
and left at 37°C shaking at 200 rpm for 16 hours in a bacterial incubator. Glycerol stocks 
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were then made from the culture by mixing 500µl bacterial culture with 500µl 50% 
sterile glycerol, and frozen at -80°C. The remaining culture was used to make plasmid 
DNA using a Mini Prep kit (Qiagen) according to the manufacturer’s instructions. The 
plasmid DNA was then sequenced using appropriate primers to cover the entire open 
reading frame of the cloned gene to exclude Taq errors. The glycerol stock (50µl) was 
used to inoculate a 500ml culture of LB containing 100µg/ml ampicillin, and left at 37°C 
shaking at 200 rpm for 16 hours in a bacterial incubator. The culture was then 
centrifuged at 6000g to pellet the bacteria, and plasmid DNA purified using a Maxi Prep 
kit (Qiagen) according to the manufacturer’s instructions. Plasmid DNA concentration 
was quantified using a Nanodrop spectrophotometer.  
 
2.3.10 Denaturing High Performance Liquid Chromatography (DHPLC) using 
WAVE  analysis 
For mutation detection, PCR products were analysed by DHPLC using the WAVE  
DNA Fragment Analysis System (Transgenomic). The WAVE  system contains a 
DNASep column consisting of packed hydrophobic poly(styrene-divinylbenzene) beads 
to which the anionic DNA binds in the presence of the ion pairing reagent 
triethylammonium acetate (TEAA). Under increasing concentrations of acetonitrile, the 
ionic bond between the beads and PCR product gradually weakens until the DNA elutes 
off the column, as detected by UV absorbance. 
 
PCR products containing a mutation or single nucleotide polymorphism (SNP) will form 
heteroduplexes after denaturation and cooling. A heteroduplex consists of one wild-type 
strand annealed to a complementary mutant strand, leading to the formation of a ‘bulge’ 
or mismatch at the position of the substitution (Figure 2.1). Such heteroduplexes are 
inherently less stable than their homoduplex counterparts, will denature more easily at a 
given temperature and acetonitrile concentration, and consequently will elute from the 
HPLC column first. Thus, whilst a wild-type PCR product (all homoduplexes) will elute 
as a single peak, a PCR product from a sample with a heterozygous substitution will  
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Figure 2.1 The principle of DHPLC analysis. A schematic showing the four possible 
combinations of a PCR product with a heterozygous A to G mutation after denaturation and 
slow cooling. (A) Heteroduplexes are more unstable than homoduplexes and elute earlier 
from the column, whilst homoduplexes are retained longer. (B) The wild-type control 
homoduplex elutes as a single peak. 
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Figure 2.2 Example of a melting profile of a PCR product (A) A typical melting profile 
for a PCR fragment as analysed by WAVEMAKER software which takes into account the size 
of the PCR product and GC content. On the Y-axis is the percentage of the PCR duplex predicted 
to be helical, such that the completely denatured portions of the PCR fragment are 0% helical, 
and non-denatured regions are 100% helical.  On the X-axis is the base position of the PCR 
fragment. (B) Heteroduplexes are best detected when the PCR fragment is 50-70% helical. The 
schematic shows an example of why two or more temperatures are often required to identify 
mutations or SNPs residing in different regions of the PCR fragment. Mutation A would have 
been missed at 66.9°C as this portion of the PCR fragment is completely denatured at this 
temperature, whilst mutation B would have been missed at 65.9oC as this portion of the PCR 
fragment would still be 100% helical. 
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contain a combination of homo- and heteroduplexes that will elute at different time 
points (Figure 2.1). In theory, this should create four peaks consisting of all four possible 
combinations of annealed PCR product – the first two peaks will be the heteroduplexes, 
followed by the wild-type homoduplex and mutant homoduplex peaks. In practice, both 
homoduplexes often elute together as a single peak, and only two or three peaks are seen.  
 
Optimal melting temperatures of the PCR products were calculated using 
WAVEMAKER  software, which takes into account the size of the PCR product and its 
GC content (Figure 2.2). Heteroduplexes are best detected when the PCR fragment is 50-
70% helical; point mutations, insertions/deletions or SNP could potentially be missed 
(give a single peak rather than a double peak) if the helical fraction is outside of this 
range for the region harbouring the mutation (Figure 2.2). For this reason, PCR products 
often need to be eluted from the DNASep column (which is heated with an oven) at two 
or more temperatures. The optimal PCR product size for sensitive detection of 
heteroduplexes is 200-500 bp. 
 
Temperature settings were optimised for each PCR product and a wild-type control was 
included with each run. In order to optimise heteroduplex formation, PCR samples were 
denatured at 95°C and slow-cooled to 25°C over 40 minutes before running on the 
column. One of the limitations of DHPLC is that it is not able to detect homozygous or 
hemizygous mutations (mutation of one allele, and loss of the other), although this can 
be overcome by mixing PCR products with a known wild-type PCR product prior to 
denaturation.  
 
2.4 SDS-polyacrylamide gel electrophoresis (PAGE) and Western Blotting 
 
2.4.1 Reagents 
• Acrylamide/NN’methylene bis-acrylamide 30%:0.8% (National Diagnostics, 
Hull, UK)  
• Ammonium persulfate (APS) (Sigma Aldrich, Poole, UK) 
• Aprotinin (Sigma Aldrich, Poole, UK) 
• Bovine Serum Albumin (BSA) (Sigma Aldrich, Poole, UK) 
• BD-Perm/Wash™ (BD-Biosciences, Oxford, UK) 
• Bradford protein assay kit (BIO-RAD, Hemel Hempstead, UK) 
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• DL-Dithiothreitol (DTT) (Sigma Aldrich, Poole, UK) 
• Enhance chemiluminescence kits (ECL and ECL-plus) (Amersham Life Sciences, 
Bucks, UK) 
• Hybond-C-Extra nitrocellulose membrane (Amersham Life Sciences, Bucks, UK) 
• Hyperfilm™ high performance autoradiography film (Amersham Life Sciences, 
Bucks, UK) 
• Leupeptin (Sigma Aldrich, Poole, UK) 
• Microcystin LR (Sigma Aldrich, Poole, UK) 
• Non-fat dried milk (Marvel) 
• Nuclear extraction kit (Active Motif, Belgium)  
• Pefabloc (Boehringer-Mannheim, Mannheim, Germany) 
• Pepstatin A (Sigma Aldrich, Poole, UK) 
• Prestained molecular weight markers (Sigma Aldrich, Poole, UK) 
• Radio-Immunoprecipitation Assay (RIPA) Buffer (Sigma Aldrich, Poole, UK) 
• Sodium dodecyl sulfate (SDS) (Sigma Aldrich, Poole, UK) 
• N,N,N′,N′-Tetramethylethylenediamine (TEMED) (Sigma Aldrich, Poole, UK) 
• Tris base (Sigma Aldrich, Poole, UK) 
• Tween-20 (Sigma Aldrich, Poole, UK) 
 
2.4.2 Lysis buffers and cell lysis 
For whole cell lysates, RIPA buffer (50mM NaCl, 1.0% IGEPAL® CA-630, 0.5% 
sodium deoxycholate, 0.1% SDS and 50mM Tris, pH 8.0) was supplemented with the 
following protease inhibitors (final concentrations given): 20mM NaF, 1mM Na 
orthovanadate, 10 µg/ml Aprotinin, 10µg/ml Pepstatin A, 10 µg/ml Leupeptin, 5µM 
Microcystin and 1mM Pefabloc. Cells were harvested by centrifugation at 300g for 5 
minutes, washed once in ice-cold PBS, pelleted by centrifugation at 300g for 5 minutes, 
and snap frozen on dry ice. The cells were thawed on ice and resuspended in 3 volumes 
of RIPA buffer containing protease inhibitors (by approximating the cell pellet volume in 
µl), vortexed and left on ice for 10 minutes. They were then spun at 12,000g at 4°C for 
15 minutes and the supernatant aspirated and stored at -80°C until required. 
 
When immunoblotting for CSL, nuclear lysates gave superior quality bands by Western 
blot than when using whole cell lysates. Nuclear lysates were prepared from 5x106 
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primary AML cells and cell lines using a nuclear extraction kit (Active Motif) according 
to the manufacturer’s instructions. The cells were first resuspended in a hypotonic buffer 
to swell the cell membrane, before addition of a detergent to cause leakage of the 
cytoplasmic proteins into the supernatant, which was then removed by pipetting. The 
remaining proteins were enriched with nuclear proteins, which were then solubilised and 
extracted.  
 
Protein quantification was performed using the Bradford Assay kit (BIO-RAD) 
according to the manufacturer’s instructions. A standard curve was generated using 
dilutions of BSA at 2µg/ml, 1µg/ml, 0.5µg/ml, 0.25µg/ml, and 0.125µg/ml. 
 
2.4.3 SDS-PAGE buffers  
Gel running buffer: 30.3g Tris base, 144.2g Glycine, 10g SDS, made up to 1l with DDW.  
Transfer buffer: 30.3g Tris base, 144.2g Glycine, 100mls Methanol, made up to 1l with 
DDW.  
Gel loading buffer (4x): 17.5mls 1M Tris pH 6.8, 4g SDS, 2.315g DTT, 20mls Glycerol, 
50mg Bromophenol blue, made up to 50mls with DDW. 
 
2.4.4 Acrylamide gels 
10% separating gel: 2.86mls deionised water, 3.74mls 1M Tris pH 8.8, 3.34mls 
acrylamide/N’N’-bis-methylene 30%:0.8%, 100µl 10% SDS, 75µl 10% APS, 9µl 
TEMED.  
Stacking gel: 3.49mls deionised water, 0.625mls 1M Tris pH 6.8, 0.835mls 
Acrylamide/NN’methylene bis-acrylamide 30%:0.8%, 50µl 10% SDS, 38µl 10% APS, 
7.5µl TEMED. 
Preparation of gels: The Mighty-Small Hoeffer gel caster (Hoeffer Scientific 
Instruments, San Francisco, USA) was used to cast 10cm x 8cm gels. The separating gel 
was prepared using the reagents stated above and poured into the gel caster, layered with 
isobutanol to create a horizontal top interface, and left to polymerise at room 
temperature. After removal of the isobutanol layer, the gel was washed once with DDW, 
the stacking gel was poured on top of the separating gel and a 10 well comb inserted at 
the top of the gel. After the gel had polymerised, the comb was removed immediately 
prior to use and the wells washed with running buffer. 
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2.4.5 SDS-PAGE  
15µg protein was mixed with 5µl 4x loading buffer, made up to 20µl with DDW, boiled 
for 5 minutes, and loaded onto the gel. A molecular size marker was loaded into one 
well. Proteins were resolved by electrophoresis in running buffer at 150V for 80 minutes 
and transferred electrophoretically to nitrocellulose membrane at 0.8mA/cm2 for 1 hour. 
The membranes were pre-blocked for 1 hour in 5% skimmed milk in PBS/0.1% Tween 
(PBST). Immunoblotting was carried out with primary antibodies at dilution factors 
specified in the relevant chapters, all diluted in PBST and 5% skimmed milk, and left 
overnight at 4°C with rotation. The membrane was washed 5 times with PBST with 
rotation. Secondary HRP-linked IgG antibodies to mouse, rabbit or rat (Cell Signalling 
Technology) were diluted 1 in 10,000 in PBST and left on the membranes for 30 
minutes. The membrane was washed 5 times with PBST with rotation, then ECL 
detection reagent was added and the membrane was exposed to autoradiography film for 
varying times in a dark room and developed.  
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CHAPTER 3. THE INCIDENCE AND SPECTRUM OF NOTCH AND FBXW7 
MUTATIONS IN T-ALL AND AML, AND THEIR PROGNOSTIC IMPACT 
 
3.1 INTRODUCTION 
 
3.1.1 Oncogenic potential of the Notch signalling pathway 
The Notch pathway has been the focus of extensive research in the field of genetics and 
embryology since the 1920s, yet it was not apparent until the end of the 20th century that 
Notch pathway dysregulation also played a bona fide role in oncogenesis. Perhaps the 
first circumstantial evidence came in 1987 with the description of common retroviral 
integrations in the Notch-4 locus (known then as int-3) in breast cancers initiated by 
mouse mammary tumour virus (MMTV) in feral mice (Gallahan & Callahan, 1987). This 
finding was corroborated by studies demonstrating that transgenic mice expressing 
Notch-4 develop not only undifferentiated breast cancer at 2-7 months, but also salivary 
gland tumours (Jhappan et al, 1992). 
 
In 1991 Ellisen and colleagues cloned the breakpoints of three paediatric cases of T-ALL 
harbouring a t(7;9)(q34;q34.3) translocation and revealed almost identical fusions in all 
three cases (Ellisen et al, 1991). The T-cell receptor-β (TCR- β) promoter on 
chromosome 7 was found to be juxtaposed to an intronic region in NOTCH-1 (described 
at that time as the TAN-1 gene) on chromosome 9, which led to constitutive expression 
of a truncated intracellular Notch (ICN-1) transcript lacking an N-terminal domain. 
Experiments in Drosophila melanogaster at that time showed that N-terminal truncations 
of this type led to a gain-of-function phenotype (Rebay et al, 1993), experiments in 
Caenorhabditis elegans having earlier demonstrated that the negative regulation of 
Notch cleavage was mediated by the HD and LNR domains (Greenwald & Seydoux, 
1990). Although the t(7;9) translocation has turned out to be rare in larger studies of T-
ALL, affecting only 1% of patients, it was the first description implicating aberrant 
Notch signalling in T-ALL.  Furthermore, it was this finding that prompted Pear and 
colleagues to express ICN-1 in murine marrow (Pear & Aster, 2004; Pear et al, 1996). 
All mice developed a highly penetrant and fatal T-ALL with a short latency. In this 
model, mice had a block in differentiation at the DN3 stage of T-cell development and 
expansion of polyclonal T-cells, before developing a monoclonal transplantable T-ALL.  
Interestingly, transgenic mice where ICN-1 is driven by the Lck-promoter have a very 
 83 
low penetrance of T-ALL, suggesting that overexpression of ICN-1 in early 
haematopoietic progenitors, rather than just at the thymic stage, is important in Notch-1-
induced leukaemogenesis (Robey et al, 1996). This is in contrast to the highly penetrant 
leukaemic phenotype in Lck-ICN-3 transgenic mice, suggesting that Notch-1 and Notch-
3 have oncogenic roles at different stages of T-cell maturation (Bellavia et al, 2000; 
Bellavia et al, 2002). 
 
Insertional mutagenesis models have also implicated Notch-1 in the pathogenesis of T-
ALL. For instance, when Moloney murine leukemia virus (MuLV) was used to 
accelerate tumour onset in myc transgenic mice, Notch-1 was found to be a retroviral 
insertion site in 52% of the T-cell leukaemias that developed (Girard et al, 1996; 
Paquette et al, 1992). Remarkably many of the insertions occurred within 300bp of the 
intronic breakpoint described in the t(7;9) translocation (Girard et al, 1996) and 
commonly integrated in two distinct sites of Notch-1: in the extracellular HD and LNR 
domains leading to high expression of ICN-1, or in the PEST domain leading to 
expression of a truncated ICN-1 protein (Hoemann et al, 2000). Similar integrations 
were found in the p27kip null, Eed null and AKXD transgenic mouse models, suggesting 
that the insertions were not particular to myc transgenic mice and that Notch was capable 
of co-operating with different signalling pathways during T-cell leukaemogenesis (Akagi 
et al, 2004; Hansen et al, 2000; Suzuki et al, 2002). Given that a high proportion of the 
integration sites found in these models are generally 'false' discoveries, representing sites 
of preferred viral integration rather than relating to genuine oncogenes or tumour-
suppressor genes, an important finding was that sustained Notch signalling was required 
for in vitro growth of some murine-derived T-ALL cell lines (Weng et al, 2003). 
Furthermore, deletions of either the 5’ extracellular domain or the 3’ PEST domain of 
Notch-1 were found in over half of T-cell thymic lymphomas in mice when the tumours 
were initiated by radiation rather than viral mutagens (Tsuji et al, 2003).  
 
3.1.2 Discovery of activating NOTCH-1 mutations in paediatric T-ALL 
Given the accumulating evidence implicating NOTCH-1 in T-ALL, and with insertional 
integrations as a guide of where to focus their sequencing efforts, the groups of John 
Aster (Brigham and Women’s Hospital, Boston) and A.Thomas Look (Dana-Farber 
Cancer Institute, Boston) chose to sequence NOTCH-1 exons 26 (coding for the HD-N), 
27 (the HD-C) and 34 (the PEST domain) in a cohort of 96 paediatric patients with T-
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ALL. They found that a striking 56% of patients harboured mutations in one or more of 
these domains (Weng et al, 2004). Mutations in the HD domain tended to be missense, 
with a particular propensity for leucine to proline substitutions, or in-frame insertions or 
deletions in highly conserved amino acids. Mutations in the PEST domain tended to be 
out-of-frame insertions or deletions, often as large and complex indels leading to a 
premature stop codon and a truncated protein. Approximately 16% of patients had 
mutations in both domains in cis. Luciferase reporter gene assays showed that these 
mutations were activating and that the combination of HD and PEST mutations had a 
marked synergistic effect on activation. Furthermore, they demonstrated that five 
NOTCH-1 mutated human T-ALL cell lines treated with a γ-secretase inhibitor (GSI) 
went into G0/G1 cell cycle arrest, although a further 25 cell lines remained resistant to 
Notch inhibition for reasons that were then uncertain.  
 
3.1.3 Mechanisms of pathway activation by NOTCH-1 mutations 
Insights into the function of the Notch HD and LNR domains have come from crystal 
radiography and biochemical analyses and support a mechanism by which the LNR 
domain folds over the HD domain, protecting the metalloprotease site from cleavage by 
TACE (S2 cleavage) (Sanchez-Irizarry et al, 2004). Upon physiological ligand-binding 
to the Notch EGF region, a mechanical force is thought to uncouple the LNR domain 
from the HD domain, exposing the S2 site to cleavage by TACE, which is followed by 
constitutive S3 cleavage by γ-secretase in the transmembrane domain and subsequent 
release of ICN.  
 
Mutations in the HD domain are thought to lead to constitutive S2 cleavage or 
hypersensitivity to ligand binding, leading to increases in ICN (Gordon et al, 2009). The 
HD domain mutations have been divided into three distinct classes (Malecki et al, 2006; 
Sulis et al, 2008). Class I mutations are missense amino acid changes or small in-frame 
insertions or deletions that disrupt the interaction between the HD and LNR domains at 
important residues leading to exposure of the S2 site. Class II mutations are larger in-
frame insertions that duplicate the S2 cleavage site, exposing it to constitutive cleavage. 
An example of the latter is the 14 amino acid insertion found in the P12-Ichikawa T-
ALL cell line, which was the most potently activating mutation of 14 mutants tested in 
an in vitro reporter assay (Malecki et al, 2006). A third class of mutation has been 
identified in a minority of patients involving duplications in exon 28 that result in 
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insertions in the juxtamembrane domain (so called juxtamembrane expansion mutations 
[JME]), although their mechanism of activation is unclear (Sulis et al, 2008).  
 
The PEST domain of NOTCH-1 contains a highly conserved serine at position 2512 
followed by a threonine residue at position 2514, which have been identified as the site 
for FBXW7-mediated ubiquitination of ICN-1 (Oberg et al, 2001). The mutations 
described in the PEST domain are predicted to disrupt or truncate ICN-1 prior to these 
residues allowing ICN-1 to escape FBXW7-mediated degradation, with a subsequent 
increase in intracellular half-life. 
 
3.1.4 NOTCH-1 activates oncogenes in T-ALL 
Chromatin immunoprecipitation and microarray analysis of promoter occupancy (ChIP-
on-chip), ChIP with DNA sequencing (ChIP-seq) and gene expression array analysis 
after Notch inhibition have all been instrumental in identifying the downstream targets of 
the ICN-1-CSL-MAML activation complex in T-ALL cells (Palomero et al, 2006a; 
Wang et al, 2011; Weng et al, 2006). The classic Notch target genes in embryonic 
development are basic helix-loop-helix transcriptional repressors such as hairy enhancer 
of split-1 and -5 (HES-1 and HES-5). Although their role in T-ALL pathogenesis is still 
unclear, HES-1 has been shown to bind and repress the PTEN promoter leading to down-
regulation of PTEN protein expression, suggesting that ICN-1 can activate PI3K 
signalling in T-ALL (Palomero et al, 2007). In addition, a number of important 
oncogenes are direct transcriptional targets of ICN-1: 
 
1) c-Myc. A number of published studies have identified MYC as a direct 
transcriptional target of Notch signalling (Palomero et al, 2006a) (Wang et al, 2011; 
Weng et al, 2006). The majority of T-ALL cell lines have high protein levels of MYC 
and inhibition of Notch signalling with GSI treatment leads to significant mRNA and 
protein depletion of MYC (Weng et al, 2006).  Furthermore, a number of Notch-
dependent T-ALL cell lines can be rendered resistant to GSI treatment by retroviral 
expression of MYC, suggesting that Notch-dependency is mediated through MYC in 
these cells (Weng et al, 2006). A compelling finding was demonstrated elegantly in the 
8946 T-ALL cell line which had been generated from transduction of murine marrow 
with a doxycycline-repressible c-Myc transgene (Weng et al, 2006). This cell line 
proliferates rapidly in vitro and undergoes apoptosis on the addition of doxycycline 
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(Felsher & Bishop, 1999). The authors demonstrated that retroviral transduction with 
ICN-1 upregulates the expression of endogenous myc and inhibits cell death after 
doxycycline administration (Weng et al, 2006).  
 
2) Cyclin D3. Overexpression of cyclin D3 has been identified in T-ALL cell 
lines as a consequence of direct transcriptional activation by NOTCH-1 and has been 
shown to regulate G1-S phase cell cycle progression in T-ALL cell lines and in vivo 
(Joshi et al, 2009). Furthermore, overexpression of cyclin D3 partially rescues Notch-
dependent T-ALL cells from cell cycle arrest induced by GSI treatment.  
 
3) IGF1R.  More recently, signalling through the insulin growth factor receptor-1 
(IGF1R), which activates the PI3K/AKT pathway, has been shown to be important for 
leukaemia-initiating cell activity in a serial transplant murine model of T-ALL (Medyouf 
et al, 2011). Although conditional deletion of the IGF1R had only a minimal impact on 
the latency of ICN-1 induced T-ALL, it dramatically reduced the ability to serially 
transplant tumours into secondary recipients. Furthermore, the authors identified that 
CSL-ICN-1 binds the IGF1R enhancer in intron 1, a finding that has since been 
corroborated in ChIP-seq studies (Wang et al, 2011). 
 
4) IL7R. IL7R is highly expressed in the majority of T-ALL cases, and is directly 
transcriptionally regulated by Notch through a pathway that is important in normal T-cell 
development (Gonzalez-Garcia et al, 2009; Wang et al, 2011). An oncogenic role for 
IL7R has recently been described in T-ALL, with activating mutations occurring in 
approximately 10% of T-ALL patients (Shochat et al, 2011; Zenatti et al, 2011). The 
majority of mutations described thus far in T-ALL involve the insertion of a cysteine in 
the transmembrane domain leading to ligand-independent IL7R homodimerisation and 
activation of JAK1 and STAT5. Crystallography data has shown that when the wild-type 
receptor is expressed at high levels it too can homodimerise, suggesting that upregulation 
of wild-type IL7R by Notch may in itself activate JAK-STAT signalling in T-ALL, 
though this is yet to be proven (McElroy et al, 2012).   
 
3.1.5 FBXW7 – a frequently mutated tumour-suppressor in T-ALL 
Ubiquitination describes the process by which proteins are first labelled by ubiquitin 
prior to their degradation by the proteosome. F-box and WD40 domain-containing 
 87 
protein 7 (FBXW7) is an E3-ubiquitin ligase (also termed FBW7, CDC4, AGO or SEL-
10) that is a member of the highly conserved SCF complex (named after its three 
members SKP1, CUL1 and F-box protein). This complex covalently attaches ubiquitin 
groups to proteins that harbour the consensus sequence of I/L-I/L/P-T-P-XXXX, where 
lysine and arginine are unfavourable in the X locations (Welcker & Clurman, 2008). 
This motif has been termed a phospho-degron, given that the threonine first requires 
phosphorylation prior to recognition by FBXW7, a process that often involves GSK3β 
(Fryer et al, 2004; McKenzie et al, 2006). FBXW7 can form homodimers mediated 
through its N-terminal dimerisation domain, although the role of dimerisation remains 
unclear given that monomeric forms can still target most of its known substrates. It may, 
however, have a role in determining particular affinity for cyclin E (Welcker & Clurman, 
2007).  
 
Crystallography data shows that FBXW7 consists of an F-box that interacts with SKP1 
to form the SCF complex, followed by eight WD40 repeats that form a configuration 
similar to petals on a flower or blades of a propeller (Figure 3.1) (Orlicky et al, 2003b). 
Each of the propeller-like structures is capable of binding one or more substrates. 
Multiple important oncogenes have been shown to be substrates of FBXW7, some of 
which are listed below:  
 
1) c-Myc. MYC is a direct transcriptional target of Notch signalling, and FBXW7 
exerts another level of control on the Notch pathway by degrading MYC 
(Palomero et al, 2006a). Interestingly, in Burkitt’s lymphoma, which in nearly all 
cases is driven by MYC over-expression, 60% of patients have mutations of 
MYC, the most common being an amino acid substitution at position T58 that 
leads to increased protein stability by the virtue of its ability to avoid FBXW7-
mediated degradation (Chang et al, 2000). Furthermore, fbxw7 conditional 
knockout (-/-) mice develop thymic lymphomas with high levels of myc	  
(Onoyama et al, 2007).  
 
2) NOTCH-1. The conserved threonine at position 2512 in the PEST domain of 
NOTCH-1 has been shown to be the target of phosphorylation by GSK3β, as well 
as by CDK8 and cyclin C, which is the priming event required for FBXW7 
binding (Figure 3.1) (Fryer, White et al. 2004,(Wu et al, 2001). Conditional in 
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vivo deletion of FBXW7 leads to stabilisation of ICN-1, which in turn 
transcriptionally activates Myc (Onoyama et al, 2007). Presenilin-1, which forms 
part of the γ-secretase complex, is also targeted by FBXW7 for degradation, 
suggesting that FBXW7 controls Notch signalling both at the level of Notch 
cleavage and degradation of ICN (Li et al, 2002). 
 
3) Cyclin E. Cdc4, the yeast homologue of FBXW7, was first discovered in a 
genetic screen of yeast mutants with an altered cell cycle (Yochem & Byers, 
1987). Subsequently, multiple groups identified Cyclin E as the first bona fide 
Cdc4 target, and the regulation of cyclin E by mammalian FBXW7 was 
confirmed soon thereafter (Hao et al, 2007; Koepp et al, 2001; Orlicky et al, 
2003a). Cyclin E controls G1 to S phase transition and is over-expressed in 
hepatocellular carcinomas (Geng et al, 2003). Cyclin E knockout mice exhibited 
almost total resistance to induction of hepatocellular carcinomas (Geng et al, 
2003). However, the importance of cyclin E in T-ALL is still uncertain. 
 
4) mTOR. In a search for proteins containing the conserved FBXW7 phospho-
degron sequence, mTOR was also identified, and functionally validated, as a 
substrate of FBXW7 (Mao et al, 2008). mTOR can also be upregulated by Notch, 
supporting the hypothesis that Notch and FBXW7 collaborate to activate multiple 
pathways in T-ALL. Of importance to therapeutic approaches, increased 
sensitivity to mTOR inhibition was seen in cell lines harbouring mutations or 
deletions of FBXW7 (Mao et al, 2008).  
 
5) Other important targets include the anti-apoptotic protein MCL-1, which is over-
expressed at the protein level in T-ALL as a consequence of mutation of 
FBXW7, MYB, which is frequently duplicated in T-ALL, and c-Jun (Inuzuka et 
al, 2011; Kitagawa et al, 2009; Zhang et al, 2011) 
 
Given its role in the degradation of such an array of oncogenes, it is not surprising that 
loss-of-function mutations, or more rarely, deletions, of the FBXW7 gene have been 
identified in many types of human cancers, including cholangiocarcinomas (35%), and 
those affecting the endometrium (9%), colon (9%), stomach (6%) and head-and-neck 
(5%) (Agrawal et al, 2011; Akhoondi et al, 2007). The discovery of a high frequency of 
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mutations in FBXW7 in T-ALL came about through analysis of thymic lymphomas from 
triple knockout mice (Tp53-/-, Terc-/- and Atm-/-), which harboured frequent deletions of 
this locus as evident by array CGH (Maser et al, 2007). Subsequent analysis of samples 
from T-ALL patients found a frequency of mutations of between 9-30% (Akhoondi et al, 
2007; Mansour et al, 2009; O'Neil et al, 2007).  
 
Figure 3.1 Schematic showing regulation of NOTCH through ubiquitination.  
GSK3β, CDK8 and cyclin C are proposed to phosphorylate T2512 of the NOTCH PEST domain 
priming it for binding by the E3 ubiquitin ligase FBXW7 which leads to its degradation. 
 
 
There are three particular amino acid mutation hotspots found in T-ALL - R465, R479 
and R505. These arginine residues form the surface of the propeller blades in the WD40 
domain required for substrate recognition. Somatic missense mutations of one of these 
arginines, often to either a histidine or cysteine, have been shown to abrogate FBXW7-
mediated degradation of both Notch and Myc, leading to their increased stability (O'Neil 
et al, 2007). This mechanism is thought to play a role in resistance of some T-ALL cell 
lines to GSIs, whereby the increased stability of Myc through FBXW7 mutation 
uncouples it from its dependence on Notch activity (O'Neil et al, 2007). Given the ability 
of FBXW7 to homodimerise, mutations may also have dominant-negative activity on the 
wild-type protein (Akhoondi et al, 2007). Cytosine methylation has been identified at 
some of these hotspots in ovarian and endometrial cancer, which is interesting given that 
the observed mutations are often C to T transitions within a CG dinucleotide that can 
result from spontaneous deamination of 5’-methylcytosine to thymine (Akhoondi et al, 
2007). 
 
 90 
3.1.6 Prognostication in T-ALL 
 
The various clinical and molecular features that are currently used in risk stratification in 
T-ALL are discussed in Chapter 1. A risk-adapted approach to the treatment of patients 
with ALL has the potential of improving survival in high-risk patients and reducing 
therapy-related long-term sequelae in those at low-risk. Whilst significant advances have 
been made in stratifying patient prognosis in AML through the use of cytogenetic and 
molecular characterisation of the presenting sample, there has been a paucity of 
informative prognostic markers in T-ALL. This can be attributed to at least three facts. 
Firstly, large cohort studies have been hampered by the relative rarity of T-ALL. 
Secondly, non-cryptic cytogenetic abnormalities are both infrequent and less 
prognostically informative in T-ALL as compared to AML. Thirdly, unlike the 
identification of a number of common molecular markers in AML, e.g. FLT3-ITDs, high 
frequency recurrent mutations in T-ALL had not been identified until relatively recently. 
Consequently, clinicians have had, and continue, to use criteria established as long ago 
as the 1980s for risk stratification, namely, presenting blast count and age (Hoelzer et al, 
1988; Rowe et al, 2005). However, the marked heterogeneity in outcome among 
standard- and high-risk patients according to these criteria limits their clinical utility.  
 
As discussed in chapter 1, minimal residual disease (MRD) kinetics using 
immunoglobulin or TCR rearrangements contributes significantly towards current 
stratification protocols (Bruggemann et al, 2006; Raff et al, 2007). However, there is 
some evidence suggesting that MRD in adult T-ALL is less robust at predicting 
prognosis and identifying early relapse than it is in adult B-ALL, or paediatric B- or T-
ALL (Gameiro et al, 2002; Szczepanski et al, 2003; Willemse et al, 2002). 
Consequently, mutation screening strategies that predict outcome could prove invaluable 
in clinical decision making in adult T-ALL, particularly in the selection of patients for 
allogeneic haematopoietic stem cell transplantation, and the use of molecular markers 
that can complement or supersede current prognostication strategies are needed. 
 
3.2 AIMS  
This chapter describes studies to investigate a number of different questions regarding 
NOTCH-1 and FBXW7 mutations in acute leukaemia. Firstly, the incidence and spectrum 
of NOTCH-1 and FBXW7 mutations in a cohort of adult patients with T-ALL was 
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investigated. The first report of NOTCH-1 mutations had been in a paediatric T-ALL 
cohort (Weng et al, 2004) and at the time the work in this thesis was started, the presence 
or incidence of NOTCH-1 mutations in adult patients had not been described. Although 
the phenotype of adult T-ALL is similar to its paediatric counterpart, there are significant 
differences, in particular adult patients have a different frequency of cytogenetic 
abnormalities and oncogene expression and a poorer prognosis (Pui & Evans, 1998). 
Some of these differences may be attributable to the incidence and characteristics of 
NOTCH-1 mutations in adult patients, which may impact on signalling events 
downstream of NOTCH-1 and, in turn, response to therapy.  
 
The second aim of the studies presented in this chapter was to assess the association of 
NOTCH-1 and FBXW7 mutations with prognostic outcome in a cohort of adult patients 
with T-ALL treated on the MRC UKALLXII/ECOG2993 trial.  
 
Thirdly, the potential for alternative mechanisms of Notch pathway activation in T-ALL 
patients were explored, specifically, the possibility that the LNR domain of NOTCH-1 
could also be a site for mutational disruption considering that it interfaces directly with 
the HD. Furthermore, given that ICN-3 can initiate leukaemogenesis in murine models, 
is highly over-expressed in T-ALL patients, and is structurally homologous to NOTCH-1 
(Bellavia et al, 2002), the possibility that NOTCH-3 is also activated by somatic 
mutations was also investigated.  
 
The fourth aim was to investigate whether NOTCH-1 mutations are also present in adult 
and infant AML patients. Mutational studies of NOTCH-1 and NOTCH-3 and the 
downstream pathway had not been carried out in AML, although gene array profile 
studies had shown increased expression of NOTCH-1 and its ligand JAGGED-1 in a 
subgroup of patients (Ross et al, 2004). Aberrant expression of T-cell markers such as 
CD2 and CD7 on AML blast cells has been reported in about 25% of adult AML cases 
(Casasnovas et al, 2003), and mixed-lineage surface antigen expression is particularly 
prevalent in infant AML (Biondi et al, 2000). The mechanism underlying this is 
unknown but may be due to either ‘lineage infidelity’, i.e. deregulation of lineage-
affiliated genes during the leukaemic transformation process, or ‘lineage promiscuity’, 
i.e. reflecting the multipotency of the progenitor cell that is transformed (Greaves et al, 
1986). Given that activated Notch signalling favours T-cell differentiation, mutational 
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activation of NOTCH-1 may lead to aberrant expression of T-cell antigens, and also play 
a role in the increased self-renewal capacity and impaired differentiation found in AML 
blasts.  
 
3.3 PATIENTS, MATERIALS AND METHODS  
 
3.3.1 Patients 
Genomic DNA samples were available from a total of 60 adult patients with T-ALL, of 
which 54 had been entered into the MRC UKALLXII trial, and 6 had samples collected 
locally after informed consent. DNA samples obtained from remission bone marrow 
were available from 15 patients. NOTCH-1 and FBXW7 mutation data was made 
available to us from an additional 34 patients treated on ECOG2993 in collaboration 
with Adolfo Ferrando’s group (who performed the mutational analysis) from Columbia 
University Medical Center, New York and Elisabeth Paietta’s group (who collected the 
samples) from Our Lady of Mercy Cancer Center, New York. DNA samples from 
patients with infant leukaemia (patients<1 year of age) (n=29) and paediatric T-ALL 
(patients<13 years of age) (n=12) were obtained from Great Ormond Street Hospital in 
collaboration with Dr Phil Ancliff and Dr Nick Goulden. DNA samples were obtained 
from 156 young adult patients with AML from the tissue bank from patients entered onto 
the MRC/NCRI AML10, 12 and 15 trials. Ethical approval for the trials and tissue 
collection for research was obtained from the Multi-Centre Research Ethics Committees 
and local research ethics committees as appropriate and informed consent was provided 
according to the Declaration of Helsinki.  
 
3.3.2 Denaturing High Performance Liquid Chromatography (DHPLC) Analysis 
 
3.3.2.1 DHPLC screening of NOTCH-1 mutations  
NOTCH-1 mutation screening and identification were carried out using denaturing high-
performance liquid chromatography (DHPLC) of PCR products followed by sequencing 
of samples with abnormal chromatograms. The principles and methods regarding PCR, 
DHPLC analysis and sequencing are discussed in Chapter 2. The LNR, HD-N, HD-C, 
TAD and PEST domains were amplified by 35 cycles of the PCR using the primer 
sequences and annealing temperatures shown in Table 3.1. Due to its size (646bp), which 
is not optimal for sensitive mutation detection by DHPLC analysis, the LNR was divided 
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into two overlapping fragments (298bp and 400bp) termed LNR-1 and LNR-2 for the 5’ 
and 3’ fragments respectively. The proofreading enzyme Optimase (Transgenomic) was 
used according to the manufacturer’s specifications for the LNR, TAD and HD-C 
domains. Given the high GC content of these fragments, 1M betaine (final concentration) 
was added to enhance PCR efficiency. PCR products of adequate quality could not be 
obtained using Optimase for the HD-N and PEST domains, and these fragments were 
amplified using the non-proofreading enzyme BioTAQ DNA polymerase (Bioline). PCR 
products were run out on an agarose gel, denatured and slow-cooled to optimise 
heteroduplex formation (see Chapter 2.2.5 and Figure 2.1) and then analysed on the 
WAVE DNA Fragment Analysis System, Transgenomic.  
 
Table 3.1 NOTCH-1 primer sequences, PCR fragment sizes, PCR annealing 
temperatures and DHPLC analysis temperatures. 
NOTCH-1 
Domain  
(Exon) 
Primer 
name Primer Sequence 
PCR 
fragment 
size 
PCR 
Annealing 
temp 
DHPLC 
Analysis 
temp 
LNR-1 
(exon 25) 25-A-F 5’-TGGCCCACCCCGACACCG-3' 298bp 63°C 
64.5°C and 
67.3°C 
 25-A-R 5’-CAAGAGCCCGTTGAATTTGGCG-3'    
LNR-2 
(exon 25) 25-B-F 5’-CGAGAGCCCCTTCTACCGTTG-3' 400bp 64°C 
63.8°C and 
66.7°C 
 25-B-R 5’-CTCCCTCAGCCCCATGAGC-3'    
HD-N 
(exon 26) 26-F 5’-GGAAGGCGGCCTGAGCGTGTC-3' 494bp 67°C 
65.9°C and 
66.9°C 
 26-R 5’-ATTGACCGTGGGCGCCGGGTC-3'    
HD-C 
(exon 27) 27-F 5’-GCCTCAGTGTCCTGCGGC-3' 320bp 
Touch down 
65-61°C 65.0°C 
 27-R 5’-GCACAAACAGCCAGCGTGTC-3'    
JM 
(exon 28) 28-F 5’-TGATTAATCGCGTAGAAAATCACCT-3' 418bp 
Touch down  
60-56°C N/A 
 28-R 5’-CACCGGGGACCCAGAAGC-3'    
TAD 
(exon 34) TAD-F 5’-GCTGGCCTTTGAGACTGGC-3' 483bp 62°C 
63.5°C and 
64.5°C 
 TAD-R 5’-GCTGAGCTCACGCCAAGGT-3'    
PEST 
(exon 34) PEST-F 5’-CAGATGCAGCAGCAGAACCTG-3' 520bp 64°C 
64.4°C and 
65.7°C 
 PEST-R 5’-AAAGGAAGCCGGGGTCTCGT-3'    
N/A = Not applicable 
 
Abnormal chromatograms were confirmed by repeat WAVE analysis. Fresh PCR 
products were then sequenced bidirectionally using the Dye Terminator Cycle 
Sequencing Quick Start kit (Beckman Coulter) and analysed on the CEQ8000 Genetic 
Analysis System (Beckman Coulter). The nucleotide and amino acid numbering used 
corresponds to RefSeq accession number NM_017617.3 and Ensembl Transcript 
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ENST00000277541. For cases with low level heteroduplex formation by DHPLC 
analysis that were below the sensitivity of sequencing, the fragment collector facility of 
the WAVE was used to collect the heteroduplex peak for reamplification by PCR and 
sequencing. The technique and results of this method are discussed in more detail in 
chapter 4.  
 
Juxtamembrane expansion (JME) mutations were analysed by PCR of exon 28 using 
BioTAQ DNA polymerase and buffer according to the manufacturers guidelines, and 35 
cycles of PCR were performed with annealing temperature and primers shown in Table 
3.1. PCR products were resolved by gel electrophoresis containing 2.5% agarose.  DNA 
from the Jurkat T-ALL cell line, which contains a 51bp duplication in exon 28, was used 
as a positive control. As duplications were often too large and complex to resolve 
comprehensively by direct sequencing, PCR products were TOPO cloned prior to 
sequencing.  
 
Table 3.2 NOTCH-3 primer sequences, PCR fragment sizes, annealing 
temperatures and DHPLC melting temperatures. 
NOTCH-3 
Domain 
(Exon) 
Primer 
name Primer Sequence 
PCR 
fragment 
size 
PCR 
Annealing 
temp 
DHPLC 
Analysis 
temp 
LNR 
(exon 24) 24-F 5’-GTTCTGGGGTCCGCGTTGC-3' 605bp 63°C 
66.5°C,68.3°C  
and 70.2°C 
 24-R 5’-GGATGCATAGACAGACGGATCG-3'    
HD-N 
(exon 25) 25-F2 5’-CTCTGACCCCTGACTCCGC-3' 499bp 63°C 
65.0°C and 
66.8°C 
 25-R 5’-TCTCCCCAGCCACCACGGC-3'    
HD-C 
(exon 26) 26-F 5’-ACCAGGGGGTGCATCGGGC-3' 298bp 62°C 
63°C and 
66.8°C 
 26-R 5’-CGAGGGCGGGGCTTTGGC-3'    
TAD 
(exon 33) TAD-F 5’-CGCTTGCTGGATCAACCCAGT-3' 451bp 61°C 
65.3°C and 
67.3°C 
 TAD-R 5’-AATCGAGGGGCACAGCCACAG-3'    
PEST 
(exon 33) PEST-F 5’-GGAGGATGTGTACTCAGCCTG-3' 535bp 60°C 
64.0°C and 
66.5°C 
 PEST-R 5’-CCCCAAGATCTAAGAACTGACG-3'    
 
 
3.3.2.2 DHPLC for the screening of NOTCH-3 mutations 
NOTCH-3 mutation screening was carried out using DHPLC analysis and sequencing as 
before. The exons corresponding to the NOTCH-1 LNR, HD-N, HD-C, TAD and PEST 
domains were identified by aligning the nucleotide sequences using BLASTN and 
showed between 73% and 86% homology for each domain. These regions were 
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amplified by 35 cycles of the PCR using the proofreading enzyme Optimase 
(Transgenomic), with the inclusion of 1M betaine for the HD-N and HD-C domain 
PCRs. The primer sequences were analysed by BLAST and in detail against the other 
Notch family members to ensure specificity to NOTCH-3 and are shown in Table 3.2 
together with the annealing temperatures. Optimal melting temperatures for DHPLC 
analysis were calculated using WAVEMAKER software and are given in Table 3.2. 
Nucleotide and amino acid numbering are according to RefSeq accession number 
NM_000435.2 (equivalent to ensembl ENSG74181). 
 
3.3.2.3 DHPLC for the screening of FBXW7 mutations 
Screening for FBXW7 mutations was only carried out for exons 8-12 since these exons 
encode the WD40 domain, which has been reported to harbour the vast majority of 
mutations in T-ALL.  Samples were analysed by Optimase PCR and DHPLC 
heteroduplex analysis as before, followed by sequencing of abnormal chromatograms. 
Primer sequences, PCR fragment sizes, PCR annealing temperatures and DHPLC 
analysis temperatures are given in Table 3.3. Unlike mutation screening for NOTCH-1, 
where the variety of mutations precluded prediction of the mutation by analysis of the 
WAVE pattern, the characteristics of the abnormal heteroduplex patterns for FBXW7 
exons were highly predictive of the mutation, although all were confirmed by 
sequencing. The nucleotide and amino acid numbering used corresponds to Ensembl 
Transcript ENST00000281708. 
 
Table 3.3 FBXW7 primer sequences, PCR fragment sizes, annealing temperatures 
and DHPLC melting temperatures. 
FBXW7 
Domain  
(Exon) 
Primer 
name Primer Sequence 
PCR 
fragmen
t size 
PCR 
Annealing 
temp 
DHPLC 
Analysis 
temp 
WD40 
(Exon 8) 8F 5’-AGATAGACTACAAATTACTGTTCCTG-3' 255bp 55°C 
56.0°C and 
58.0°C 
 8R 5’-CTTTGTGAAGTGTAGGAAGAGTAAAC-3'    
WD40 
(Exon 9) 9F 5’-TCTACCCAAAAGTAATCATCTTAAGTG-3' 259bp 56.0°C 58.6°C 
 9R 5’-ATAGAGGAAGAAGTCCCAACCAT-3'    
WD40 
(Exon 10 ) 10F 5’-GTTTTTCTGTTTCTCCCTCTGCA-3' 300bp 58.0°C 
56.0°C and 
59.6°C 
 10R 5’-ACCTTATGATTCATCAGGAGAGC-3'    
WD40 
(Exon 11) 11F 5’-GTAATTGATAGGAAGAGTATCCATAC-3' 374bp 60.0°C 
56.6°C and 
59.0°C 
 11R 5’-AACCATTCTGTATGAGGTTGACTC-3'    
WD40 
(Exon 12) 12F 5’-CAAATTATAATGTAACTAACTCATAGCCA-3' 385bp 56.0°C 
57.6°C and 
61.5°C 
 12R 5’-GAGTATATCGTCTACACAATTGGAC-3'    
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3.3.3 Statistical analysis of clinical outcome data 
Statistical analysis of the MRC UKALLXII/ECOG2993 cohort was performed by 
Georgina Buck and Sue Richards at the Clinical Trial Service Unit, Oxford, UK.  The 
association between NOTCH-1 and FBXW7 mutation status with age (<35 years vs. ≥35 
years) and WCC (<30x109/l vs. 30-99 vs. ≥100x109/l) at diagnosis were investigated 
using Fisher’s Exact test in 2x2 tables and Mantel Haenszel test for trend. Outcome was 
analysed according to overall survival (OS) and event-free survival (EFS), the latter 
defined as time to relapse or death. Kaplan-Meier curves were used to assess survival, 
and differences between groups were compared by the log-rank test. Multi-variate 
analyses were performed using the Cox model. All p-values quoted are two-sided 
 
 
3.4 RESULTS 
At the commencement of these studies, NOTCH-1 mutations had only been reported in 
paediatric patients with T-ALL, therefore the first question addressed was whether the 
incidence and characteristics of NOTCH-1 mutations was similar in adult patients.  
 
3.4.1 NOTCH-1 mutations are highly prevalent in adult patients with T-ALL 
DHPLC analysis was used to screen the HD-N, HD-C, TAD and PEST domains of 
NOTCH-1 in samples from 60 adult patients. A wide range of different abnormal 
patterns were identified, and examples for the HD-N domain are shown in Figure 3.2. 
Given the wide variety of patterns, prediction of the specific mutation purely from the 
chromatogram was not possible, so all fragments with abnormal patterns were 
sequenced. Overall, heteroduplex patterns indicative of an alteration in at least one PCR 
fragment were seen in 40 of 60 (67%) patients (Table 3.4). However, in two patients 
(T17 and T26), the only alteration was a previously described single nucleotide 
polymorphism (SNP) (5094C>T, rs10521) which was synonymous at the amino acid 
level (D1699D) and thus not thought to be of functional or pathological significance. 
According to the dbSNP database (http://www.ncbi.nlm.nih.gov/projects/SNP/) it is 
found at a frequency of 0.43 in the normal population. Therefore, 38 patients (63%) had 
at least one NOTCH-1 mutation, the details of which are listed in Table 3.4. Twenty-
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Figure 3.2 DHPLC patterns for the HD-N domain. The wild type HD-N PCR fragment 
has a single homoduplex peak, whereas heteroduplex peaks are detected in 3 representative 
examples of mutations identified in adult T-ALL patients. 
 
 
three patients (38% of the total cohort) had mutations in the HD domain only, none in 
the TAD domain, five (8%) in the PEST domain only, two (3%) had JME mutations 
only, and eight (13%) had mutations in both the HD and PEST domains (Table 3.5).  
 
Mutations in the HD-N domain were the most frequent, affecting 24 of the total cohort 
(40%), and tended to cluster in the conserved region between residues 1593 and 1597 
(Table 3.4 and Figure 3.3). Thirteen patients had point mutations in the HD-N domain, of 
which eight were leucine to proline substitutions and eleven had in-frame insertions or 
deletions. Three of the latter had complex alterations with contiguous insertions and
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Table 3.4 NOTCH-1 and FBXW7 mutational status of the 60 adult T-ALL patients studied  
Case# 
NOTCH-1 
mutation  
status 
FBXW7 
mutation 
status 
NOTCH-1 
Mutation (nucleotide) 
NOTCH-1 
Mutation (amino acid) 
FBXW7 
Mutation 
(nucleotide) 
FBXW7 
Mutation 
(amino acid) 
T1 PEST MUT WT 7469-7470insAA Y2491X   
T2 WT WT - -   
 T5* HD-C + 
PEST MUT 
WT 5011G>A (SNP); 5019-5020insGGG 
7515T>G (SNP); 7327-7328insGAGGAAAA 
V1672I (SNP); 1674-1675insG 
P2506P (SNP); fs@2444 STOP@2480 
1944A>G (SNP) L648L (SNP) 
 T9* HD-N+ 
PEST MUT 
WT 4721T>C+G4722G>T; 4754T>C+4755G>T 
7387delG 
L1575P and L1586P (different alleles) 
fs@2464, STOP@2477 
  
T11 HD-N MUT MUT 4849-4851delTTC 1618delF 1393C>T R465C 
T15 HD-N MUT WT 4787T>A L1597H   
T16 WT WT - -   
T17 WT WT 5094C>T (SNP) D1699D (SNP)   
T18 HD-N MUT MUT 4778T>C L1594P 1393C>T R465C 
T19 HD-C MUT MUT 5026-5028delGTC 1677delV 1393C>T R465C 
T20 HD-N MUT WT 4777-4778delCTinsGCTTT 1594-1595insA   
T21 HD-C MUT WT 5094C>T (SNP); 5087C>A D1699D (SNP); A1697D   
T22 HD-N MUT MUT 4776-4777insGTCGCC F1593L+1593-1594insSP 1393C>T R465C 
T23 WT WT - -   
T24 JME MUT WT 5205-5206ins20bp + 5206-5221duplication 16bp 1737-1738ins7aa+5 aa duplication 1737-1741   
T25 HD-N+ 
PEST MUT 
WT 4847T>A 
7301-7302insTGGGG 
I1617N 
2435-2436insGX 
  
T26 WT WT 5094C>T (SNP) D1699D (SNP)   
T27 HD-N MUT WT 4778T>C L1594P   
 T28* HD-N MUT MUT 4849-4851delTTC 1618delF 1393C>T R465C 
T29 HD-N MUT MUT 4721T>C L1575P 1393C>T R465C 
T30 HD-N+ 
PEST MUT 
WT 4774-4780delTTCCTGC+insCACTTCGATG 
7535C>T 
1593-1595delFLR+insHFDG 
P2513L 
  
T31 HD-N MUT MUT 4841-4850delAGATGATCTT+insTGTGCCG 1615-1618delQMIF+insLCR 1436G>T R479L 
T32 HD-N+ 
PEST MUT 
WT 4754T>C 
7541-7542delCT 
L1586P 
fs@2515, STOP @2518 
  
T33 JME MUT WT 5229-5230insTT+5230-5269 duplication 40bp 
5094C>T (SNP) 
14aa duplication 1744-1757 
D1699D (SNP) 
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Case# 
NOTCH-1 
mutation  
status 
FBXW7 
mutation 
status 
NOTCH-1 
Mutation (nucleotide) 
NOTCH-1 
Mutation (amino acid) 
FBXW7 
Mutation 
(nucleotide) 
FBXW7 
Mutation 
(amino 
acid) 
T36 HD-C MUT WT 5160-5161insCCCCCGGGCAGTCTGCTG 
+5161-5163delGTG 
1721-1722insPPGSL+1722delV   
T39 WT WT     
T40 HD-N MUT WT 4793G>C R1599P   
T43 WT WT     
T51 WT WT     
T53 WT WT     
T54 HD-N MUT WT 4734-4735insGTG 1579-1580insV   
T55 HD-N MUT WT 4817-4890del75bp 1607-
1631delFKRDAHGQQMIFPYYGREEELRKHP 
  
T57 HD-N MUT MUT 4842-4844delGAT M1616I+1617delF 1393C>T R465C 
T58 HD-C MUT WT 5160-5161ins66bp 1721-
1722insASFLGALASLGSLNFPYRIEA+V1722D 
  
T59 WT WT     
T60 PEST MUT WT 7555C>T Q2520X   
T61 PEST MUT WT 7534C>T P2513S   
T62 WT WT     
T63 PEST MUT WT 7429-7435delACCGCAG fs@2478, STOP@2481   
T64 HD-N+ 
PEST MUT 
WT 4778T>C 
7487-7488insGCTACCCGTGTTT  
L1594P 
fs@2497, STOP@2507 
  
T65 HD-C MUT WT 5039T>A I1681N   
  T66* HD-N+ WT 4754T>C L1586P   
 PEST MUT  7561-7562insGGCTAGCCCTCTACACT  2495insG, STOP@2496   
  T67* PEST MUT WT 7438-7439insACAGTACC fs@2479, STOP@2481   
T70 HD-C MUT WT 5033T>A L1679Q   
T71 WT WT     
T72 HD-N MUT MUT 4747-4748insGTACCCACCCTAAGG 1583-1584insGTHPK 1268G>T G423V 
T73 WT WT     
T74 WT WT     
T75 HD-N MUT MUT 4855delTA+4855-4856insCCAGGGTC 1619-1620insPGS 1393C>T R465C 
T78 WT MUT   1436G>T R479L 
T83 WT WT     
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Case# 
NOTCH-1 
mutation  
status 
FBXW7 
mutation 
status 
NOTCH-1 
Mutation (nucleotide) 
NOTCH-1 
Mutation (amino acid) 
FBXW7 
Mutation 
(nucleotide) 
FBXW7 
Mutation 
(amino 
acid) 
T86 WT WT     
T87 WT WT     
T88 WT WT     
T89 WT WT     
T101 WT WT     
T102 WT WT     
T103 HD-N+ 
PEST MUT 
WT 4799T>C 
7397-7398insGG 
L1601P 
fs@2467 STOP@2478 
  
T107 HD-N MUT WT 4793G>C R1599P   
T109 HD-N MUT WT 4775-4776insAAG F1593L+1594insS   
T# local patient case number, * adult patient not entered onto UKALLXII study. MUT mutant, WT wild type, ins insertion, del deletion, SNP single nucleotide 
polymorphism, HD-N N-terminal heterodimerisation domain, HD-C C-terminal heterodimerisation domain, JME juxtamembrane expansion mutation, fs   
frameshift, X stop codon, Low level mutation.  Data on patients treated on ECOG2993 are shown in Appendix Table 1. 
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deletions (indels). Subsequent TOPO cloning of products from case T9 showed that the 
two leucine to proline mutations were on different alleles and were therefore either in 
trans in the same cell or present in different cells. Several mutations were low level as 
estimated visually from the WAVE pattern, which indicated either the presence of non-
leukaemic cells in the sample studied or secondary mutations reflecting clonal evolution. 
The incidence of low level mutations, the methods used to identify them and their 
biological significance is presented in Chapter 4. 
 
Of the seven patients with an HD-C domain mutation, four had an insertions or deletions, 
whereas all mutations previously described in this domain in the paediatric cohort were 
point mutations. Two of the three insertions (T36 and T58) contained the amino acid 
sequence GSL, which forms an integral part of the recognition motif for S2 cleavage 
(usually occurring at amino acid position 1711). Thirteen mutations were detected in the 
PEST domain, of which ten were insertions and/or deletions that led to premature stop 
codons, either through a frameshift or through direct insertion of a stop codon, truncating 
the receptor by 39 to 119 amino acids. In a further case there was an amino acid 
substitution (nucleotide 7535C>T resulting in P2513L), which had been initially reported 
as a SNP (Weng et al, 2004), but more recent studies have shown is recurrent in T-ALL 
(Medyouf et al, 2010). It is located at the FBXW7 binding site and is likely to be 
somatic, although remission DNA was not available to prove this definitively. All the 
PEST mutations would be predicted to abrogate binding of the negative regulator 
FBXW7. Notably, both insertions in the JME contained the amino acid sequence QLHF, 
as has been found in the Jurkat cell line and the majority of reported primary T-ALL 
cases (Sulis et al, 2008).  
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Figure 3.3. The location of NOTCH-1 mutations identified in 60 adult T-ALL 
patients. Downward pointing arrowheads signify point mutation whilst upward arrowheads 
indicate insertions and or/deletions. Patients with more than one mutation are indicated with 
white arrowheads, whilst those with only one mutations are represented by a filled arrowhead. 
EGF Epidermal growth factor-like repeat, LNR Lin-Notch repeat, HD-N N-terminal 
heterodimerisation domain, HD-C C-terminal heterodimerisation domain, TM transmembrane 
domain, ANK Ankyrin  domain,TAD transactivation domain, PEST proline (P) glutamic acid 
(E) serine (S) threonine (T) rich domain.     
 
Remission DNA samples were available from 15 patients, nine of whom had a mutation 
at disease presentation.  In each case the mutation was no longer detectable in remission, 
indicating they were somatic in origin.  
 
NOTCH-1 mutations were therefore highly prevalent in an adult cohort of T-ALL 
patients. Although there was a higher number of insertions and/or deletions in the HD-C 
in adult T-ALL compared to those reported in paediatric patients (Weng et al, 2004), the 
overall incidence of NOTCH-1 mutations were not significantly different between these 
two age groups (Table 3.5).  
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Table 3.5 A comparison of the frequency and characteristics of NOTCH-1 
mutations in 60 adult T-ALL patients versus those published for paediatric 
patients. 
       Mutant in 96 
paediatric patients† 
       Mutant in 60 
      adult patients 
     P value 
Mutant in any domain  (% of total 
cohort) 
54 (56%) 36* (60%) 0.64 
         HD only 25 (26%) 23 (38%) 0.11 
         TAD/PEST only 12 (12%) 5 (8%) 0.42 
         HD + TAD/PEST  17 (18%) 8 (13%) 0.47 
    
HD-N  (% of all HD-N mutations) (n = 34) (n = 24) 0.56 
         Leucine to proline  14 (41%) 8 (35%) 0.82 
         Other point mutations 7 (21%) 5 (17%) 0.81 
         Insertions and/or deletions 13 (38%) 11 (48%) 0.42 
    
HD-C (% of all HD-C mutations) (n = 8) (n = 7) 0.49 
         Leucine to proline 4 (50%) 0 (0%) 0.11 
         Other point mutations 4 (50%) 3 (42%) 0.81 
         Insertions and/or deletions 0 (0%) 4 (58%) 0.01 
    
TAD/PEST (% of all TAD/PEST 
mutations) 
(n = 29) (n = 13) 0.24 
         Point mutations 10 (34%) 3 (23%) 0.23 
         Insertions and/or deletions 19 (66%) 10 (77%) 0.62 
†Data from Weng et al. (Weng et al, 2004). *Data excludes JME mutations as they were not 
analysed by Weng et al. P values calculated using Chi-square test.  
 
3.4.2 FBXW7 mutations in adult patients with T-ALL 
DHPLC analysis was used to screen the WD40 domain of FBXW7 (exons 8-12) in 
samples from 60 adult patients. Twelve patients had an abnormal chromatogram pattern 
in one of these exons. In patient T5 the nucleotide change 1944A>G was found which is 
synonymous at the amino acid level (L648L), and although not reported on the dbSNP 
database, was present in the remission DNA sample and thus likely to be a private SNP.  
Thus overall, eleven patients (18%) had a mutation in FBXW7 (Figure 3.4 and Table 
3.4); eight with R465C, two R479L and one G423V, and, of note, all except one of these  
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mutations altered conserved arginine residues in the WD40 domain thought to be 
responsible for binding to the NOTCH-1 PEST domain. Consistent with this finding, 
FBXW7 mutations and NOTCH-1 PEST domain mutations were mutually exclusive 
(Table 3.6). There was a positive association between having a mutation in the NOTCH-
1 HD domain only and an FBXW7 mutation (10 of 22 patients with HD domain only 
mutations were FBXW7 mutant vs. 1 of 37 other patients; Fisher’s exact test P<.001) 
(Table 3.6). Such a combination of mutations been shown to be synergistically activating 
in vitro by a mechanism similar to that of dual HD and PEST domain mutations, ie. 
ligand-independent NOTCH cleavage and prolonged ICN half-life (Malyukova et al, 
2007). A similar incidence of FBXW7 mutations has been shown in paediatric T-ALL	  
(Kox et al, 2010; Park et al, 2009; Zuurbier et al, 2010). 
 
 
 
 
 
Figure 3.4 FBXW7 mutations in adult T-ALL patients. (A) DHPLC patterns for 
FBXW7.  Characteristic chromatograms for the R465C and R479Lmutations in exon 9 
performed at 58.6°C. (B) The location of FBXW7 mutations identified in 60 adult T-
ALL patients.  Schematic for FBXW7 showing position of mutations in the adult T-
ALL patients. WD WD40 domain  
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Table 3.6 The association of NOTCH-1 and FBXW7 mutation status of 60 adult T-
ALL patients. 
 
(% of total cohort) 
FBXW7 
WT 
(n=49) 
 
FBXW7 
MUT 
(n=11) 
 NOTCH-1 WT 21 (35%) 
 
1 (2%) 
 NOTCH-1 HD only 
 
13 (21%) 
 
10 (16%) 
 
 NOTCH-1 JME 2 (3%) 0  
 NOTCH-1 PEST only 
 
5 (8%) 
 
0 
 
 NOTCH-1 HD+PEST 
 
8 (15%) 
 
0 
 
 
3.4.3 Prognostic implications of NOTCH-1 and FBXW7 mutations in adult T-ALL 
Of the 60 patients studied, 54 were entered into the UKALLXII trial. Therefore, to 
address the prognostic implications of NOTCH-1 and FBXW7 mutations in adult patients 
with T-ALL, the data on these 54 patients were combined with data from 34 patients 
treated on the same protocol in the ECOG2993 trial (note ECOG2993 and UKALLXII 
were joint trials) and studied by Adolfo Ferrando’s group. An outline of the trial protocol 
is shown in Figure 3.5. All the following data therefore refers to the combined group of 
88 patients.  
 
 
Figure 3.5 A simplified algorithm of the UKALLXII/E2993 treatment  
protocol.  HD-MTX, high-dose methotrexate. 
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3.4.3.1 Clinical features of patient cohort 
The cohort analysed was representative of all 356 T-ALL patients entered onto the 
clinical trial in terms of sex and median age, but had a higher presenting WCC, which 
probably reflects a bias towards the collection and banking of samples with abundant 
material (Table 3.7). Median follow-up for the 88 patients in the cohort was shorter than 
for all 356 patients, but complete remission rates, OS and EFS were similar.  
 
 
Table 3.7 Comparison of the UKALLXII/ECOG 2993 trial T-ALL patients with  
     and without molecular data 
 Patients with 
NOTCH-1/FBXW7 
Mutation data 
Other 
UKALLXII 
T cell 
patients 
P value 
Total 88 268  
Male 65 (74%) 195 (73%) 0.8 
Median (range) age 30.5 (16-60) 28.5 (15-60) 0.8 
Median (range) WCC x 
109/l 
50 (1-653) 31 (0.6-541) 0.003 
Median follow-up (yrs) 3.6 7.9 <0.0001 
Achieved remission 85 (97%) 251 (94%) 0.3 
Survival * 49.4% 41.3% 0.98 
Event free survival * 42.7% 44.9% 0.88 
* Percents at 5 years; p-value = log rank over all follow-up 
 
In the cohort analysed, there was no significant association with WCC or age according 
to either NOTCH-1 or FBXW7 mutational status (Mantel Haenszel test for trend P>0.1 
for each case). Complete remission was achieved in 97% of patients; 33 of 35 (94%) 
NOTCH-1/FBXW7 WT (ie. wild-type for both NOTCH-1 and FBXW7) and 52 of 53 
(98%) NOTCH-1/FBXW7 MUT patients (ie. mutant for either NOTCH-1 and/or FBXW7) 
(P=.56). The NOTCH-1/FBXW7 WT and MUT groups received similar treatment (WT 
vs. MUT: 7 (20%) vs. 16 (30%) sibling allograft; 3 (9%) vs. 7 (13%) autograft; 3 (9%) 
vs. 3 (6%) matched unrelated donor allograft; 18 (51%) vs. 25 (47%) chemotherapy with 
maintenance alone; chi square P=.69).  
 
3.4.3.2 NOTCH-1 and FBXW7 mutation incidence and features  
The mutation rate for NOTCH-1 was similar in the UKALL and ECOG cohorts (59% vs. 
62% respectively, P=.77). Of the total 88 T-ALL patients analysed, 53 (60%) had at least 
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one NOTCH-1 mutation; 36 patients (41%) had a mutation in the HD domain only, seven 
(8%) in the PEST domain only, six (7%) in both HD and PEST domains, one (1%) in the 
TAD and three (3%) had JME mutations (Table 3.4 and Appendix Table 1). For further 
analysis the TAD mutation was grouped with the PEST domain mutations, given that it 
truncated the PEST domain and would be functionally analogous to a PEST domain 
mutation.  
 
The mutation rate for FBXW7 was the same in the UKALL and ECOG cohorts (18% in 
both cohorts, P=1.0). Fifteen of the 16 patients had a mutation affecting one of the 
conserved arginine residues in the WD40 domain thought to be responsible for binding 
to the NOTCH-1 PEST domain (Table 3.4 and Appendix Table 1). Five of the FBXW7 
MUT patients (31%) were wild-type for NOTCH-1, whilst the other eleven FBXW7 
MUT patients (69%) had HD-N domain mutations. Details of the nucleotide and amino 
acid changes for NOTCH-1 and FBXW7 for the 34 additional ECOG2993 patients are 
shown in Appendix Table 1. 
 
3.4.3.3 Patient outcome according to mutation status 
Importantly, patients with standard-risk disease (≤35years old with WCC <100x109/l) 
and high-risk disease (>35years and/or WCC ≥100 x109/l) were evenly distributed 
between the NOTCH-1/FBXW7 MUT and WT groups. For WCC, 61% patients with 
WCC<100x109/l were NOTCH-1/FBXW7 MUT vs. 62% patients with WCC ≥100 x109/l, 
Fisher’s Exact test P=1.0. By age, 55% patients ≤35years were NOTCH-1 MUT vs. 69% 
>35 years, P=.37). The overall outcome of all patients on the trial has recently been 
reported (Goldstone et al, 2008). Comparison of outcome in patients with a mutation in 
the Notch pathway (NOTCH-1 and/or FBXW7) with those without a mutation showed a 
trend towards improved outcome in those with a mutation. At 5 years, EFS and 95% 
confidence interval (CI) were 51%±14% vs. 27%±19% (P=.10) in MUT and WT patients 
respectively (hazard ratio 0.6, 95% CI = 0.3-1.1) (Figure 3.6A).  The OS at 5 years was 
54%±14% and 41%±20% respectively (P=.30) (Figure 3.6B). Analysis of patients with 
or without a NOTCH-1 mutation alone revealed a 5 year EFS of 49%±15% vs. 
34%±18% (P=.2) (Figure 3.6C) and OS of 53%±15% vs. 45%±17 (P=.41) (Figure 3.6D) 
respectively. Comparison of patients with or without an FBXW7 mutation alone showed 
a 5 year EFS of 53%±26 vs. 41%±13 (P=.72) (Figure 3.6E) and OS of 62%±24 vs. 
47%±12% (P=.51) (Figure 3.6F). On the trial as a whole, treatment, age and WCC  
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Figure 3.6. Outcome of adult patients with T-ALL treated on UKALLXII/E2993 
protocol stratified by NOTCH-1 and FBXW7 mutational status. (A) Event-free 
survival (EFS) and (B) overall survival (OS) by NOTCH1 and/or FBXW7 mutation. (C) EFS and 
(D) OS by NOTCH-1 mutation status alone. (E) EFS and (F) OS by FBXW7 mutation status 
alone. MUT mutated; WT wild type.
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significantly influenced outcome (Goldstone et al, 2008; Rowe et al, 2005). Of these 
factors, only treatment received was significant in the Cox model in this smaller cohort 
of T-ALLs (P=.03), and inclusion of these variables did not materially affect EFS (Table 
3.8). There was insufficient data to test the effect of transplant by means of a donor-
versus-no donor comparison. Standard risk patients with a NOTCH-1 and/or FBXW7 
mutation did not fair significantly differently from standard risk WT patients (EFS for 
patients with WCC<100 was 47.7% in patients with a NOTCH-1 and/or FBXW7 
mutation vs. 30.3% for WT patients, P=.5; EFS for patients <35years was 45.5% in 
patients with a NOTCH-1 and/or FBXW7 mutation vs. 39.3% for WT patients, P=.6) and 
there was no interaction between effects of mutation and risk group. 
 
Table 3.8  Multivariate analyses of event free survival for patients treated on 
UKALLXII/ECOG2993 according to age, WCC, treatment arm and NOTCH-
1/FBXW7 mutation status.  
Model Hazard ratio 
(95% confidence interval) 
for variable shown in italics 
NOTCH-1/FBXW7 0.62 (0.34-1.11) 
NOTCH-1/FBXW7, age, log(WCC+1) 0.66 (0.34-1.29) 
NOTCH-1/FBXW7, age, log(WCC+1), treatment* 0.73 (0.37-1.44) 
NOTCH-1 0.70 (0.39-1.24) 
NOTCH-1, age, log(WCC+1) 0.77 (0.42-1.42) 
NOTCH-1, age, log(WCC+1), treatment* 0.85 (0.45-1.61) 
FBXW7 0.85 (0.38-1.91) 
FBXW7, age, log(WCC+1) 0.91 (0.40-2.08) 
FBXW7, age, log(WCC+1), treatment* 0.87 (0.36-2.13) 
    *First remission transplant or chemotherapy (n=84) 
 
Considering the marked in vitro synergistic activation of the Notch pathway by dual 
NOTCH-1 HD and PEST domain mutations or dual NOTCH-1 HD domain and FBXW7 
mutations (Malyukova et al, 2007), the outcome of this ‘synergistic’ subgroup (n=17) 
was analysed versus the WT patients. The EFS was 62% versus 30% respectively, but 
this did not reach statistical significance (P=.17).  
 
Overall, this data showed a trend towards improved EFS in patients with a Notch 
pathway mutation, but did not identify a subgroup of patients with a significantly 
favourable outcome to warrant treatment reduction on future trials. 
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3.4.4 Mutational screening of the LNR domain of NOTCH-1 
The NOTCH-1 NRR (negative regulatory region) consists of three LNR modules, termed 
LNR-A, -B and -C, that form a protective ‘knuckle’ over the hydrophobic core of the HD 
domain, preventing access of TACE to the S2 cleavage site in the absence of ligand. 
Given that the LNR-HD interface is an important negative regulator of NOTCH-1 
activation, mutational disruption of the LNR could potentially activate Notch in those 
patients without HD mutations. This region was therefore screened in the 54 adult 
patients from the UKALLXII cohort. Twelve paediatric T-ALL patients were also 
analysed in case mutations of this domain happened to be a feature related to patient age. 
The age range of the latter patients was 5 months to 12 years (median age 4 years) and 7 
(58%) were male.  
Overall, seven of the patients had an abnormal WAVE pattern in the LNR domain. In 
five patients this was due to a SNP (rs61751542; 4132C>T; P1378S). Remission DNA 
from one patient showed an identical DHPLC pattern suggesting that the alteration was 
of germline origin. The reported frequency in the population is 0.02 on dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP/). The other two patients had somatic 
missense mutations that are detailed below. 
• Somatic H1545P LNR mutation 
An H1545P mutation was identified in a sample from a 5 month old girl who was 
also found to have a PEST domain mutation (S2514F). Both mutations were 
absent in the remission sample. Although diagnostic RNA was available, it was 
not of adequate quality to amplify the relevant region of NOTCH-1 mRNA in 
order to assess whether these particular mutations were in cis, trans or different 
clones. Given its likely functional significance, a collaboration was set up with 
Jon Aster and Stephen Blacklow’s group at Brigham and Women’s Hospital in 
Boston, USA, who were in the process of crystallising the NRR domain of 
NOTCH-1 and had developed assays to assess the activating potential of 
NOTCH-1 mutations. The following data was produced in their laboratory, 
predominantly by Wendy Gordon, and is included here for interest and 
completeness (Gordon et al, 2008). Briefly, they identified by crystallography 
that H1545P was located in a loop of the LNR-C module, within the interface 
with the HD domain and the calcium-binding pocket. In luciferase reporter assays 
the mutation resulted in a 20-fold increase in ligand-independent reporter gene 
transcription, which was intermediate between the weak activating leucine-to-
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proline mutations and the more potent type II mutations. Previous studies had 
shown that the LNR-C is directly involved in calcium binding, which is required 
to maintain this domain in its inhibitory conformation (Aster et al, 1999), and 
H1545 maps directly to the calcium-binding interface. It is therefore likely that 
the proline of H1545P activates signalling through disruption of calcium binding.  
 
• Somatic C1522G LNR mutation.  
This mutation was identified in a sample from an adult patient who also had a 
PEST mutation (P2513S) but no HD mutation. Remission DNA was available 
from this patient and showed a wild-type DHPLC pattern, suggesting that the 
mutation was somatic in origin. The cysteine residue at position 1522 is thought 
to be one of three cysteine residues that provide disulphide bridging of the 
NOTCH-1 heterodimer after S1 cleavage. In order to further ascertain its 
function, Jon Aster’s group expressed the C1522G mutation with a CSL 
luciferase reporter in U2OS cells. The mutation was not activating. Although 
speculative, one possible reason for the lack of activation is stimulation of the 
unfolded response by misfolding of the Notch heterodimer in U2OS cells that is 
tolerated in T-ALL cells. Another possibility is that the mutation increases 
sensitivity to stimulation by ligands that are expressed in T-ALL cells but not in 
U2OS cells. 
 
3.4.5 Analysis of NOTCH-3 in T-ALL and infant AML patients 
The LNR, HD-N, HD-C, TAD and PEST domains of NOTCH-3 were analysed by 
DHPLC using samples from 38 adult T-ALL patients and 30 infant leukaemia samples, 
followed by sequencing of those cases with abnormal chromatograms. No somatic 
mutations were identified. The following SNPs were identified: 
• rs1044006; 4639A>G; P1521P synonymous SNP. This was identified in 6 of 38 
patients (16%). The reported frequency in the population is 0.16 on dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP/). 
• rs56277836; intron 26, 4891+23 G>C heterozygous alteration 23 bp 
downstream of the exon 26 intron/exon boundary. This was identified in 3 of 
38 patients (8%). Remission DNA from one patient showed the same sequence 
alteration. The reported frequency in the population is 0.04 on dbSNP. 
 112 
• rs1044008; 6514G>A; A2416A synonymous SNP. This was identified in 5 of 
38 patients (13%). Remission DNA from one patient showed an identical 
sequence alteration. The reported frequency in the population is 0.03 on dbSNP. 
• rs1044009; 6744C>T; A2223V. This was identified in 12 of 38 patients (31%). 
Remission DNA from three patients showed an identical sequence alteration. The 
reported frequency in the population is 0.4 on dbSNP.  
 
3.4.6 NOTCH-1 mutations are not a common feature of infant leukaemia 
Of the 29 samples obtained from patients with infant leukaemia (occurring prior to the 
age of 1 year), immunophenotype data showed 13 cases had AML and 16 had B-ALL, of 
which six had pre-B-ALL and 10 pro-B ALL.  Of the 26 patients where cytogenetic 
analysis was successful, 14 had a rearrangement involving the mixed lineage leukaemia 
gene (MLL) on chromosome 11q23. FISH data for MLL was not available. Sixteen of the 
29 patients (55%) had expression of at least one T-cell marker in 10% or more of the 
cells, with 12 patients expressing CD7, eight with cytoplasmic CD3 expression, none had 
surface CD3 expression, and six had expression of CD4. DHPLC analysis was carried 
out for the NOTCH-1 HD-N, HD-C, TAD and PEST domains and 12 patients (41%) 
were heterozygous for the 5094C>T SNP (rs10521) previously described in section 
3.4.1. No other abnormalities were detected.  
 
3.4.7 NOTCH-1 mutations are not a common feature of adult AML 
Samples from a cohort of 157 AML patients were screened for mutations in NOTCH-1 
as before. Of the cohort, 52 had good risk cytogenetics, of which three had t(8;21) and 48 
had t(15;17) (acute promyelocytic leukaemia [APML]). Of the remainder, 77 had 
standard risk cytogenetics, three had poor risk and in 25 patients the cytogenetic data was 
not available. The cohort was intentionally enriched for patients with APML given 
reports of their particularly high frequency of aberrant T-cell marker expression. In one 
study of 196 APML patients, CD2 expression was detectable in 28% of cases (Guglielmi 
et al, 1998), whilst another study of 36 APML patients showed CD2 expression in 38% 
of cases and also the presence of TCR rearrangements in 15% (Chapiro et al, 2006). In 
this cohort, none of the T-ALL associated mutations were detected, although a number of 
SNPs were identified as outlined below.  
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Previously reported SNPs: 
• rs10521; 5094C>T; D1699D synonymous SNP. The characteristic DHPLC 
pattern for the heterozygous 5094C>T SNP was identified in 46% patients in this 
cohort. The reported frequency in the population is 0.43 on dbSNP. 
• rs76371972; 4823G>A; R1609H SNP. This was identified in two APML 
patients. Remission DNA from both patients showed persistence of the nucleotide 
substitution by sequencing, suggesting they were germline in origin. The reported 
frequency in the population is 0.006 on dbSNP. 
• rs61751489; 6853G>A; V2285I SNP. This was identified in two AML patients. 
No remission/germline DNA was available for either patient, but this alteration is 
reported as a SNP on dbSNP with a frequency in the population is 0.02. 
 
Nucleotide changes not previously reported and of uncertain significance: 
• 4656G>A; A1553T. This was identified in one AML-M2 patient. A1553 is just 
upstream of the HD-N domain. Remission or germline DNA samples were not 
available to assess whether or not this change was somatic, and it was not 
assessed in a functional assay. 
• 4626C>T; D1543D synonymous. No remission/germline DNA was available for 
this patient, but given the absence of alteration in the amino acid sequence, is 
unlikely to be of functional significance. 
• Intron 26 delTGAT 12bp upstream of the exon 27 intron/exon boundary. 
This was identified in one APML patient. Unfortunately no remission/germline 
DNA was available to investigate whether this alteration was somatic. RNA was 
not available to investigate splicing, although it was thought unlikely to affect 
splicing given its distance from the acceptor site. 
• 7510G>A; V2505M. This was identified in one AML-M0 patient. No 
remission/germline DNA was available to investigate whether this alteration was 
somatic. 
 
3.5 DISCUSSION 
 
Overall, the frequency of NOTCH-1 mutations detected in the UKALLXII cohort of 60 
adult T-ALL patients studied was comparable with results reported in paediatric patients 
(61% versus 56% respectively), and remained the same when the cohort was increased to 
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88 patients by including the ECOG cohort (60%). The presence of mutations was not 
simply a feature of the young adult patients as 55% of patients less than 35 years of age 
were NOTCH-1 mutant compared to 69% of patients over 35 years. This suggests that a 
similar pathogenic mechanism may underlie the development of most cases of T-ALL 
irrespective of age, and that the difference in curability in the two groups is not related to 
a differing frequency of NOTCH-1 mutations.  
 
Despite their marked heterogeneity, no particular type of mutation appeared to be 
associated with age. The majority of mutations identified were likely to be functionally 
significant since they either truncated the PEST domain or affected highly conserved 
residues in the HD domain. The importance of the latter is supported by crystallography 
data that has shown that it is the conserved amino acids in the HD domain that form the 
interface with the LNR domain, such that amino acid substitutions of these residues are 
likely to disrupt the HD-LNR interaction (Gordon et al, 2009). All the insertions and/or 
deletions in the HD domain were in-frame, consistent with the requirement of a 
functional ICN for leukaemic transformation. In the HD-N domain, there was a 
particular propensity for amino acid substitutions to prolines, which can be structurally 
detrimental because of their acute angle in the amino acid backbone. Eight of the 24 HD 
domain mutations detected in the UKALLXII cohort (L1594P, L1597H, R1599P, 
I1617N, I1681N, the S2 cleavage site duplication, L1601P and F1593L+1594insS) have 
been functionally tested in reporter assays in separate studies and shown to be activating 
(Chiang et al, 2008; Malecki et al, 2006; Palomero et al, 2006b).  
 
Two patients had duplications of the S2 cleavage site in the HD-C domain. A similar 
duplication of the S2 cleavage site (also containing the GSL sequence) has been 
identified in the P12-Ichikawa cell line and was the most potently activating of 14 HD 
domain mutations tested (Malecki et al, 2006). Furthermore, this mutation is capable of 
initiating leukaemia in its own right in murine models, in comparison to the L1594P and 
L1601P mutations which are not transforming in vivo, but are able to accelerate KRas 
G12D-induced leukaemia (Chiang et al, 2008). It is likely that a dosage effect exists 
relating to the site and type of each individual mutation. In vitro reporter gene assays 
have demonstrated that HD domain mutations are more activating than PEST truncations 
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alone, whilst dual HD and PEST mutations in cis have a synergistic effect on Notch 
activation (Weng et al, 2004).  
 
All the frame-shift mutations identified in the PEST domain truncated the protein prior 
to, or disrupted, the FBXW7 binding site at position T2512. However, in this study three 
missense mutations that would be predicted to affect the FBXW7 binding site were also 
detected: S2514F, P2513L and P2513S. Point mutations of this type had not previously 
been described. It would be of interest to functionally test these mutations to investigate 
whether they disrupt binding to FBXW7 in co-immunoprecipitation studies, and if they 
can activate signalling. The other mutation identified of particular interest was an 
H1545P substitution in the LNR-C domain. This does not appear to be a common 
mutational site and this was the first known description of an activating mutation 
affecting this domain in T-ALL.  We were fortunate to collaborate with the Aster and 
Blacklow laboratories, who were able to model this mutation on their crystallography 
data and showed that it most likely inhibits calcium binding in the LNR-C which would 
result in loss of structural integrity and subsequent activation of Notch signalling. Such a 
mechanism is reminiscent of the ability of EDTA to activate Notch signalling through its 
ability to chelate calcium in vitro (Aster et al, 1999).  
 
There was a significant positive association between having a NOTCH-1 mutation in the 
HD domain only and an FBXW7 mutation, and a negative association between having a 
NOTCH-1 PEST domain mutation and an FBXW7 mutation. This observation is 
consistent with the hypothesis that NOTCH-1 HD domain and FBXW7 mutations act in 
concert, similar to dual NOTCH-1 HD and PEST domain mutations (Malyukova et al, 
2007; Thompson et al, 2007). Although FBXW7 also targets c-Myc for degradation 
(O'Neil et al, 2007; Thompson et al, 2007), the association described here favours the 
concept that FBXW7 mutations are acquired by T-ALL cells primarily as a means of 
increasing NOTCH-1 signal strength. If FBXW7 mutations were acquired by tumour cells 
predominantly to upregulate c-Myc, they would likely be found in conjunction with 
PEST mutations in some cases.  
 
No NOTCH-1 mutations were identified in the cohort of AML patients analysed, 
including those with APML or infant AML, where there is a high frequency of aberrant 
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expression of T-cell markers. However, it is still possible that Notch is activated by 
alternative mechanisms in AML. For instance, over-expression of NOTCH-1 itself has 
been identified by microarray in a subset of AML patients with poor prognosis 
(Bullinger et al, 2004). Additionally, transduction of bone marrow cells with AML1-
ETO, PML-RARA or PLZF-RARA fusion constructs was shown to increase expression 
of the Notch ligand JAGGED-1, a gene that is also up-regulated in some patients with 
AML (Alcalay et al, 2003; Ross et al, 2004). Other groups have similarly reported that 
NOTCH-1 is not commonly mutated in AML (Fu et al, 2006), although one group 
identified an activating HD-N domain mutation in a single patient with AML-M0 from a 
cohort of 121 patients screened (Palomero et al, 2006b). There is, however, a rare select 
AML subset where NOTCH-1 mutations have been described at higher frequency. A 
small group of six patients clustering together by gene set enrichment analysis (described 
as ‘Cluster 4’) in a large AML cohort of 285 patients have been identified as having 
frequent CEBPA promoter methylation and three had NOTCH-1 mutations (Wouters et 
al, 2007), although it is unclear whether these patients should be truly classified as AML 
or would fulfil criteria described by the European Group for the Immunological 
Characterization of Leukemias (EGIL) for mixed lineage T-ALL/AML (Bene et al, 
1995). A NOTCH-1 mutation has also been described in a so-called ‘lineage switch 
leukaemia’, as identified in two sister cell lines (ML1 and ML2), where one cell line is 
derived from a patient with AML at presentation, and the other cell line from the same 
patient at relapse with T-ALL, with both cell lines having the same NOTCH-1 mutation 
(Palomero et al, 2006b).  
 
Despite the strong oncogenic potential of ICN-3 in inducing T-ALL in murine models, 
no mutations were found in NOTCH-3. Studies have shown that NOTCH-3 is markedly 
over-expressed in the majority of T-ALL patients, in some cases this is secondary to 
direct transcriptional up-regulation by NOTCH-1 (Bellavia et al, 2002; Palomero et al, 
2006a). As such, mutational activation of NOTCH-3 may not add a selection advantage 
to cells in addition to a NOTCH-1 mutation, and it is possible that a larger cohort of 
NOTCH-1 mutation-negative patients needs to be screened to definitively exclude the 
possibility of mutational activation of NOTCH-3 in T-ALL. However, it should be noted 
that it has not been reported whether T-ALL samples actually express ICN-3 protein, 
which would be indicative of NOTCH-3 activation rather than just over-expression of 
total NOTCH-3. 
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In terms of prognostic implications, the data presented here did not show a significantly 
improved outcome in those patients with mutations in the Notch pathway, although the 
trend towards a good prognosis is in accord with data previously presented in paediatric 
patients treated on the ALL-BFM protocol (Breit et al, 2006) and more recently in adults 
on the French LALA-94 and GRAALL-2003 trials (Asnafi et al, 2009), and in contrast to 
the association with poor prognosis reported for NOTCH-1 mutations in adults by Zhu et 
al. When the three most robust prognostic factors on the overall UKALLXII/ECOG 2993 
trial were taken into account (age, WCC and treatment arm), the differences in EFS and 
OS were unaffected. Additionally, the standard and high-risk patients had a similar 
incidence of NOTCH-1/FBXW7 mutations, suggesting that the data was not confounded 
by a disparate representation of the mutation-positive patients in either risk group. 
 
Whilst no significant difference in outcome in NOTCH-1 or FBXW7 MUT patients was 
observed when analysed individually, the combined NOTCH-1/FBXW7 MUT group 
showed a trend towards improved outcome (P=.1) highlighting the importance of the 
addition of FBXW7 status to that of NOTCH-1. More recent studies support the 
additional value of FBXW7 mutation data to NOTCH-1 mutation data in stratifying risk 
in both paediatric and adult patients (Asnafi et al, 2009; Kox et al, 2010), suggesting that 
it is the degree of Notch pathway activation itself that is important in determining 
treatment response. The marked variability in activation strength of individual mutations 
in in vitro assays suggests that validation of a robust marker of downstream Notch 
activation could be useful in prognosticating patients in future studies. 
 
Other molecular markers have been reported to have some impact on prognostic outcome 
in adult T-ALL. For example, TLX1 mRNA upregulation has been shown to be 
associated with an improved prognosis (Ferrando et al, 2004). It was not possible to 
evaluate this in the cohort studied here due to lack of RNA samples from all patients. 
However, patients with TLX1 up-regulation constitute a minority of patients and are 
strongly associated with NOTCH-1 mutations (20 of 21 patients with TLX1 up-regulation 
were NOTCH-1 MUT in the French study) (Asnafi et al, 2009). NOTCH-1/FBXW7 
mutations have also been shown to be prognostically important independently of TLX1 
(Asnafi et al, 2009).  
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Since the completion of these studies, a number of other groups have published data 
addressing outcome by NOTCH-1/FBXW7 mutation status in T-ALL patients on 
different treatment cohorts and the results of these studies are summarised in Table 3.9. 
Consistent with the data from the UKALLXII/ECOG2993 cohort, most trials showed no 
association of NOTCH-1/FBXW7 mutation status with WCC or age, though several 
groups showed a higher incidence of mutations in the cortical subgroup of patients 
(CD1a positive) and those with high expression of TLX3 (Baldus et al, 2009; Breit et al, 
2006; Kox et al, 2010; Zuurbier et al, 2010). Data from the largest and best-characterised 
paediatric cohort comes from 301 patients treated on the ALL-BFM trial (Kox et al, 
2010). This showed that paediatric patients with NOTCH-1 and/or FBXW7 mutations had 
an excellent early treatment response and favourable MRD at day 33. In terms of EFS, 
when patients were stratified by NOTCH-1 mutation status alone or by NOTCH-1 and/or 
FBXW7 mutation status, the mutant-positive patients had a superior outcome, but this 
was not seen when stratifying by FBXW7 mutation status alone. There was no 
association of EFS with NOTCH-1 and/or FBXW7 mutation status in their high-risk 
patient group (as defined by induction failure or poor early treatment response). This 
contrasts with the dismal prognosis seen in high-risk NOTCH-1 mutant patients treated 
on the EORTC trial, which relates predominantly to a high-risk of CNS relapse (Clappier 
et al, 2010). The major difference in treatment approach between the BFM and EORTC 
trials is the use of prophylactic cranial radiation in the former, suggesting cranial 
radiotherapy may have a particular role in preventing CNS relapse in NOTCH-1 mutant 
high risk T-ALL (Kox et al, 2010). In adult T-ALL, the largest study was reported by the 
French with 87 patients treated on the LALA-94 and 54 patients treated on the GRAAL-
2003 protocols (Asnafi et al, 2009). The authors identified NOTCH-1 and/or FBXW7 
mutations as an independent prognostic factor for improved outcome (P=.01), with an 
EFS for the WT group of 17 months compared to 36 months for those with either a 
NOTCH-1 and/or an FBXW7 mutation (P=.01).  However, much larger studies of adult 
patients will be required to demonstrate this unequivocally, and differences in treatment 
protocols are likely to be an important variable. On the UKALLXII/ECOG2993 trial, 
there was an 80% power to detect a 30% increase in EFS. The data on this adult cohort 
does therefore indicate that, even if there is a better outcome in those with a Notch 
pathway mutation, the magnitude of the improvement in EFS is likely to be too low to 
consider de-intensification of therapy in this group of patients, as has been suggested by 
other groups (Asnafi et al, 2009).  
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Table 3.9 Summary of trials in paediatric and adult T-ALL that have investigated prognostic implications of NOTCH-1 and FBXW7 
mutations 
 Reference Age group Protocol/trial Number 
tested 
% with 
NOTCH-1 
mutations 
% with 
FBXW7 
mutations 
Association of mutation status with outcome 
Breit et al 2006 Paediatric ALL-BFM 2000 157 52% NT NOTCH-1 mutations associated with good early treatment response, 
improved EFS and low RR 
(Zhu et al, 2006) Paediatric 
and adult 
VDCP induction/high 
dose MTX 
 53 
paediatric 
24 adult 
38% NT Paediatric patients:  No association with outcome 
Adult patients: NOTCH-1 mutations associated with increased 
relapse rate and poor EFS 
(van Grotel et al, 
2008) 
Paediatric DCOG-ALL7/8/9 70 57% NT No association with outcome 
(Larson Gedman et 
al, 2009) 
Paediatric POG 8704/9086/9295/ 
9296/9297/9398 
47 34% 11% No association with outcome 
(Park et al, 2009) Paediatric JACLS-ALL-97 55 40% 15% NOTCH-1 and/or FBXW7 mutation positive patients associated with 
improved EFS  
(Kox et al, 2010) Paediatric ALL-BFM 2000 350 50% 14% NOTCH-1 and/or FBXW7 mutation associated with good early 
treatment response; improved EFS and OS with NOTCH1 MUT 
alone but not FBXW7 MUT alone 
(Zuurbier et al, 2010) Paediatric DCOG-ALL7/8/9; 
COALL-97 
141 56% 16% Good early treatment response but no association with EFS. Trend 
towards worse outcome in NOTCH1 MUT patients on DCOG cohort 
(Clappier et al, 2010) Paediatric EORTC 58881/58951 134 60% NT Good early treatment response but no association with EFS or OS 
(Mansur et al, 2012) Paediatric GBTLI-99 138 44% 19% No association with outcome 
(Jenkinson et al, 
2012) 
Paediatric UKALL2003 162 62% 18% Patients with double NOTCH1 and/or FBXW7 mutations had 
excellent OS (100%). 
(Baldus et al, 2009) Adult GMALL 05/93; GMALL 
06/99 
126 57% 12% No association with outcome 
(Asnafi et al, 2009) Adult LALA-94; GRAALL-
2003 
141 62% 24% NOTCH-1 and/or FBXW7 mutations independent prognostic markers 
for improved EFS and OS 
(Mansour et al, 2009)  Adult UKALLXII/ECOG2993 88 60% 16% No association with outcome, though trend towards improved 
outcome in NOTCH-1/FBXW7 MUT group 
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One question of particular interest, given the very high incidence of NOTCH-1 and 
FBXW7 mutations in T-ALL, is the mechanism by which these alterations occur. One 
possibility is that the high expression of Recombinase-activating gene 1 and 2 (RAG-1 
and RAG-2) leads to promiscuous double-strand DNA breaks with faulty mismatch 
repair, a mechanism that has been implicated in causing the abundance of translocations 
and genomic deletions found in lymphoid malignancies in general, a recent example 
being the PAR1 deletions leading to CRLF2 upregulation in B-ALL (Mullighan et al, 
2009). During V(D)J recombination, RAG proteins recognise a recombination sequence 
consisting of a conserved heptamer, a 12 or 23bp non-conserved spacer, followed by a 
conserved nanomer – the so-called ‘12/23 rule’ (Hesse et al, 1989). A search was 
performed to look for these conserved sequences in the vicinity of mutational hotspots of 
the HD and PEST domains in the UKALLXII cohort, but no such motifs were identified 
in these areas. Furthermore, acquisition of Notch-1 mutations has been observed in the 
majority of rag-2 deficient mice that develop T-ALL, indicating that, at least in this 
model, rag recombination is not involved in mediating these mutations (O'Neil et al, 
2006). On the other hand, 11 of the 16 missense mutations identified in FBXW7 were C 
to T transitions within CG dinucleotides and consistent with the mechanism of mutation 
acquisition due to deamination of methylated cytosines that was proposed originally by 
Arthur Bird (Bird, 1996). No studies on methylation within the FBXW7 gene in T-ALL 
have been reported and this would be an interesting area for future study. A trend 
towards C to T transitions was not seen in the NOTCH1 mutations identified in this 
cohort.  
 
γ-secretase inhibitors (GSI) have been shown to induce cell cycle arrest in vitro in T-
ALL cell lines harbouring NOTCH-1 mutations (Weng et al, 2004), and the experience 
gained from clinical trials using GSIs for Alzheimer’s disease, where they inhibit the 
production of beta amyloid peptide from amyloid precursor protein, has expedited trials 
of these agents in T-ALL. As discussed in further detail in chapter 6, they offer a rational 
molecularly targeted approach for these patients who, particularly in the older age group, 
have a poor outcome with current therapy.  
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CHAPTER 4. NOTCH-1 MUTATIONS CAN BE SECONDARY EVENTS IN 
SOME PATIENTS WITH T-ALL 
 
4.1. INTRODUCTION 
 
4.1.1 Significance of low level mutations detected by DHPLC 
Screening for NOTCH-1 mutations, as outlined in Chapter 3, showed that a significant 
number of patients had abnormal DHPLC chromatograms where the heteroduplex peak 
was of a low level as compared to the wild-type peak. An example is shown in Figure 
4.1. Such samples had no detectable mutation by direct sequencing of the PCR product, 
although the presence of a mutation could be detected by collection of the low level peak 
with the fraction collector facility of the WAVE®, followed by re-amplification by PCR 
and sequencing (as described below in section 4.3.2).  
 
 
 
 
 
Figure 4.1 Enrichment of a low level mutation using the fraction collector facility of 
the WAVE®.The chromatogram for patient T22 showed a low level heteroduplex peak for the 
HD-N domain. The fraction collector of the WAVE® (DHPLC) was programmed to collect the 
heteroduplex peak (highlighted in red) which was then re-amplified by PCR. DHPLC analysis of 
the PCR product confirmed enrichment of the heteroduplex which was then detectable by 
sequencing.. 
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Although contamination of tumour DNA with that of normal cells is a possible 
explanation for the presence of the low level mutations detected by DHPLC, if DNA is 
prepared from a pure population of tumour cells the most likely interpretation for this 
finding is that of subclonal evolution. In this scenario, the mutation is not present in the 
tumour-initiating cell but is acquired during disease pathogenesis/progression in a 
subclonal population of cells (Figure 4.2). An alternative explanation would be presence 
of the mutation in the initiating cell, but deletion of the mutant allele in the major 
population of cells during disease progression, although this would seem less likely if the 
mutation offered a significant survival advantage to cells.  
 
 
 
 
Figure 4.2 Timing of the acquisition of a NOTCH-1 mutation can be reflected in the 
mutant level. (A) Occurrence of a NOTCH-1 mutation in the leukaemia-initiating cell means 
that, even if there is clonal evolution with the acquisition of other mutations, the NOTCH-1 
mutant level will approximate 50%, assuming heterozygosity. (B) If the NOTCH-1 mutation 
occurs as a late secondary event then the mutant level in the bulk population of cells is likely to 
be significantly less than 50%. 
 
 
4.1.2 Multi-hit models and clonal heterogeneity in cancer 
In 1953 Nordling hypothesised that an average of at least six mutations of a single cell 
are required to induce cancer, a figure he deduced by analysing statistics showing the 
association of cancer with increasing age (Nordling 1953). In 1971, Knudson published 
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his ‘two hit’ model of tumourigenesis, based on the age of onset of sporadic versus 
inherited forms of retinoblastoma (Knudson 1971), and this ‘multi-hit’ model was further 
refined by Vogelstein in a study of colorectal cancer (Fearon and Vogelstein 1990). Such 
studies and calculations were based on an assumption that cancers were of monoclonal 
origin, a model that was supported by the work of Nowell that proposed a carcinogen 
could induce multiple mutations within different cells, most of which were deleterious, 
but that only a single cell that had acquired a combination of mutations that conferred a 
selection advantage would go on to produce the tumour bulk (Nowell 1976). Fidler and 
Kripke went on to show that single cell clones derived from an individual tumour (in this 
case, melanoma) had marked differences in their ability to metastasise to the lungs in 
murine xenografts, one of the first convincing experimental examples of the clonal 
heterogeneity present in cancer (Fidler and Kripke 1977).  
 
The exact number and type of mutations that are required to initiate tumourigenesis is 
highly variable. Work from the Weinberg laboratory has shown that anywhere between 
two and seven genetic pathways need to be perturbed for cellular transformation, 
dependent on cell type and species (Rangarajan, et al 2004).  Other studies have 
identified up to 20 driver mutations in an individual tumour, consistent with a 
mathematical model in which each mutation provides a relatively small selective 
advantage to the cell (Beerenwinkel, et al 2007, Sjoblom, et al 2006).  
 
With the recent development of next generation sequencing and high resolution copy 
number analysis, it should be noted that alternative models of tumourigenesis have been 
proposed. For instance, rather than the progressive accumulation of mutations occurring 
over time, the recent discovery of chromothripsis (the presence of tens to hundreds of 
genomic rearrangements and mutations on a single chromosome) has implicated the 
occurrence of a one-off catastrophic genetic event in some cancers such as osteosarcoma 
(Stephens, et al 2011). Furthermore, cells within a given tumour can be highly 
heterogeneous, as exemplified by the multiple different mutations, ploidy and gene 
expression signatures obtained from sampling different regions of an individual tumour 
(Gerlinger, et al 2012). The degree and complexity of clonal heterogeneity in ALL had 
not been established at the time the studies presented in this thesis were being performed, 
although several recent papers have addressed this in some detail (see Discussion).  
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4.1.3 ‘Passenger’ and ‘driver’ mutations in cancer 
Several authors have made analogies between Darwinian theories of evolution and 
cancer; tumour cells are under constant environmental pressure and genetic changes that 
offer a survival advantage will be selected for, whilst cells acquiring unfavourable 
genetic changes will be lost (Anderson, et al 2011, Greaves 2007, Merlo, et al 2006, 
Nowell 1976, Stratton, et al 2009). Despite the many thousands of somatic mutations 
identified by next generation sequencing in a variety of cancers, it is likely that most of 
them do not confer an advantageous phenotype to cells, and may have been present by 
chance in the cell of origin or acquired as a result of genetic instability during tumour 
progression. Such mutations have been described as ‘passenger’ mutations, as opposed to 
‘driver’ mutations that provide a survival advantage to cells and have undergone positive 
selection (Stratton et al., 2009). This is of considerable importance when interpreting 
data from next generation sequencing and particularly in determining which mutations 
should be pursued as therapeutic targets.  
 
4.1.4 NOTCH-1 mutations - disease initiators or collaborative events in T-ALL? 
After the seminal discovery of NOTCH-1 mutations in the majority of paediatric patients 
with T-ALL, it was argued that the acquisition of a NOTCH-1 mutation was the initiator 
of T-ALL in the majority of cases and that the other mutations or chromosomal 
aberrations found in T-ALL were acquired as secondary co-operating events after 
activation of the Notch pathway (Malecki, et al 2006). Given that NOTCH-1 is capable 
of T-cell lineage determination of uncommitted progenitors, the authors postulated that 
activating mutations of NOTCH-1 were the ‘first hit’, causing expansion of the T-cell 
pool, prior to acquisition of other mutations. Support for this theory came from mouse 
models of T-ALL where animals transplanted with cells transduced with either ICN-1 or 
the Notch ligand Delta-like 4 developed a lethal T-cell leukaemia, suggesting that Notch 
activation in itself was sufficient to initiate leukaemia (Pear, et al 1996, van den Brandt, 
et al 2006, Yan, et al 2001). Furthermore, Mel Greaves’ group at the Institute of Cancer 
Research, London, had analysed DNA extracted from a Guthrie card and shown that a 
NOTCH-1 HD-N mutation was present prenatally in a child who developed T-ALL at 6 
years of age (Eguchi-Ishimae, et al 2008). This patient had a SIL-TAL1 deletion 
detectable at disease presentation that was not present in the Guthrie card sample 
suggesting that, at least in this particular case, the NOTCH-1 mutation was acquired as 
the primary event.   
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However, many of the NOTCH-1 mutations described in human T-ALL are insufficient 
in their own right to initiate disease in mouse models, and can only accelerate T-ALL 
onset in collaboration with activation of other oncogenic pathways such as Ras (Chiang, 
et al 2008, Kindler, et al 2008, Mansour 2009). Notch-1 mutations have also been found 
in the majority of mice with Tal-1-induced T-ALL, as well as in mice that develop T-
ALL as a result of deficiencies in various combinations of Tp53, H2ax and Rag2 genes, 
suggesting that the mutations can occur as secondary events and play a collaborative role 
in T-ALL pathogenesis (Lin, et al 2006, O'Neil, et al 2006). Interestingly, the vast 
majority of the mutations acquired as secondary events in murine models are deletions of 
the PEST domain, with a conspicuous absence of HD mutations as compared to human 
disease. However, it has since transpired that in a high proportion of murine models of T-
ALL, including the Ikaros-driven T-ALL model, ligand-independent activation of Notch-
1 occurs by a different mechanism. Here, tumours acquire a deletion of the Notch-1 
promoter including exon 1 (type I deletion), or a deletion of sequences between exons 1-
28 (type II deletion), which leads to transcription of a spliced transcript that is translated 
from an alternative start site at amino acid M1727 (murine sequence) within the 
transmembrane domain (Ashworth, et al 2010, Jeannet, et al 2010). Such a mechanism 
has recently been described in a single patient with human T-ALL who had a deletion of 
the 5’ portion of NOTCH-1 as detected by SNP array, which led to an alternative start 
site at M1668 in the HD-C domain that produced high levels of ICN-1 (Haydu, et al 
2012). 
 
4.1.5 Analysis of matched presentation-relapse samples  
One possible way to dissect the chronology of mutation acquisition in T-ALL is to 
analyse paired presentation-relapse samples for mutations in particular genes. There are a 
number of possible outcomes to such analyses: 
 
1. No detectable mutation at presentation or relapse 
2. The same mutation is detectable at presentation and relapse  
3. A mutation in the presentation sample is lost at relapse 
4. A mutation in the relapse sample is not detectable at presentation 
5. Mutations are detected in the presentation and relapse samples but are 
different 
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The most likely explanation for scenario 2 is that the mutation occurs early in the 
leukaemia-initiating cell, is present in all clones and is thus detectable at relapse, 
irrespective of which clone is responsible for relapse. This would be the expected 
scenario if the mutation was a primary disease initiator. An alternative possibility is that 
the mutation has been acquired as a secondary event that confers an additional survival 
advantage to the cell, for instance by increasing chemoresistance, and is present in the 
relapse sample, at which point the mutant level may be seen to increase.  A third 
possibility is that the relapse clone by chance acquires the same mutation as a new event, 
which is plausible if the mutation was highly recurrent in that particular cancer, but much 
less likely if the mutation was unique. This would be technically difficult to prove, 
although a comprehensive analysis of other concurring mutations, including assessing 
mutant level, could assist in the interpretation of this finding.  
 
Although there are technical explanations that could account for scenarios 3, 4 or 5, for 
instance, a sample mix-up with either incorrect patient identity, or incorrect time point 
(eg. remission sample), there are several biological possibilities that could lead to such 
occurrences. For instance, a mutation occurring as a late secondary event at presentation 
that is not present in the clone responsible for relapse is arguably the most likely cause 
for scenario 3. Another possibility is that the relapse is not derived from an ancestral 
clone but is in fact a true secondary leukaemia occurring after treatment for the primary 
T-ALL.  Whilst most cases of relapsed T-ALL occur early in the first 18 months after the 
completion of therapy, secondary leukaemias typically occur after a longer interval and 
can be identified by the presence of a unique TCR-rearranged clonal sequence unrelated 
to the initial clone (Szczepanski, et al 2003).  
 
Scenario 4 could be explained by the acquisition of a mutation during therapy that 
confers chemoresistance or a survival advantage to cells. Although the genetic damage 
induced by chemotherapy has the potential of introducing mutations that confer 
chemoresistance, several recent studies support a mechanism in which a resistant clone 
pre-exists at low level prior to the initiation of therapy, but is seemingly ‘undetectable’ 
by low sensitivity techniques such as Sanger sequencing. For instance, a study in mice 
transplanted with primary human T-ALL cells showed that engraftment often occurs 
from a population of cells that exist as a minor subclone in the diagnostic sample 
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(Clappier, et al 2011). In this study, analysis of paired presentation and relapse human 
samples showed that the murine xenograft leukaemias were genetically similar to the 
relapse clone, harbouring lesions such as PTEN deletions that could be identified at a low 
level in the diagnostic sample only when analysed by highly sensitive techniques such as 
quantitative PCR. A recent study of colorectal cancer by Vogelstein’s group showed that 
resistance to the anti-EGFR antibody panitumumab occurs at 5-6 months after therapy 
and is mediated by cells harbouring KRAS mutations (Diaz, et al 2012). These tumours 
had been classified as KRAS wild-type at presentation when analysed by Sanger 
sequencing, but analysis by highly sensitive techniques identified the existence of rare 
minor clones harbouring KRAS mutations that became prominent by the selection 
pressure conferred by panitumumab therapy. 
 
4.1.6 T-ALL secondary to gene therapy for X-linked Severe Combined 
Immunodeficiency (SCID) 
Severe Combined Immunodeficiency (SCID) is a rare and often fatal congenital disorder 
that results in recurrent infections from impaired T-cell, B-cell and/or NK- cell function. 
A variety of loss-of-function mutations involving genes important in the T-cell 
differentiation or activation pathway have been described to date (Table 4.1). The first 
genetic defect described was in 1972, involving the adenosine deaminase gene (ADA) 
(Giblett, et al 1972), and since then at least 10 further genes have been identified as 
causing SCID including IL2RG (the IL2 receptor γ-chain), JAK3, IL7RA (IL-7 receptor 
α), CD3δ, CD3ε, CD3ζ, CD45, RAG1, RAG2, and Artemis (Buckley 2004). The most 
common cause of SCID, comprising nearly half of cases, is the X-linked type (known as 
SCID-X1) occurring as a result of mutations in IL2RG. IL2RG is also known as the 
common gamma chain because it heterodimerises with six other lymphocyte receptors 
including IL2RB, IL4R, IL7R, IL9R, IL15R, and IL21R, that are involved in a variety of 
functions including T-, B- and NK-cell proliferation and differentiation.  Patients with 
SCID-X1 typically present in early childhood with apthous ulcers, intractable nappy 
rash, and recurrent infections (including oral candidiasis, Varicella and Pneumocystis 
Jirovecci pneumonia) and, without allogeneic bone marrow transplantation (BMT), 
usually succumb to their disease. Although allogeneic BMT can be curative, it carries a 
significant morbidity and mortality, particularly if the donor is not an HLA-matched 
matched sibling (Antoine, et al 2003, Buckley, et al 1999).  
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Table 4.1 The classification of SCID according to causative genes, mechanism of 
immunodeficiency, inheritance and cell type affected.	  
Mechanism Genes involved Inheritance Cells affected 
Induction of apoptosis ADA AR T, B, NK 
Defective cytokine 
signalling 
IL2Rγ X-linked T, NK 
 JAK3 AR T, NK 
 IL7RA AR T 
Defective V(D)J 
rearrangement 
RAG1 or RAG2 AR T, B 
 Artemis AR T, B 
Defective TCR 
signalling 
CD45 AR T 
 CD3 δ, ζ, ε AR T 
AR, autosomal recessive; TCR T-cell receptor. Classification based on Cavazzana-Calvo and Fischer, 
2007. 
 
 
In 2000, a seminal French study was published showing that a lentiviral vector 
expressing a functional IL2RG gene could correct the T-cell defect in children with 
SCID-X1 (Cavazzana-Calvo, et al 2000), a finding that was reproduced in a British trial 
(Gaspar, et al 2004).  However, a total of five of these patients have to date developed T-
ALL, four on the French trial (of 10 treated) and one on the British trial (of 10 treated). 
In four of the five cases, the lentiviral insertion occurred in the vicinity of the LIM 
domain only 2  (LMO2) oncogene leading to its upregulation by the enhancer effect of 
the viral long-terminal repeats (LTR) (Hacein-Bey-Abina, et al 2008, Hacein-Bey-Abina, 
et al 2003a, Hacein-Bey-Abina, et al 2003b, Howe, et al 2008). Given that the viral 
insertions occur as the primary initiating event for the leukaemia, the presence of other 
somatic mutations are likely to have occurred as secondary events. Thus, the analysis of 
NOTCH-1 mutation status in this setting may be informative as to whether NOTCH-1 
mutations occur exclusively as primary events. 
 129 
4.2 AIMS  
Although NOTCH-1 mutations occur in all cytogenetic and molecular subgroups, it is 
unclear whether they are primary initiating or secondary cooperating events. The aim of 
the studies presented in this chapter was to investigate whether NOTCH-1 mutations are 
always the primary initiating event in T-ALL and/or whether they can occur as 
secondary events. In order to address this issue, the relative level of NOTCH-1 mutated 
alleles in a cohort of human patients at presentation with T-ALL was assessed, and the 
stability of these mutations examined at disease relapse. This has implications for the use 
of NOTCH-1 mutations as MRD markers, as well as for the use of Notch inhibitors in 
clinical trials for T-ALL. 
 
Whilst these studies were ongoing, a patient with SCID-X1 presented to Great Ormond 
Street Hospital with T-ALL secondary to gene therapy. In this case, the driver of 
leukaemogenesis was overexpression of the LMO2 oncogene as a result of viral 
integration within its vicinity. The presence of pre-diagnostic serial samples gave a 
unique opportunity to investigate the chronology of acquisition of a NOTCH-1 mutation 
during T-ALL pathogenesis. 
  
4.3 MATERIALS AND METHODS 
 
4.3.1 Patients and samples 
Details on the samples from 60 patients with adult T-ALL were given in Chapter 3. DNA 
samples from 12 paediatric T-ALL patients at disease presentation were obtained from 
Great Ormond Street Hospital in collaboration with Dr Phil Ancliff, and from six 
adolescent T-ALL patients treated locally at University College Hospital. Samples were 
available from 16 patients at first relapse; three also had samples at second relapse. 
Ethical approval for tissue collection for research was obtained from the Multi-Centre 
Research Ethics Committee for patients entered into clinical trials or from local research 
ethics committees as appropriate, and informed consent was obtained according to the 
Declaration of Helsinki. 
 
The patient with SCID-X1 was one of ten who received gene therapy for SCID-X1 at 
Great Ormond Street Hospital, and DNA samples were made available by Professor 
Adrian Thrasher. The patient/parents had received independent counselling prior to the 
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trial with regard to the potential risks of leukaemogenesis and fully informed parental 
consent was obtained. The study had ethical and regulatory approval from the Gene 
Therapy Advisory Committee (GTAC) and the Medicines and Healthcare Regulatory 
Authority (MHRA). The Gibbon ape leukaemia virus (GALV)–pseudotyped 
gammaretroviral vector encoding the IL2RG cDNA regulated by intact murine leukaemia 
virus (MLV) long terminal repeats (LTRs) and the transduction protocol have been 
described previously (Gaspar, et al 2004). A total of 7 × 106 CD34+γc+ cells/kg were 
infused in the absence of conditioning.  
 
4.3.2 NOTCH-1 mutational analysis and enrichment of low level mutations 
NOTCH-1 mutation screening and identification were carried out using heteroduplex 
analysis and sequencing as described in Chapter 3. For samples where the heteroduplex 
peaks were much smaller than the homoduplex peaks, the former were purified using the 
fraction collector facility of the WAVE® and sequenced. The procedure is based on the 
less stable heteroduplex peak eluting from the column prior to the homoduplex peak 
during DHPLC. At a given temperature the elution time is highly reproducible between 
successive runs, making it possible to utilise the fraction collector facility of the 
WAVE® to capture the desired fractions (Figure 4.1). The collected product can then be 
re-amplified by PCR, re-analysed by DHPLC to ensure the desired fraction had been 
collected, and sequenced. As outlined below, this strategy made it possible to identify 
mutations in a number of patients that would have been missed by direct sequencing 
strategies.  
 
4.3.3 Quantification of NOTCH-1 mutations by fluorescent PCR 
In samples with insertions or deletions, relative mutant levels were quantified using the 
PCR methods described in Chapter 3 with the following modifications: one primer was 
fluorescently-labelled, only 30 cycles of amplification were performed, BioTAQ DNA 
polymerase was used for all reactions and primer concentrations were reduced to 60nM. 
Products were size-separated using fragment analysis on the CEQ8000 Genetic Analysis 
System and mutant size could be resolved to within two base pairs. Results for mutant 
level were expressed as a percentage of total alleles i.e. a heterozygous mutation in all 
cells would be expressed as 50% of total alleles.  
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4.3.3 T-cell receptor (TCR) rearrangements 
TCR rearrangements were analysed by Drs Letizia Foroni and Veronique Duke at the 
Royal Free Hospital, London, using heteroduplex analysis and fluorescently-labelled 
primers at the TCRγ locus as previously reported (Gameiro, et al 2002, Szczepanski, et al 
2003, van Dongen, et al 2003). For those patients where no suitable marker was detected 
at the TCRγ locus, the TCRδ locus was analysed. 
 
4.3.4 Same patient identity 
Same patient identity was confirmed in the paired presentation-relapse samples using 
size analysis at four highly informative polymorphic short tandem repeat (STR) loci 
(VWA, FES, D11S-554, F13I) (http://www.cstl.nist.gov/div831/strbase/) using primer 
sequences shown in Table 4.2 (Sellathamby, et al 2006). PCR reactions were carried out 
using BioTAQ DNA polymerase, a fluorescently-labelled forward primer (dye D4) at 
60nM and 30 cycles of amplification, with annealing temperatures of 54°C for F131, 
FES and VWA, 61°C for D11S-554. Products were analysed for size by fragment 
analysis using the CEQ8000 Genetic Analysis System (Beckman Coulter).  
 
 
Table 4.2 Primer sequences used in this study 
Primer name Primer sequence 
FES-F 5'-GGGATTTCCCTATGGATTGG-3' 
FES-R 5'-GCGAAAGAATGAGACTACAT-3' 
VWA-F 5'-AGCTATATATATCTATTTATCAT-3' 
VWA-R 5'-AGATACATACATAGATATAGG-3' 
F13A1-F 5'-GAGGTTGCACTCCAGCCTTT-3' 
F13A1-R 5'-ATGCCATGCAGATTAGAAA-3' 
D11S-554-F 5’-GGTAGCAGAGCAAGACTGTC-3’ 
D11S-554-R 5’-CACCTTCATCCTAAGGCAGC-3’ 
NOTCH-1 26-F 5’-GGAAGGCGGCCTGAGCGTGTC-3 
NOTCH-1 26-R 5’-ATTGACCGTGGGCGCCGGGTC-3 
R1599P-R 5’-CACGTTGGTGTGCAGCACGG-3’ 
All forward primers were fluorescently-labelled with dye D4 
 
 
4.3.5. Sensitive detection of R1599P mutation 
Serial doubling dilutions of mutant (obtained at presentation from the SCID-X1 patient) 
and WT genomic DNA (obtained from NB4 cells) were performed to create mixtures of 
mutant and WT DNA of 50%, 25%, 12.5%, 6.25%, 3.125% and 1.56%. These were then  
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amplified by PCR using NOTCH-1 exon 26 primers and subject to DHPLC analysis of 
the HD-N as described in Chapter 3. This is based on the assumption that the 
presentation sample is 50% mutant, which was approximated by the DHPLC 
chromatogram and Sanger sequencing results (Figure 4.7)  
 
To increase the sensitivity of detection of the NOTCH-1 G4793C mutation (R1599P), an 
amplification-refractory mutation system (ARMS) was developed using a common 
forward primer (26-F), common reverse primer (26-R) and an internal mutation-specific 
reverse primer (R1599P-R), with primer sequences shown in Table 4.2. The principle of 
this assay is based upon the specificity of the internal primer being complementary to the 
mutant sequence (usually through the most 3’ base of the primer), so that annealing and 
amplification of only the mutant allele should occur (Figure 4.3). Inclusion of all three 
primers in the same PCR reaction should generate just a single band for wild-type alleles, 
but a double band if mutant alleles are present due to the presence of either a 
heterozygous or homozygous mutation. Although other mismatches are often required to 
increase specificity of the mutant primer using this method, a single mismatch was 
sufficient in the mutation described here. To increase the sensitivity of the assay, a 
fluorescently-labelled forward primer was used and products were sized by fragment 
analysis. PCR reactions were carried out using BioTAQ DNA polymerase, MgCl2 
(1mM), dNTPs (200mM), with the primers NOTCH-1 26-F (dye D4) at 60nM, NOTCH-
1 26-R at 60nm and R1599P-R at 40nM (Table 4.2). Cycling parameters were 95°C for 1 
minute, 67°C for 1 minute and 72°C for 1 minute for 30 cycles. HD-N PCR product 
containing the R1599P mutation were TOPO-cloned and DNA was isolated from one 
mutant and one WT clone and quantified. Mutant DNA was then mixed with WT DNA 
in the following ratios: 1 in 10 (10% mutant), 1 in 100 (1%), 1 in 200 (0.5%), 1 in 1000 
(0.1%) and 1 in 2000 (0.05%) and used to determine the sensitivity of the fluorescently-
labelled ARMS assay.  
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Figure 4.3 Principles of the amplification-refractory mutation system (ARMS) 
technique for the detection of the R1599P mutation. (A) The common outer primers 26-F 
and 26-R are used in the same reaction as a mutant-specific inner primer in which the most 3’ 
base is mismatched to the wild-type sequence (G), but matched to the mutant sequence (C). A 
single band is generated for wild-type allele. The R1599P-R primer can anneal to the mutant 
base, creating a smaller additional band. (B) Agarose gel electrophoresis of the PCR products. 
(C) Fragment analysis of PCR products from a WT control (left) and the leukaemic presentation 
DNA sample from the SCID-X1 patient (right). Red peaks represent size standards. 
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4.4 RESULTS  
 
4.4.1 NOTCH-1 and FBXW7 mutation status of paediatric and adolescent T-ALL 
patients 
NOTCH-1 mutation screening was extended to include 12 paediatric and six adolescent 
patients for two reasons. Firstly, matched presentation and relapse samples were 
available from several of these patients. Secondly, it offered an opportunity to quantify 
NOTCH-1 mutant level in a larger more diverse cohort of T-ALL patients. Overall, 
NOTCH-1 mutations were identified in 16 of the 18 patients (89%) (Table 4.3). Seven 
patients had mutations in the HD-N domain only, three in the PEST domain only, three 
in both the HD-N and PEST domains, one in both the HD-C and PEST domain, one with 
mutations in both the HD-N and HD-C and one with mutations in the LNR and PEST 
domain (as reported in Chapter 3).  
 
4.4.2 NOTCH-1 mutation level 
By DHPLC, in the total cohort of 78 patients analysed (60 adult patients and 18 
paediatric/adolescent patients), there were a total of 66 mutations detected in the LNR, 
HD-N, HD-C, TAD and PEST domains of NOTCH-1. Mutations affecting the JME, 
which were screened by PCR, were not included in the study of NOTCH-1 mutant level. 
Visual estimation of the WAVE pattern was consistent with a heterozygous mutation in 
the majority of cells for 56 of 66 mutations (85%). For 10 cases (15%), the relative 
height of the heteroduplex peak was considerably lower than the homoduplex peak, 
consistent with the presence of a low-level mutation or conversely a very high-level 
mutation (Figure 4.1 and 4.4). Sanger sequencing of these fragments failed to detect the 
presence of a mutation suggesting it was not the latter. However, after the early 
heteroduplex peaks were subjected to fraction collection and re-amplified by PCR, 
mutations were detectable with sequencing.  These were unlikely to have occurred by 
sample-to-sample contamination because eight of the ten mutations were unique to this 
cohort of patients. In two further cases, Sanger sequencing of the collected fractions did 
not reveal any mutations and it is most likely that the abnormal chromatograms were due 
to the presence of DNA degradation that can, on occasions, resemble low-level 
mutations. These fragments were classed as wild-type when no mutation was identified 
after fraction collection on two attempts.
 135 
  Table 4.3 NOTCH-1 and FBXW7 mutational status of the paediatric and adolescent T-ALL patients studied  
Case# 
NOTCH-1 
mutation  
status 
FBXW7 
mutation 
status 
NOTCH-1 
Mutation (nucleotide) 
NOTCH-1 
Mutation (amino acid) 
FBXW7 
Mutation (nucleotide) 
FBXW7 
Mutation (amino 
acid) 
PAEDIATRIC       
T3 WT WT - -   
T6 HD-N MUT 4799T>C L1601P 1513C>T  R505C 
T8 HD-N MUT MUT 4733T>A V1579G 1393C>T R465C 
T10 HD-N MUT MUT 4721T>C L1575P 1394G>A R465H 
T14 PEST MUT WT 7475-7476insCCCCTTGACAGG 2492-2493insSPX   
T38 HD-N MUT WT 4778T>C L1594P   
T46 HD-N MUT MUT 4721T>C L1575P 1393C>T R465C 
T47 PEST MUT WT 7326-7327insAGGAATCCGGT fs@2444, STOP@2481   
T48 LNR MUT WT 4631A>C H1545P   
 PEST MUT  7538T>C S2514F   
T49 PEST MUT WT 7398-7390delGTinsTTAGAGAA STOP@2468   
T50 HD-N MUT MUT 4817-4818insGGGACC F1607L;1608-1609insGP 1436G>T R479L 
 HD-C MUT  5019-5027del9bp+ins18bp 1675-1676delSI+insTGSHA   
T108 HD-N WT 4793G>C R1599P   
ADOLESCENT       
T7 HD-N+ 
PEST MUT 
MUT 4754T>C 
7324-7331del8bp+ins16bp 
L1586P 
2443-2444insNGAX 
1185-1186 
insGGTCCGAATAGTT 
396-397 
insGPNS STOP@400 
T34 HD-N+ 
PEST MUT 
WT 4744-4746delCCG 
7326-7327insGACCTGGTATG 
1583delP 
fs@2444, STOP @2481 
  
T35 HD-N+ 
PEST MUT 
WT 4799T>C  
7534C>G 
L1601P 
P2513A 
  
T44 HD-C+ 
PEST MUT 
WT 5127-5128ins39bp
 
7326-7327insCCTCATAGCTC  
1711-1712insVNSLNIPYKIEAV 
fs@2444, STOP@2481 
  
T45 HD-N MUT WT 4847T>A I1617H   
T69 WT WT     
T# local patient case number. MUT mutant, WT wild type, ins insertion, del deletion, SNP single nucleotide polymorphism, HD-N N-terminal 
heterodimerisation domain, HD-C C-terminal heterodimerisation domain, fs   frameshift, X stop codon, Low level mutation 
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Figure 4.4 Examples of high and low level mutations of NOTCH-1. (A) DHPLC 
chromatograms showing a wild type peak (left), a high level 3bp insertion in the HD-C domain 
(middle) and a low level 3bp insertion in the HD-N domain (right). (B) Fragment analysis 
showing a high level 3bp insertion (left) and low level 39bp insertion in the HD-C domain 
(right). Red peaks represent size standards 
 
 
Of the 66 mutations identified, 29 (44%) were nucleotide substitutions and not amenable 
to quantification using fragment analysis, which relies on size changes. However, only 
one of the 29 nucleotide substitutions (patient T40 – Table 3.4) had an apparent low level 
mutation by visual estimation of the WAVE chromatogram, all others were high level.  
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Of the 37 mutations with size changes, 32 were quantified by fragment analysis for the 
HD-N, HD-C and PEST domains. Examples of the appearance of the DHPLC 
chromatograms for high and low level mutants are shown in Figure 4.4, together with 
examples of fragment analysis traces. The median mutant level for the 32 investigated 
cases was 40% of total NOTCH-1 alleles (range 5%-49%) (Table 4.4, Figure 4.5). The 
mutant level was greater than 30% of total alleles for 21 (66%) of the mutations, and 
therefore consistent with presence of a heterozygous mutation in the majority of cells 
(60% of cells or more). No mutant level was greater than 50%, suggesting that there was 
no loss of the wild-type allele or uniparental disomy. 
 
 
 
 
 
 
 
 
Figure 4.5 Distribution of the relative mutant level for 32 insertions or deletions in 
the NOTCH-1 gene. Mutant level was quantified using fluorescently-labelled primers and 
fragment analysis for the HD-N, HD-C and PEST domains of NOTCH-1.
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Table 4.4 Quantification of 32 insertions or deletions detected in the NOTCH-1 gene 
in 28 patients  
Patient number NOTCH-1 domain Net ins/del‡  %mutant allele 
T11 HD-N 3bp del 40% 
T20 HD-N 3bp ins 10% 
T22 HD-N 6bp ins 6% 
T28 HD-N 3bp del 39% 
T30 HD-N 3bp ins 49% 
T31 HD-N 3bp del 42% 
T34* HD-N 3bp del 26% 
T50* HD-N 6bp ins 8% 
T54 HD-N 3bp ins 48% 
T55 HD-N 75bp del 50% 
T57 HD-N 3bp del 13% 
       
T5 HD-C 3bp ins 47% 
T19 HD-C 3 bp del 9% 
T36 HD-C 12bp ins 47% 
T44* HD-C 39bp ins 6% 
T50* HD-C 9bp ins 5% 
T58 HD-C 66bp ins 19% 
       
T1 PEST 2bp ins 46% 
T5 PEST 8bp ins 44% 
T7* PEST 8bp ins 47% 
T14* PEST 12bp ins 43% 
T25 PEST 5bp ins 45% 
T32 PEST 2bp del 45% 
T34* PEST 11bp ins 38% 
T43 PEST 5bp ins 19% 
T44* PEST 11bp ins 15% 
T47* PEST 11bp ins 46% 
T49* PEST 6bp del 39% 
T63 PEST 7bp del 31% 
T64 PEST 13bp ins 48% 
T66 PEST 18bp ins 40% 
T67 PEST 8bp ins 37% 
Actual adult mutations are shown in Table 3.4  *Patient <18yrs of age as per Table 4.3 ‡ Net ins/del refers 
to the net overall size difference of a particular insertion or deletion, or complex indel. 
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However, the mutant level was less than 30% for 11 of the mutations and in six of these 
it was 10% or less (Figure 4.5), indicating that in these patients 20% or less of cells 
carried the mutation (Table 4.4). Two of the low level mutations were in the same patient 
(T50 – Table 4.3). In each patient morphological examination revealed at least 75% 
leukaemic blasts (mean 87%). To exclude the possibility the mutations were present in 
contaminating normal cells as germline aberrations, mutational analysis was conducted 
from four patients where remission DNA was available from bone marrow samples. In 
no case was the mutation present at remission, consistent with the hypothesis that these 
were somatically acquired mutation. Furthermore, three of these patients had a high level 
mutation in another domain. None of the patients with low level mutations had evidence 
of ploidy or loss of genomic material of chromosome 9q by G-banding cytogenetics.  
These results suggest that the low level mutations were acquired in a subclone as a later 
event. 
 
4.4.3 Paired presentation-relapse samples 
The NOTCH-1 mutation status of paired presentation-relapse samples from 16 patients 
with available material (patients designated as ‘PR1-16’ for Presentation-Relapse) was 
studied to examine the stability of these mutations at relapse. STR analysis of four loci 
confirmed that each paired sample was from the same individual. Seven cases were WT 
at both presentation and relapse (PR1-7, Table 4.5). Of nine mutant-positive patients at 
presentation, five relapsed with the same mutation(s) at approximately the same or 
increased mutant level (PR8-12).  In one patient (PR10), the same mutation was also 
present at second relapse. In two patients (PR11, PR12) high level mutations were 
present in two different domains, both of which recurred at relapse, suggesting that they 
were in the same cell. In these five patients, it is likely that the NOTCH-1 mutation 
occurred as an early event. However, in four mutant-positive patients there were changes 
at relapse. 
 
At presentation, one patient (PR13, Table 4.5) had only a PEST domain mutation 
(insertion of stop codon at amino acid 2468), which was not detected at relapse. The 
same TCR Vγ1 clone was identified at both presentation and relapse. Another patient 
(PR14) had an 11bp insertion in the PEST domain at presentation which was not 
detected at first or second relapse (22 and 29 months respectively). However, a 39bp 
 
 140 
 
 
Table 4.5 NOTCH-1 mutational status at presentation and relapse in 16 patients  
 Presentation /1st Relapse/ 2nd Relapse 
Patient 
no. 
HD-N 
 
HD-C 
 
PEST 
 
Overall 
(% mutant) § 
PR1  -/- -/- -/- WT/WT 
PR2  -/- -/- -/- WT/WT 
PR3  -/-/- -/-/- -/-/- WT/WT/WT‡ 
PR4  -/- -/- -/- WT/WT 
PR5  -/- -/- -/- WT/WT 
PR6  -/- -/- -/- WT/WT‡ 
PR7 -/- -/- -/- WT/WT 
PR8  +/+ 
L1601P 
    -/- -/- MUT/MUT 
(H/H) 
PR9  -/- -/- +/+* 
fs@2467 
MUT/MUT 
(22/45) 
PR10  -/-/- -/-/- +/+/+ 
fs@2444 
MUT/MUT/MUT‡ 
(46/42/47) 
PR11  -/- +/+ 
insG1675 
+/+ 
fs@2444 
MUT/MUT 
(47/46; 44/37) 
PR12  +/+ 
L1586P 
-/- +/+ 
2442NGA-STOP 
MUT/MUT 
(H/H;47/42) 
PR13  -/- -/- +/- 
2468-STOP 
MUT /WT 
(39/-) 
PR14  -/-/- +/+/+* 
13aa ins 
+/-/- 
fs@2444 
MUT/MUT/MUT‡ 
(6/21/33; 15/-) 
PR15  -/+ 
H1592Q;F1593T 
+/- 
delV1677 
-/- MUT/MUT† 
(-/H; 9/-) 
PR16  +/- 
H1545P¶ 
-/- +/+† 
S2514F/fs@2515 
MUT/MUT† 
(H/-; -/34) 
†different mutation at relapse, ‡post-allograft but donor cells undetectable; *increasing mutant  
level; §% mutant level as quantified by fragment analysis; H indicates high mutant level by visual  
estimation of WAVE chromatogram; fs frameshift; MUT indicates NOTCH-1 mutation present;  
WT wild-type NOTCH-1 status 
 
 
insertion in the HD-C domain was present at a low level (6%) at diagnosis and 
progressively increased at each relapse (21% and 33% respectively) (Figure 4.6). Of 
note, at each time point the patient had the same TCR Vγ11 clone; no new clone was 
detectable. Case PR15 had a low level HD-C mutation at presentation (delV1677; 9% 
mutant) that was undetectable at relapse. However, the patient relapsed with a new high 
level HD-N mutation (H1592Q;F1593T). Furthermore, the same TCR Vγ1 clone was 
seen at both presentation and relapse. In these three cases the results suggest that the 
NOTCH-1 mutations occurred after the TCR rearrangement.  
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Case PR16 presented at 5 months of age and relapsed 20 months later. Two high level 
mutations (H1545P and S2514F), which were detected at presentation, were lost at 
relapse, but a new high level (34% mutant) 2bp deletion in the PEST domain was 
acquired. TCR analysis at the gamma locus showed loss of the original clone and 
acquisition of a new unrelated clone (Vγ4 to Vγ2 clone respectively), with different 
CDR3 sequence. Therefore, in this patient the results most likely reflect development of 
a secondary leukaemia, similar to cases previously described (Szczepanski, et al 2003). 
 
 
 
 
 
 
Figure 4.6 Changes in the NOTCH-1 mutations detected at 1st and 2nd relapse in 
patient PR14. (A) An 11bp insertion in the PEST domain detected at presentation was not 
detectable at first and second relapse, as seen by DHPLC analysis. (B) Fragment analysis for the 
HD-C domain of the same patient showed progressive increase in mutant level of a 39bp 
insertion. Size standards are shown in red.   
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 4.4.4 Clinical presentation and molecular characteristics of patient with SCID-X1 
The patient presented at Great Ormond Street Hospital at the age of 10 months (Patient 
T108) and was shown to have an IL2RG C182Y mutation, which resulted in marked 
reduction in the expression of the IL2RG on the patient’s lymphocytes (Howe, et al 
2008). He received gene therapy with an IL2RG-expressing vector at the age of 13 
months and regained normal T-cell numbers within 6 months of therapy. Despite normal 
haematological and immunological parameters when seen in clinic at 23 months post-
treatment, he presented at 24 months (day 717) with T-ALL with a high WCC of 
524×109/l, with circulating blasts. He was commenced on standard chemotherapy 
according to the UKALL2003 regimen B protocol and was in remission at 1 year post 
therapy, by which time he had reconstituted a normal T-cell count that retained 
expression of the IL2RG transgene. 
 
Molecular characterisation of the diagnostic T-ALL sample at Great Ormond Street 
Hospital revealed marked over-expression of LMO2, NOTCH1, HES1 and c-MYC by 
gene expression array and an antisense insertion of the viral vector 35 kb upstream of the 
transcription start site of the LMO2 gene by LAM-PCR. A specific PCR that flanked the 
insertion site was positive at a sensitivity of 0.01-0.1% in a pre-leukaemic sample at day 
539, but not before this time. Cytogenetics showed a t(1;7)(1p32;q35) translocation 
which juxtaposed the TCRβ promoter to TAL1, and SNP array analysis showed a 
deletion of 9p that included the tumour suppressor gene cyclin-dependent kinase 2A 
(CDKN2A) (Howe, et al 2008).  
 
4.4.5 NOTCH-1/FBXW7 mutation analysis of the gene therapy-induced T-ALL 
DNA from the presentation T-ALL sample (day 717 after gene therapy) was screened for 
mutations in the LNR, JME, HD-N, HD-C, TAD and PEST domains of the NOTCH-1 
gene, and exons 8-12 of the FBXW7 gene as described in Chapter 3. FBXW7 was wild-
type, but an R1599P missense mutation was identified in the HD-N domain of NOTCH-1 
(Figure 4.7).  By DHPLC analysis, this mutation was not present in the DNA samples 
isolated from the patients’ mononuclear cells prior to gene therapy, CD34+ cells after 
viral transduction, or CD3+ cells isolated at day 539 (178 days prior to presentation with 
T-ALL). Mixes of normal DNA with DNA from the T-ALL sample showed that DHPLC 
had a sensitivity of approximately 6% to detect the R1599P mutation (Figure 4.7). 
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Unfortunately, no cells or DNA were available for investigation from the clinic visit 1 
month prior to presentation with T-ALL. 
 
 
 
 
 
 
 
 
 
Figure 4.7 Identification of a NOTCH-1 R1599P mutation in gene therapy-induced 
T-ALL. (A) DHPLC analysis of the HD-N of DNA isolated from mononuclear cells pre-
transduction, CD34+ cells immediately post-transduction, CD3+ cells 539 days after transduction 
and blast cells at presentation with T-ALL. The right box shows wild-type control (WT) and 
dilutions of DNA at T-ALL presentation with normal control DNA. (B) Sequencing trace from 
the reverse (26-R) primer of the HD-N domain showing a C to G transition (G4796C). (C) The 
arginine at 1599 is highly conserved amongst diverse species, suggesting it has importance to the 
HD-N domain structure and/or function.
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As the LMO2 insertion would have occurred at the time of viral transduction, an 
important question was whether this occurred as the primary event with later acquisition 
of the NOTCH-1 mutation, or whether by chance the CD34+ cell with the viral 
integration had a pre-existing NOTCH-1 mutation. In an attempt to address this, a 
fluorescent amplification-refractory mutation system (ARMS) assay was developed 
(Figure 4.3). HD-N PCR products containing the R1599P mutation were TOPO-cloned, 
and DNA was isolated from one mutant and one WT clone and quantified. Mutant DNA 
was then mixed with WT DNA in the following ratios: 1 in 10 (10% mutant), 1 in 100 
(1%), 1 in 200 (0.5%), 1 in 1000 (0.1%) and 1 in 2000 (0.05%). These dilutions were 
then used as input into the fluorescent ARMS assay and the products analysed by 
fragment analysis. The assay had a reliable and consistent sensitivity of 0.5% (one 
mutant clone in 199 normal clones) (Figure 4.8), equivalent to one heterozygous mutant 
cell in 99 normal cells. Although a small peak could be visualised on the majority of runs 
at 0.1% mutant (Figure 4.8), the peak height of the mutant was not always of adequate 
intensity above background to be definitive, and thus the limit of the assay was 
determined to be 0.5%.  
 
Analysis of the available DNA samples from the SCID-X1 patient using the 
fluorescently-labelled ARMS assay was only positive in the presentation sample, but not 
in any of the preceding material, including the CD3-selected T-cell sample collected 178 
days prior to T-ALL diagnosis (at which point the LAM-PCR was positive for the LMO2 
integration at a sensitivity of 0.01-0.1%). Thus, within the limits of the assay, there was 
no evidence of the NOTCH-1 mutation prior to overt T-ALL.  
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Figure 4.8 Fluorescent amplification-refractory mutation system technique for the 
detection of the R1599P mutation.  (A) At presentation of overt T-ALL, the SCID-X1 
patient had clear evidence of  a peak at 256bp corresponding to the R1599P mutant allele. (B) A 
small peak was consistently seen  when the assay is performed on mixes of 1 mutant clone TOPO 
PCR clone with 199 WT clones (0.5%). (C) Dilution of mutant TOPO clone 1 in 1000 (0.1%) 
with WT TOPO clones. D) DNA from CD3 selected T-cells from the patient 178 days prior to 
the diagnosis of T-ALL. 
 
 
4.5 DISCUSSION 
 
Cancer is thought to occur through the accumulation of multiple genetic events that 
perturb a number of cellular pathways that confer a growth and survival advantage to 
tumour cells over time (Nowell 1976). Hanahan and Weinberg recently described six 
hallmarks of cancer: sustaining proliferative signaling, evading growth suppressors, 
resisting cell death, enabling replicative immortality, inducing angiogenesis, and 
activating invasion and metastasis (Hanahan and Weinberg 2011). Cells that acquire 
genetic events that contribute to these capabilities will ultimately prevail to form the 
tumour bulk, whilst those acquiring deleterious lesions will be lost. In a similar fashion, 
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cells that have acquired genetic lesions that confer resistance to chemotherapy (either 
prior to, or during treatment) will be responsible for disease relapse. Thus, maintaining a 
wide clonal heterogeneity of cells, together with the ability to adapt to selection pressure 
through the rapid accumulation of new genetic events, provides tumour cells with a 
powerful armoury for the evasion of targeted therapy. 
 
As increasing numbers of genetic abnormalities are being described in T-ALL, it has 
become feasible to examine the chronology in which these molecular events are 
acquired. Such information could help to elucidate the mechanisms by which oncogenic 
pathways interact, further characterise the leukaemic cells responsible for relapse and 
possibly rationalise the molecular pathways that could be targeted for drug development, 
including combination therapies. 
 
In murine models of T-ALL, Notch activation can both directly induce leukaemia and 
collaborate with other initiating genetic events to perpetuate leukaemic growth (Lin, et al 
2006, O'Neil, et al 2006, Pear, et al 1996, van den Brandt, et al 2006). Mice transgenic 
for Scl/Lmo1 have often acquired a Notch-1 mutation by the time of overt transformation 
to T-ALL (Lin, et al 2006). Oligoclonality, as defined by the presence of clones with 
different TCR rearrangements, predates acquisition of the NOTCH-1 mutation, but it is 
not until after the latter event that these thymocytes form transplantable tumours. It has 
also become apparent that activation of Notch-1 as a secondary event occurs on a diverse 
genetic background in mouse models of T-ALL, suggesting that Notch can collaborate 
with multiple different genetic pathways. For instance, as well as the frequent Notch-1 
PEST domain mutations described in lck-Scl/Lmo1, Tp53 null, H2ax null, and rag-2 null 
backgrounds, activation of Notch-1 through either PEST domain mutation or 5’ deletion 
has also been shown in Ikaros deficient mice, transgenic Kras (G12D) mice and mice 
transplanted with marrow overexpressing rasgrp1 (Jeannet, et al 2010, Kindler, et al 
2008, O'Neil, et al 2006, Oki, et al 2012).  Whether NOTCH-1 mutations are an initiating 
or secondary collaborating event in human T-ALL is unclear. The results described in 
this chapter suggest that both events may occur.  
 
Of the 32 mutations that were quantified in the patients studied here, the majority (66%) 
had high-level mutations (>30% mutant), which was consistent with the presence of a 
heterozygous mutation in the majority of cells. Furthermore, in five of nine (55%) 
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mutant-positive patients in the paired presentation-relapse cohort, the same mutation was 
present at relapse. In these patients it is likely that the mutation had occurred early in 
disease pathogenesis. Two of these patients had mutations in both the HD and PEST 
domains at presentation and relapse, suggesting that they were in the same cell. It is also 
noteworthy that two patients (PR9 and PR14) had evidence of increasing mutant level, 
and one (PR15) acquired a new high-level mutation at relapse, suggesting that Notch 
activation may offer a selection advantage to these cells. 
 
Conversely, the results in some patients suggested that the NOTCH-1 mutations occurred 
not as a primary event but later in the pathogenesis of the disease. Six (19%) were 
present at a particularly low level in the presentation sample. This was not due to 
contamination by large numbers of non-leukaemic haematopoietic cells, as review of the 
morphology showed that all cases had blast counts of 74% or greater. A low mutant level 
could also occur if the majority of leukaemic cells either lost genomic material including 
a mutated NOTCH-1 allele or gained copies of the WT allele. However genomic loss of 
chromosome 9q34 has not been described by either genome-wide analysis or fluorescent 
in situ hybridisation in two substantial cohorts of T-ALL patients (Irving, et al 2005, 
Mullighan, et al 2007). Furthermore, the finding that murine T-ALL tumours frequently 
acquire a second synergistically activating NOTCH-1 mutation suggests that leukaemic 
cells favour increased, rather than decreased, Notch signal strength, making genomic loss 
of mutated NOTCH-1 alleles unlikely. Whilst homozygosity of the NOTCH-1 mutated 
allele has been found in some human T-ALL lines as a result of loss-of-heterozygosity 
(Lin, et al 2006), the fact that no patient in our cohort had a mutant level of greater than 
50% supports the finding of others that this is not a common phenomenon in human T-
ALL (Irving, et al 2005, Mullighan, et al 2007, Wang and Armstrong 2007). NOTCH-1 
gene duplication has been described in T-ALL, occurring in a small population of cells 
as a subclonal phenomenon, which supports the hypothesis that Notch activation can be a 
late secondary event (van Vlierberghe, et al 2006). However, if this was the explanation 
for the low mutant levels observed in our cases, it would require duplication of the WT 
gene in the majority of cells, with the mutant-carrying clone in the minority. Our results 
therefore suggest that the low level mutants described here in 19% of the mutant-positive 
patients analysed are due to the gain of a mutation in a subclone, which, in the presence 
of high blast counts, must be a secondary event. These results were supported by the 
demonstration that three mutations were lost at relapse whilst the TCR rearrangements 
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remained unchanged. This suggests that the NOTCH-1 mutation was acquired after the 
TCR rearrangement in these three patients, a situation analogous to the secondarily 
acquired NOTCH-1 mutations in murine models of T-ALL. 
 
The risks of T-ALL caused by gene therapy for SCID-X1 have proven to be substantial, 
with five of 20 patients developing the disease (Hacein-Bey-Abina, et al 2008, Hacein-
Bey-Abina, et al 2003a, Hacein-Bey-Abina, et al 2003b, Howe, et al 2008). In four of 
the five cases described thus far, the viral integrations have occurred within the vicinity 
of the LMO2 oncogene, with the other patient having an integration in the proximity of 
the CCND2 gene. In the case described here, the viral LTRs led to upregulation of all 
genes within 200kb of the integration, which included LMO2. This mechanism of 
oncogenesis is similar to that induced by wild-type MuLV that sporadically effects feral 
mice (Cameron, et al 1996). Large-scale mapping of 572 retroviral integration sites 
(RISs) isolated from cells of 9 patients with SCID-X1 in the French trial showed non-
random integration of the viral vector, with two-thirds of integrations occurring in or 
within the vicinity (<10kb) of genes that are expressed in normal CD34+ cells 
(Deichmann, et al 2007). This suggests that access of the gamma-retrovirus to sites of 
integration is influenced by the chromatin state of the cell, and the favouring of LMO2 
integrations may occur due to high expression of this gene in early haematopoiesis. 
Furthermore, activation of LMO2 is capable of forming a transcriptional complex with 
TAL1, RUNX1, and GATA3 to activate other oncogenic genes including MYB, TRIB2 and 
STAT5A (Sharp 2005). 
 
The SCID-X1 patient described here had many of the hallmarks of sporadic cases of T-
ALL, suggesting that over-expression LMO2 is not sufficient in its own right to induce 
T-ALL. They had deletion of the negative cell cycle regulator CDKN2A gene, which 
occurs in over 80% of T-ALL cases, and a translocation involving TAL1, which has been 
reported to lead to activation of TAL1. The latter occurs in 40-60% of patients with T-
ALL (Ferrando and Look 2000, Ferrando, et al 2002). As TAL1 forms a transcriptional 
complex with LMO2, over-expression of both genes may act in concert to activate their 
downstream targets. Indeed, collaboration between Tal1 and Lmo2 in terms of 
accelerated T-ALL onset and increased disease penetrance has been shown in a mouse 
model (Larson, et al 1996).  
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The high incidence of Notch-1 mutations (>70%) identified in Lmo2 transgenic mice 
suggests strong collaboration between the Notch and Lmo2 pathways in murine T-ALL. 
The presence of the R1599P mutation identified here in NOTCH-1 in the SCID-X1 
patient suggests this collaboration also occurs in human T-ALL. The R1599P mutation 
has been described previously in sporadic T-ALL and has been shown to be strongly 
activating in reporter assays (Malecki, et al 2006). By visual estimation of the WAVE 
pattern it appeared to be of high level in the presentation sample, suggesting that it was 
present in the majority of cells. While specific PCR for the viral insertion site was able to 
detect the presence of the integration at day 539, 178 days prior to presentation with T-
ALL, the R1599P mutation was not detectable at this time point. However, given the 
disparate sensitivities of detection in the two assays (0.5% for the ARMS for R1599P, 
0.01-0.1% for the integration PCR), it is not possible to conclude definitively that the 
NOTCH-1 mutation occurred as a late event after the viral integration. It seems unlikely 
that a CD34+ cell harbouring a pre-existing NOTCH-1 mutation, TAL1 translocation and 
CDKN2A deletion would acquire a viral integration in LMO2.  
 
Limiting dilution analysis of leukaemia initiating cells (LICs) has been performed in 
mice triple transgenic for Tal1/Lmo1/ICN1, and the time to overt T-ALL after 
transplantation of a single LIC is only 31 days (Tremblay, et al 2010). Although there are 
obvious caveats in comparing human and murine T-ALL, this rapid onset of leukaemia is 
far quicker than the onset of leukaemia seen in any of the five SCID-X1 patients, with 
the latter having a minimum latency of 18 months, more consistent with accumulative 
acquisition of secondary events. Such a latency is comparable with the Lmo2 transgenic 
mice (12-18 months) (Larson, et al 1994, Larson, et al 1996). Furthermore, thymocytes 
from Tal1/Lmo1 transgenic mice are blocked at the DN4 checkpoint and only able to 
proceed to the DP stage after acquisition of a Notch-1 mutation, at which point they 
become fully transformed leukaemic cells capable of secondary transplantation 
(Tremblay, et al 2010). Although it is unclear exactly how Notch activation mediates this 
final step in transformation, the most compelling explanation is that it is, at least in part, 
mediated through the upregulation of MYC, activation of which has been shown to 
enable T-cells to evade negative selection and proceed through physiological T-cell 
checkpoints (Cameron, et al 1996, Palomero, et al 2006, Weng, et al 2006). It is 
conceivable that an analogous scenario occurs in gene therapy induced T-ALL; 
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activation of LMO2 occurs through viral integration as the primary event at the time of 
ex vivo transduction, followed by progressive stepwise acquisition of mutations, each 
conferring an additional selective advantage to the clone, before overt leukaemic 
transformation.  
 
There have now been several studies addressing the issue of clonal heterogeneity in 
ALL. Mel Greaves’ group used FISH and copy number analysis (CNA) to study genetic 
alterations in ETV6-RUNX1 positive childhood B-ALL at the single cell level (Anderson, 
et al 2011). They detected up to eight genetic abnormalities in a single cell and were able 
to assemble complex ancestral trees showing wide diversity in the clonal evolution of the 
leukaemia. ETV6-RUNX1 translocations were presumed to be the early initiating event, 
but subclonal evolution of subsequent events was so heterogeneous that some subclones 
appeared to have independently acquired the same genetic alteration. They proposed a 
Darwinian model for relapse in cancer, whereby chemotherapy exerts a selection 
pressure that favours the expansion of resistant clones. James Downing’s group used 
SNP arrays to analyse 61 cases of matched presentation-relapse B-ALL samples and 
showed that the CNAs in the relapse clones were often different from the primary 
leukaemia, with both loss of some alterations and gains of others (Mullighan, et al 2008). 
However, the new CNAs identified at relapse were detectable in the presentation sample 
when analysed by highly sensitive techniques. As discussed earlier, Jean Soulier’s group 
have shown highly similar findings in human T-ALL samples transplanted into immuno-
deficient mice (Clappier, et al 2011). John Dick’s group used xenograft models and 
CNAs to model the clonal architecture of BCR-ABL positive B-ALL, and identified a 
branching multi-clonal rather than linear evolutionary path (Notta, et al 2011). Thus the 
results of the studies of NOTCH-1 mutations in T-ALL presented in this chapter are 
consistent with the highly heterogeneous and complex clonal architecture of ALL, and 
possibly cancer in general. 
 
The acquisition of NOTCH-1 mutations at different stages of disease may influence the 
role of Notch in disease pathogenesis. Development of a mutation early in the disease 
process may lead to expansion of the T-cell population prior to acquisition of other 
pathogenic events, whereas with later development its impact on activation of other 
oncogenic pathways may be more important (Chan, et al 2007, Sharma, et al 2006). 
Dissecting this phenomenon, and the impact this has on disease pathogenesis and 
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response to therapy, will be challenging. The ability to now analyse insertion sites and 
the chronology of somatic mutations through next generation sequencing technology in 
gene therapy induced T-ALL offers a rare and unique opportunity to monitor individual 
clones through disease pathogenesis, and may shed light on the role of NOTCH-1 
mutations in T-ALL induction in humans.  
 
Irrespective of the underlying mechanisms, however, results of the current study have 
implications for NOTCH-1 as a target for both minimal residual disease (MRD) analysis 
and for therapy. NOTCH-1 is an attractive target for MRD analysis due to specificity of 
many of the mutations observed in individual patients, although its application would 
also be challenging due to the high GC content of the gene. Nevertheless, the lack of 
mutation stability at relapse and the evident acquisition after the TCR rearrangement 
observed in a proportion of our patients means that caution should be exercised in using 
them as solitary markers for MRD analysis. In addition, there may be implications for 
Notch pathway inhibitors that are currently in clinical trials, which, even if effective 
against constitutively activated mutant-positive cells, may select out remaining WT cells 
which are unlikely to respond to such therapy.  
 152 
CHAPTER 5. ALTERNATIVE SPLICING OF THE CSL TRANSCRIPTION 
FACTOR IN ACUTE MYELOID LEUKAEMIA 
 
 
5.1 INTRODUCTION 
 
5.1.1 Pre-mRNA splicing 
The marked differences in length between nuclear and cytoplasmic RNA was first 
described in the 1970s, which led to the discovery that the entire gene locus containing 
both introns and exons is first transcribed into a pre-mRNA, before removal of the non-
coding introns prior to translation (Berget et al, 1977; Sharp, 2005). This finding was of 
significant importance to basic cellular biology and genetics and was rewarded with the 
1993 Nobel Prize in Physiology and Medicine to Richard Roberts and Philip Sharp. 
Regulation of splicing has turned out to be incredibly complex involving over 100 
proteins and five small nuclear RNAs (snRNA), which together make up the spliceosome 
(Sharp, 2005). Recognition of exon-intron boundaries is mediated through identification 
of consensus sequences at the 5’ intronic splice site (also referred to as the donor splice 
site) and 3’ intronic acceptor site (Breathnach & Chambon, 1981). The 5’ splicing 
typically occurs between an exonic AG and intronic GT sequence, although AG-GC 
donor sites are present in 0.6% of transcripts (Burset et al, 2000).  
 
The first stage of splicing requires the recognition of a 5’ splice site at the exon-intron 
boundary through binding of U1 snRNA by complementary base pairing, with assistance 
from serine-arginine rich (SR) proteins (Padgett et al, 1986). Together with members of 
the SF3 protein family, the branch point (an intronic adenine residue at a conserved 
distance from the 3’ splice site) is then recognised by U2 small nuclear ribonucleoprotein 
(snRNP), prior to binding of U4, U5 and U6 snRNPs to the pre-mRNA. A two-step 
trans-esterification reaction then takes place that first involves the intronic branch point 
reacting with the first nucleotide of the 5’ splice site to form what is known as an RNA 
lariat intermediate (so named because of its likeness to a lasso). This is followed by the 
released 5’ exon reacting with the acceptor site such that the intronic lariat RNA is 
liberated and the exons are ligated.  
 
The usage of particular donor or acceptor splice sites can vary considerably, such that 
strong splice sites are utilised in the majority of transcripts whilst weak splice sites 
contribute only to minor mRNA isoforms. This is in part governed by exonic flanking 
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sequences known as exonic sequence enhancers (ESEs) and exonic splicing silencers that 
promote or suppress splicing respectively. Sequences with similar roles have also been 
identified within nearby intronic regions (Fairbrother et al, 2002; Wang et al, 2004).  
 
5.1.2 Alternative splicing  
Alternative splicing (AS) involves the differential inclusion or exclusion of exonic and 
intronic sequences from pre-mRNA into the mature mRNA transcript (Luco et al, 2011). 
Genome wide analysis has shown that somewhere between 75-90% of genes are 
alternatively spliced, each gene often having multiple different transcripts (Pan et al, 
2008). Considering the relatively small number of coding genes within the genome, AS 
is a mechanism of markedly increasing protein diversity as well as allowing tissue-
specific protein regulation at the pre-translational stage (Diaz et al, 2012; Luco et al, 
2011). The importance of AS in contributing to a cellular phenotypic is perhaps best 
exemplified by AS of the doublesex gene (dsx) in the fruitfly D.melanogaster. The sex-
lethal gene (sxl) is only expressed in the female fly and leads to AS of dsx to produce a 
shorter isoform (termed dsxf) that initiates the female gene expression signature, leading 
to female characteristics (Nagoshi et al, 1988). In the absence of sxl, dsx is not 
alternatively spliced and male characteristics are produced. Transcripts that occur 
through AS occur at approximately three times greater frequency in higher organisms 
than they do in lower organisms, which, at least in part, contributes to the increased 
tissue complexity that occurs in such organisms despite similar numbers of coding genes 
(Sharp, 2005). 
 
There are a number of different AS events as exemplified in Figure 5.1: 
1. Skipped exon 
2. Retained intron 
3. Alternative 5’ donor site (may change the frame of the downstream sequence)  
4. Alternative 3’ acceptor site (may change the frame of the downstream sequence)  
5. Mutually exclusive exons 
 
5.1.3 Mechanisms of AS  
Although splicing enhancer and silencer sequences contribute significantly to whether a 
particular splice site is utilised by the spliceosome, their presence cannot explain the 
tissue specificity seen with AS, nor the increased AS observed in various cancers 
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Figure 5.1 A schematic depicting some examples of alternative splicing patterns of 
RNA. Coloured bars represent exons whilst the black lines signify introns. The pre-mRNA is 
shown above the mature mRNA
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(Faustino & Cooper, 2003). The mechanisms governing AS in cells remain poorly 
understood, although recent evidence has made conceptual advances in this 
regard.Firstly, the kinetics of RNA polymerase action during transcription has been 
shown to be important in determining the degree of AS, with slower transcription and 
pausing favouring utilisation of weak/alternative splice sites (de la Mata et al, 2003). 
Secondly, AS is influenced by chromatin and histone modifications, with of lysine 36 in 
histone H3 (H3K36me3) modification directly regulating splicing of a multitude of 
genes, for example, fibroblast growth factor receptor 2 (FGFR2) (Luco et al, 2010).  
 
5.1.4 AS in disease  
In their review of AS, Faustino and Cooper described four mechanisms of AS that can 
contribute to human disease (Faustino & Cooper, 2003). 
 
1. Cis-acting mutations that disrupt the use of constitutive splice sites. These are 
usually single base pair substitutions affecting one of the bases of the exon-intron 
junction. The consequences of such mutations can vary, but most commonly they 
lead to loss-of-function transcripts through intron retention and nonsense 
mediated decay, although they can lead to exon skipping or use of alternative 
splice sites. Multiple examples of such mutations leading to loss-of-function in 
tumour suppressor genes such as neurofibromatosis-1 (NF1), phosphatase and 
tensin homolog (PTEN), Tp53, adenomatous polyposis coli (APC) and breast and 
ovarian cancer susceptibility protein 1/2 (BRCA1/2) have now been described in 
many cancer types (Charames et al, 2002; Jolly et al, 1994; Liu et al, 2012; Reiss 
et al, 1992; Welander et al, 2012).  
 
2. Cis-acting mutations that alter the use of alternative splice sites. A well-
characterised example of this is AS of the Wilm’s tumour-1 gene (WT1) in 
Frasier syndrome, a disease causing urogenital developmental abnormalities and 
high risk of Wilm’s tumour. WT1 has two isoforms, a predominant +KTS isoform 
and a minor –KTS isoform, depending on the inclusion or exclusion respectively 
of 9 bases at the start of exon 9. In Frasier syndrome, an intronic splice site 
mutation at the intron/exon junction for exon 9 results in predominance of the –
KTS isoform that is thought to cause the disease phenotype (Klamt et al, 1998).   
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3. Trans-acting mutations that disrupt the basal splicing machinery. Mutations in 
members of the U4/U6 snRNP complex, such as those affecting the pre-mRNA 
processing factor 3 homolog gene (HPRP3), have been described in families with 
retinitis pigmentosa, although the mechanism by which this causes the disease is 
not known (Chakarova et al, 2002).  
 
4. Trans-acting mutations that disrupt splicing regulation. Although many of the 
proteins involved in the regulation of AS are not fully characterised, Faustino and 
Cooper hypothesised that mutations affecting proteins that regulate the activity or 
specificity of the splicing machinery may be responsible for the widespread 
dysregulation of splicing observed in cancer (Faustino & Cooper, 2003). Indeed, 
mutations affecting the spliceosome have recently been discovered in 
myelodysplastic syndromes (MDS), and more rarely in AML, and these are 
addressed later in the discussion. 
 
With the advent of whole genome sequencing and RNA-Seq technology, widespread 
dysregulation of splicing is now being recognised in human cancer, possibly occurring 
through dysregulation of the spliceosome machinery and subsequent selection of cells 
bearing transcripts favourable to maintenance of the neoplastic phenotype (Beerenwinkel 
et al, 2007; Xu & Lee, 2003). For example, AS can lead to loss of normal protein levels 
causing reduced tumour suppressor function, or generate neomorphic proteins that can 
function as oncogenes (Venables, 2004).  
 
One of the best-characterised examples of the role AS plays in tumourigenesis is the 
extensive alternative splicing of CD44. CD44 encodes a transmembrane glycoprotein 
that can act as a tumour suppressor and is involved in cell proliferation, migration, 
adhesion and trafficking (Cheng & Sharp, 2006). It has 10 constitutive exons and 10 
variable exons (encoded between constitutive exons 4 and 7), the inclusion or exclusion 
of which have significant consequences for downstream signalling. For instance, in 
human glioblastoma cells, the CD44v6 isoform (that contains variable exon 6) can bind 
to hepatocyte growth factor (HGF) and the tyrosine kinase receptor c-Met and activate 
downstream Ras signalling (Orian-Rousseau et al, 2002). This in turn alters CD44 
splicing, favouring inclusion of variable exon 6, to form a feed-forward loop that 
generates the high levels of Ras signalling that are essential to cell growth (Cheng et al, 
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2006; Orian-Rousseau et al, 2002). It is not known whether this signalling axis also 
exists in AML cells, but expression of higher levels of the CD44v6 transcript in AML, 
correlates with poor survival, and a high proportion of AML patients also co-express 
HGF/MET (Kentsis et al, 2012; Legras et al, 1998). 
 
As well as CD44, many alternatively spliced gene transcripts have been identified in 
AML such as CD13 (Dybkaer et al, 2001), RUNX1 (Miyoshi et al, 1995), PTPN6 
(Beghini et al, 2000), PML (Pandolfi et al, 1992), and the α and β-intracytoplasmic 
chains of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor 
(Chopra et al, 1996; Gale et al, 1998). Although the relative contribution of many of 
these isoforms to the pathogenesis of AML remains to be determined, an alternatively 
spliced transcript detected in ALL has been shown to directly induce tumourigenesis in 
vivo in a mouse model. AS of the Ikaros gene produces non-DNA binding isoforms that 
have dominant-negative activity, are found at high level in childhood ALL, and induce 
T-ALL when expressed in murine marrow and transplanted into irradiated recipients 
(Hahm et al, 1994; Sun et al, 1999; Winandy et al, 1995).  
 
5.1.5 Notch as a tumour suppressor 
The consequences of Notch signalling are highly cell context-dependent. Whilst 
upregulation of Notch activity has been associated with a diverse range of different 
cancer types besides haematological malignancies, including breast, colorectal and 
pancreatic cancer, Notch has been shown to have a tumour suppressor role in several 
other cellular tissues (Lobry et al, 2011). Conditional Notch-1 knockout mice develop 
cutaneous basal cell carcinomas, and mice chronically treated with gamma-secretase 
inhibitors (GSIs) are highly prone to carcinogen-induced skin cancers (Nicolas et al, 
2003).  Similarly, transgenic mice engineered to express dominant-negative Maml-1 (that 
acts as a pan-Notch inhibitor) in the epidermis develop squamous cell carcinomas (SCC) 
of the skin (Proweller et al, 2006). One of the interesting features of the tumour-
suppressor function for the Notch pathway in this context is that Notch may have a non-
cell autonomous role in disease pathogenesis, as mice with conditional deletion of Csl in 
the mesenchymal compartment develop epithelial tumours (Hu et al, 2012).  NOTCH-1 
may also have a tumour suppressor function in the pathogenesis of hepatocellular 
carcinoma (HCC), as expression of ICN-1 causes cell-cycle arrest in HCC cell lines, and 
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treatment with GSIs can accelerate tumour onset in a mouse model of HCC (Viatour et 
al, 2011). 
 
More recently, loss-of-function mutations of NOTCH-1 and NOTCH-2 have been 
described in 75% of cutaneous SCCs, 12.5% of lung SCCs, and nearly 20% of head and 
neck SCCs (Agrawal et al, 2011; Wang et al, 2011). The majority (73%) of the 
mutations identified in SCC of the skin were G>A transitions typical of UV-induced 
DNA damage. There is also data to suggest that loss of Tp53 activity in murine epithelial 
cells contributes to cellular transformation to SCC through the down-regulation of 
Notch-1 (Lefort et al, 2007).  
 
The presence of inactivating mutations of NOTCH-1 and NOTCH-2 in lung cancer is in 
contrast to the Notch pathway activation that had previously been described in 40% of 
patients with non-small cell lung cancer (NSCLC) (which includes the adenocarcinoma 
and SCC subtypes), either through activating mutations of NOTCH-1 (10% of cases) or 
loss of expression of the negative regulator Numb (30% of cases) (Westhoff et al, 2009).  
Whilst the description of oncogenic and tumour suppressor functions for Notch in the 
same tumour subtype, namely SCC of the lung, is seemingly contradictory and requires 
further experimental validation, it suggests that the consequences of Notch pathway 
activation/inactivation may be influenced by the genetic landscape of the individual 
tumour.   
 
The majority of studies of haematological malignancies have implicated an oncogenic 
role for mutations in the Notch pathway.  For example, besides T-ALL, Notch activation 
through somatic mutation has also been described in chronic lymphocytic leukaemia 
(CLL) and mantle cell lymphoma (MCL) (Fabbri et al, 2011; Kridel et al, 2012; Puente 
et al, 2011; Robinson et al, 2011), and several of these studies have shown that NOTCH-
1 mutation status is associated with patient outcome. However, the role of Notch 
signalling in myeloid malignancies remains contentious.  Over-expression of NOTCH-1 
mRNA has been identified by microarray analysis of samples from a subset of AML 
patients with poor prognosis (Bullinger et al, 2004). Tribbles homolog 2 (Trib2), a direct 
Notch target, enhances proliferation of myeloid progenitors and Trib2 transgenic mice 
develop AML through degradation of Cebp/α, a transcription factor that is essential for 
myeloid differentiation (Keeshan et al, 2006). Notch signalling is also integrally 
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involved in the rare subset of patients with acute megakaryocytic leukaemia (AMKL) 
initiated by the OTT-MAL fusion transcript, whereby CSL is directly activated by OTT-
MAL independently of NOTCH (Mercher et al, 2009). However, Notch signalling may 
also have a tumour suppressor role in myeloid cells. Loss of Notch signalling through 
compound deletion of Notch-1 and -2, or through homozygous inactivation of the 
gamma-secretase complex by deletion of Nicastrin (Ncstn -/- ) in the haematopoietic 
compartment of mice leads to a myeloproliferative disease akin to chronic 
myelomonocytic leukaemia (CMML) (Klinakis et al, 2011). 
 
5.1.6 CSL isoforms 
CSL is a transcription factor that binds to NOTCH, MAML and DNA, and the structure 
of this complex is discussed in the general Introduction, sections 1.4.3.4 and 1.4.3.5. At 
the time of undertaking the practical work described in this thesis, four main isoforms 
were annotated on both the National Center for Biotechnology Information (NCBI) 
(www.ncbi.nlm.nih.gov) and Ensembl (www.ensembl.org) websites, and are listed 
below. All are identical from exon 3 onwards, with the same amino acid sequence, but 
differ in their 5’ regions and translational start sites. They are referred to here according 
to the NCBI annotation as isoforms 1-4. Figure 5.2 shows how the four isoforms differ in 
their 5’ region and their putative transcriptional start sites.   
 
 
• Isoform 1  NM005349 (ENST 342295; RBPSUH-201) 
• 12 exons 
• 2388 bp and 500 residues 
 
• Isoform 2  NM015874 (ENST 348160; RBPSUH-202) 
• 11 exons  
• 2316 bp and 517 residues 
 
• Isoform 3  NM203283(ENST 345843; RBPSUH-001) 
• 11 exons 
• 2272 bp and 485 residues 
 
• Isoform 4  NM203284 (ENST 342320; RBPSH-003) 
• 12 exons 
• 2500 bp and 486 residues 
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5.2 AIMS 
 
As described in chapter 3, no NOTCH-1 mutations were detected in diagnostic samples 
in a substantial cohort of AML patients. To determine whether other components of the 
Notch signalling pathway were affected, all coding exons from CSL were screened by 
DHPLC analysis in samples from 100 AML patients from the same cohort. No mutations 
were detected (data not shown). Expression of CSL was therefore investigated by RT-
PCR in primary AML patient samples, which led to the discovery of an additional 
unexpected smaller PCR product, often as the predominant band. Further analysis 
identified it as a novel alternatively spliced isoform. This chapter presents results of 
studies investigating the functional and prognostic significance of this isoform in AML.   
 
 
5.3 MATERIALS AND METHODS 
 
5.3.1 RNA samples from cell lines, patients and normal subjects 
RNA samples were made from 13 different cell lines (ALL-SIL, HEK-293T, HL60, 
Jurkat, KG-1, Monomacs-6, NALM-6, NB4, RAJI, SEM, THP-1, U2OS and U937) and 
from CD34+ cells isolated as described in section 5.3.11 using the Trizol method as 
described in Materials and Methods, section 2.3.3. RNA samples from neutrophils (n=6) 
and T cells (n=6) purified from haematologically normal individuals and from diagnostic 
peripheral blood or bone marrow of 278 AML patients treated on the UK MRC/NCRI 
AML10 (n=15), 12 (n=27) or 15 (n=236) trials were available from the departmental 
tissue bank. All samples were anonymised. A panel of RNA from normal donor tissues 
was obtained from Ambion. cDNA was generated by RT-PCR as described in Chapter 2, 
section 2.3.4.  
 
5.3.2 Identification of 5’ CSL isoforms 
In order to identify the predominant 5’ CSL isoform expressed in primary AML cells, 
such that the relevant isoform could be cloned for functional studies, two separate RT-
PCR reactions were performed. The first reaction used primers 2bF and 5R (Table 5.1), 
which amplify CSL isoforms 2 (expected product 208bp) and 4 (392bp) (Figure 5.2), and 
the second reaction used primers 1aF and 5R, which amplify CSL isoforms 1 (400bp) 
and 3 (284bp). Both reactions mixes were performed with Bioline PCR reagents as
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Figure 5.2 Alternative 5’ CSL isoforms (A) A schematic showing annotated CSL mRNA 
isoforms. Coloured bars represent exons whilst the black lines signify introns. The red dots 
indicate predicted transcriptional start sites. The pre-mRNA is shown above the mature mRNA 
isoforms and the primers used in the study are shown with arrowheads. (B) RT-PCR results from 
primary AML patient samples using primers 2bF-5R (top) and 1aF-5R (bottom), suggesting that 
isoform 2 is the most predominant isoform in AML patients. L Hyperladder IV 
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described in Materials and Methods Chapter 2, section 2.3.5. PCR conditions were 95°C 
for 20 seconds, 60°C for 20 seconds, 72°C for 30 seconds, repeated for 32 cycles, 
followed by a final extension at 72°C for 5 minutes. PCR products were resolved by 
agarose gel electrophoresis as described in Materials and Methods Chapter 2, section 
2.3.6, and are shown in Figure 5.2B.  
 
5.3.3 Identification and quantification of CSL-TREX 
 
In order to investigate the mRNA expression of CSL in haematopoietic cells, CSL exons 
9 to 12 that are common to all four isoforms were amplified by RT-PCR from 2µl cDNA 
(diluted 1 in 5 from the original RT reaction) using BioTaq DNA polymerase (see 
Chapter 2, section 2.3.5) and primers CSL-9F and CSL-12R (Table 5.1) in a 20µl 
reaction. Cycling parameters were: denaturation at 95°C for 30 seconds, annealing at 
62°C for 30 seconds, extension at 72°C for 30 seconds, repeated for 30 cycles, followed 
by a final 5 minute extension at 72°C. PCR products were examined by gel 
electrophoresis (see Chapter 2, section 2.3.6). PCR products were TOPO cloned 
(TOPO® TA, Invitrogen) and sequenced using M13 primers (see Chapter 2, section 
2.3.8).  
 
For accurate quantification of the two bands identified in the RT-PCR described above, 
size separation by fragment analysis was used with the same PCR reaction mix but with 
a fluorescently-labelled forward primer (CSL-9F-dye4). PCR amplification was limited 
to 28 cycles to avoid preferential amplification of the smaller PCR product. Optimised 
cycling parameters were: denaturation at 95°C for 1 minute, annealing at 62°C for 1 
minute, extension at 72°C for 1 minute, with slow ramping of 0.5°C per second between 
cycles, followed by a final 10 minute extension at 72°C. PCR products were sized by 
fragment analysis (CEQ8000 Genetic Analysis System) and relative quantification was 
expressed as a proportion of total CSL alleles.  
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Table 5.1 Primer names and sequences used in the study 
Primer 
name 
Sequence 5’ to 3’ 
CSL-1aF 5’-GTTTCGGGCGGCGAATTCCAG 
CSL-2bF 5’-GTTTGTGGAAGATGGCGCCTG 
CSL-5R 5’-AGATATACACAAGGAGGTGGGC 
CSL-10F 5’-ATTTCAGGCCACTCCATGTCCA 
CSL-
10F-d4 
5’-dye4-ATTTCAGGCCACTCCATGTCCA 
CSL-12R 5’-ATGTCTGGGACGACACAGAGC 
MP2932 5’-AACGTAGCCAATTGGGATCCGCCACCATGGCGCCTGTTGTGACAGGGA 
MP2938 5’-GTTTCCGCACGGCACTCGAGTTAGGATACCACTGTGGCTGTAGATGATGTG 
MP3739 5’-GGCCAGACTCCAGGATCCGCCACCATGGACTACAAAGACCATGACGGTGATTATAAAGATC 
MP3740 5’-CCGCCGCTCTTGTCATCGTCATCCTTGTAATCGATGTCATG 
MP3741 5’-ATGACGATGACAAGAGCGGCGGCGGCAGCGCGCCTG 
MP3742 5’-TGAGAAAGGCACAAATACATTCTTTCTGTATC 
 
 
5.3.4 Statistical analysis of patient outcome 
The UK AML MRC trials are registered at http://www.controlled-trials.com under 
ISRCTN17833622 (AML12) and ISRCTN17161961 (AML15) (Burnett et al, 2011; 
Burnett et al, 2010). Consent was obtained from all patients at trial entry according to the 
Declaration of Helsinki. The trials were approved by the Wales Multicentre Research 
Ethics Committee and each participating institution’s ethics review committee. Median 
follow-up was 40 months. The following definitions were used: overall survival (OS) is 
the time from randomisation to death; for remitters, disease-free survival (DFS) is the 
time from remission to first event (either relapse or death in CR), and the cumulative 
incidence of relapse (CIR) is the cumulative probability of relapse, with death as a 
competing risk. Mantel-Haenszel test for trend and chi-squared tests were used to test for 
differences in clinical and demographic data by CSL-TREX levels. Kaplan-Meier life 
tables were constructed for survival data and compared by means of the log-rank test. 
Multivariate Cox models were used to analyse CIR, DFS and OS. Mutational status of 
FLT3 internal tandem duplications (FLT3-ITD), FLT3-tyrosine kinase domain (FLT3-
TKD), and nucleophosmin 1 NPM1 was available, as previously reported (Gale et al, 
2008; Kottaridis et al, 2001; Mead et al, 2007). 
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5.3.5 Creation of constructs 
The pcDNA3-ICN-1 plasmid was a kind gift from Jon Aster of Brigham and Women’s 
Hospital Boston. For the creation of inserts for cloning, the proof-reading enzyme 
Phusion DNA polymerase (Finnzymes) was used for all PCR reactions. PCRs were set 
up in 50µl reactions with a mix consisting of 10µl Phusion buffer (which includes 
magnesium chloride at 1.5mM final concentration), 200µM each dNTP (final 
concentration), 500nM each primer (final concentration), 200ng template DNA, and 1U 
Phusion DNA polymerase. Primer sequences for the cloning reactions are given in Table 
5.1. PCR cycling conditions were an initial denaturation step of 98°C for 2 minutes 
followed by 35 cycles of 98°C for 30 seconds, 64°C for 30 seconds, 72°C for 30 seconds 
per kb, followed by a final extension of 10 minutes at 72°C. Products were run out on a 
low-melt agarose gel, cut-out and extracted using a gel purification kit (Qiagen), and 
eluted in 100µl DDW. The relevant vector and PCR products were each digested with 
the appropriate restriction enzymes (New England Biolabs) in a 100µl reaction mix 
containing 5µl each enzyme, 10µl NEB buffer, and 1µl 100mg/ml BSA, left at 37°C for 
2 hours. Vector and insert DNA were then ligated using the Quick Ligation Kit (New 
England Biolabs) in a 20µl reaction mix containing 1.5µl  Quick ligase enzyme, 10µl 
Quick ligase buffer and a 1:1 molar ratio of vector:insert. A negative control reaction 
was set up using the same reaction mix but with digested vector alone and no insert. The 
reaction was left at room temperature for 10 minutes and then 2µl was used to transform 
DH5α cells as described in Chapter 2, section 2.3.9. Colonies were harvested and 
expanded (see Chapter 2, section 2.3.9) and plasmid DNA was prepared using a Maxi 
prep kit (Qiagen). The entire open reading frame of each construct was sequenced using 
the CEQ8000 sequencer.  
 
5.3.5.1 Creation of MSCV-CSL-WT and MSCV-CSL-TREX constructs 
MSCV-CSL-WT and MSCV-CSL-TREX plasmids were constructed as shown in Fig. 
5.3. Full-length isoform 2 of CSL (which was considered the predominant isoform, 
according to its intensity by RT-PCR, Figure 5.2B) was amplified from normal T-cell 
cDNA for generation of CSL-WT, and from a primary AML cDNA sample for 
generation of CSL-TREX, using primers CSL-2bF and CSL-12R. Cycling parameters 
were: initial single denaturation step at 98°C for 2 minutes, denaturation at 98°C for 20  
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Figure 5.3 A schematic of the cloning strategy used to generate MSCV-CSL-WT 
and MSCV-CSL-TREX retroviral constructs. TOPO clones containing full-length 
isoform 2 CSL-WT or CSL-TREX were used as template for a PCR reaction using forward 
primer MP2932 which has an MfeI digest site at the 5’end, and reverse primer MP2938 which 
has an XhoI site at the 5‘end. The PCR products were digested with MfeI and XhoI, the MSCV-
IRES-GFP vector with EcoRI and XhoI, and the insert was ligated to create MSCV-CSL-WT 
and MSCV-CSL-TREX. Note MfeI and EcoRI overhangs are compatible. LTR long terminal 
repeats; MCS multi-cloning site; IRES internal ribosomal entry site; AMP-R ampicillin 
resistance gene.
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seconds, annealing at 64°C for 20 seconds, extension at 72°C for 90 seconds, repeated 
for 35 cycles, followed by a final 10 minute extension at 72°C. PCR products were 
examined by gel electrophoresis. The PCR products were TOPO cloned and sequenced 
to identify the correct insert and to exclude Taq-errors, and were then used as template in 
subsequent reactions.  
 
Insertion into the cloning site of the retroviral MSCV-IRES-GFP vector requires 
EcoRI/XhoI restriction digest sites. However, CSL has an internal EcoRI site and 
therefore an MfeI site, which has compatible overhangs with EcoRI but would not cut 
the CSL sequence, was substituted in the cloning strategy. A CSL coding sequence 
fragment was generated using a forward oligonucleotide (MP2932) containing 5’ MfeI 
and BamHI digest sites, a Kozak sequence and ATG, followed by a region 
complementary to the 5’ CSL sequence, and a reverse primer (MP2938) containing a 5’ 
XhoI digest site followed by a region complementary to the 3’ CSL sequence, using 
Phusion DNA polymerase and conditions as described above. The 1.5 Kb fragment was 
gel purified and digested with MfeI and XhoI, and then gel purified a second time. The 
MSCV-IRES-GFP plasmid was digested with EcoRI and XhoI and gel purified. The 
digested products were mixed and ligated at a vector: insert 1:1 molar ratio. The ligation 
was then used to transform DH5α cells and prepare purified plasmid DNA as described 
in Materials and Methods, section 2.3.9.  
 
5.3.5.2 Creation of MSCV-FLAG-CSL-WT and MSCV-FLAG-CSL-TREX (5’ 
triple FLAG sequence) constructs 
A schematic representation of the cloning strategy to create 5’ triple-FLAG tagged CSL 
constructs is shown in Figure 5.4. A triple FLAG construct was provided by Martin Pule 
in the department; this contained a Kozak-ATG sequence prior to three consecutive 
FLAG sequences. This was amplified by PCR (conditions given above, section 5.3.5) 
using forward oligonucleotide MP3739 (containing a BamHI restriction digest site in the 
5’ end) and reverse oligonucleotide MP3740 (containing a sequence complimentary to 
the start of the CSL transcript in the 5’ end), to create a 100bp fragment coded BamHI-
Kozak-ATG-FLAGx3; this was gel purified and termed fragment A.  
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Using MSCV-CSL-WT as template, a 5’ CSL fragment was generated by PCR 
(conditions given above, section 5.3.5) using oligonucleotides MP3741 and MP3742, 
which codes for CSL up to amino acid 281 (prior to the alternative splice site) termed 
fragment B. Because 30% of primer MP3740 and MP3741 are complementary to each 
other, fragments A and B were ligated by mixing an equal ratio of DNA from each in a 
PCR reaction and amplifying with outer primers MP3739 and MP3742 (Figure 5.4), to 
create fragment C. This could then be cloned into MSCV-CSL-WT or MSCV-CSL-
TREX using the BamHI site introduced in oligonucleotide MP2932 (Figure 5.3) and the 
internal CSL EcoRI site. MSCV-CSL-WT and MSCV-CSL-TREX and fragment C were 
digested by EcoRI and BamHI (5µl each enzyme, 10µl EcoRI buffer, 1µl 100mg/ml 
BSA, 30µl PCR product and 49µl DDW, incubated at 37°C for 2 hours) and ligated 
using the Quick ligase kit to produce MSCV-FLAG-CSL-WT and MSCV-FLAG-CSL-
TREX. The ligation was then used to transform DH5α cells and make purified plasmid 
DNA as described in section 2.3.9.  
 
 
5.3.5.3 Creation of pHR-SIN-CSL-WT-IRES-GFP and pHR-SIN-CSL-TREX-
IRES-GFP constructs 
The pHR-SIN-eGFP vector is a third generation self-inactivating vector based on the 
pHR-SIN-SE vector originally described by Demaison, designed for efficient 
transduction and expression in CD34+ cells (Demaison et al, 2002), and was a kind gift 
from Professor Adrian Thrasher at UCL Institute of Child Health. It has a central HIV 
polypurine tract that increases vector titres by about 10 fold, a woodchuck hepatitis virus, 
post-translational regulatory element (WPRE) that increases stability of mRNA, and a 
spleen focus forming virus (SFFV) promoter, which has strong promoter activity in 
haematopoietic cells.  MSCV-CSL-WT and MSCV-CSL-TREX, or the triple FLAG-
tagged versions, were digested with BamHI and NotI and cloned into the BamHI and 
NotI sites of pHR-SIN-eGFP using the Quick ligase kit (as described above in section 
5.3.5). The ligation was then used to transform DH5α cells and make purified plasmid 
DNA as described in section 2.3.9.  
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Figure 5.4 A schematic of the cloning strategy used to generate 5’ triple FLAG 
tagged MSCV-CSL-WT and MSCV-CSL-TREX constructs. PCR products termed 
fragment A and fragment B were mixed and used as template in a PCR reaction using outer 
primers MP3742 and MP3739, leading to ligation of the fragments due to primer 
complementarity. Fragment C was cloned into the BamHI and EcoRI sites of MSCV-CSL-WT  
or MSCV-CSL-TREX. 
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5.3.6 Western blotting 
Nuclear lysates from primary AML samples or cell lines were made from 5x106 cells 
using a nuclear extraction kit (Active Motif) (see chapter 2.4.2). Proteins were resolved 
by electrophoresis on 10% SDS-polyacrylamide gels and transferred electrophoretically 
to a nitrocellulose membrane (see chapter 2.4.3). The membranes were pre-blocked for 1 
hour in 5% skimmed milk dissolved in PBS containing 0.1% Tween (PBS-T). 
Immunoblotting was carried out as described in chapter 2, section 2.4.5 with the 
following primary antibodies, all diluted in PBS-T and 5% skimmed milk, and left 
overnight at 4°C: rat monoclonal anti-RBP-JK antibody diluted 1 in 500 (clone SIM-
2ZRBP3, T6719, Cosmobio, Japan), mouse monoclonal anti-Notch-1 antibody specific 
to cleaved Notch-1 diluted 1 in 2000 (clone mN1A, N-6786, Sigma Aldrich, Poole, UK), 
mouse monoclonal anti-FLAG M2 antibody diluted 1 in 2000 (Sigma Aldrich, Poole, 
UK). Secondary horse-radish peroxidise (HRP)-linked IgG antibodies to mouse, rabbit or 
rat were diluted 1 in 10,000 in PBS-T (all from Cell Signalling Technology, Hitchin, 
UK) and left on the membranes for 30 minutes.  
 
5.3.7 Co-immunoprecipitation experiments 
HEK-293T cells were seeded at 1x105/ml in a 10cm tissue culture plates in 10mls 
DMEM supplemented with 10% FCS and Penicillin-Streptomycin (100U/ml and 
100µg/ml respectively) (D10). The following day, provided that the cells were at 
approximately 70% confluent, they were transfected by adding 18µl Genejuice reagent 
(Novagen) mixed with 800µl DMEM and a total of 8µg DNA and left at 37°C in 5% 
CO2 for 48 hours. The negative control plate was transfected with 4µg pcDNA3-ICN-1 
and 4µg MSCV-CSL-WT (no FLAG tag), the positive control plate with 4µg pcDNA3-
ICN-1 and 4µg MSCV-FLAG-CSL-WT, and the test plate with 4µg pcDNA3-ICN-1 and 
4µg MSCV-FLAG-CSL-TREX . The cells were then washed 2 times with PBS, scraped 
from the plate, transferred into a 15ml conical tube and pelleted at 400g at room 
temperature. After removal of the supernatant, the cells were resuspended in 200µl NP40 
lysis buffer containing protease inhibitor cocktail, transferred into 1.5ml Eppendorf 
tubes, incubated on ice for 15 minutes and then pelleted at 16,000g at 4°C. An aliquot of 
50µl of the supernatant was added to 50µl SDS loading buffer as the total extract control 
and stored at -80°C. The remainder of the supernatant was added to a tube containing 
40µl FLAG-M2 agarose bead slurry (Sigma Aldrich) and rotated at 4°C for 2 hours. The 
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beads were then washed 6 times with ice-cold NP40 buffer containing protease inhibitor 
cocktail, and proteins were eluted with 40µl SDS loading buffer, and run on SDS-PAGE 
gels and Western blotted as described in Chapter 2, section 2.4.  
 
5.3.8 Luciferase Reporter assays 
Dual-luciferase reporter assays to assess Notch signalling were performed as described 
below using the Promega Dual Luciferase Kit with the adherent osteosarcoma cell line 
U2OS because of its low baseline Notch activity. The cell line was confirmed as wild 
type for NOTCH-1 and FBXW7 by DHPLC analysis as described in chapter 3. The Notch 
reporter plasmid CBF1x10-luc, which contains 10 TGGGAA motifs upstream of 
luciferase, was kindly given by Graeme McKenzie (McKenzie et al, 2006). In this assay, 
luciferase activity is proportional to the degree of Notch activity in the transfected cells, 
and the transfection efficiency and cell number are controlled for by co-transfection of a 
renilla luciferase construct. The kit contains a lysis buffer, a firefly luciferin substrate 
(LARII), and Stop-and-Glo, which quenches the firefly luciferin and provides a substrate 
for the renilla luciferase. 
 
For the reporter assays, 4 x 104 U2OS cells in 500µl D10 per well were seeded the day 
before transfection in 24-well plates. For optimum transfection efficiency, cells were 
only used if they were 60-70% confluent at the time of transfection. Transfection and 
luminometry were performed in triplicate as follows: 
a. Firstly, 0.75µl Genejuice (Novagen) was added to 20µl serum free 
medium, mixed by vortexing and left for 5 minutes at room temperature. 
The luciferase reporter and Renilla plasmids were added to the mastermix 
so that their concentrations were kept equal in each well. The DNA 
quantities used were 100ng CBFx10-luc reporter construct, 30ng renilla, 
2.5ng pCDNA3.1-ICN1 and 50ng MSCV-CSL-WT or 50ng MSCV-CSL-
TREX in a total volume of 9.25µl. Total DNA was made up to 250ng per 
well by adding 67.5ng MSCV-GFP. The mix was incubated for 15 
minutes at room temperature.   
b. The total volume of transfection mixture (30µl) was then added dropwise 
to each well, and the cells incubated for 48 hours at 37°C in 5% CO2 
before being harvested.  
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c. The culture supernatant was removed and the cells were washed once 
with PBS, then 100µl 2x Passive Lysis Buffer (Promega Dual Luciferase 
Kit) was added per well, and the plate left on a shaker for 15 minutes at 
room temperature. 
d. To measure luminescence, 10µl lysate was then added to 50µl firefly 
reagent (LARII reagent) in a clear polystyrene tube, pipetted up and down 
10 times, and the luciferase luminescence measured in a luminometer to 
assess expression of the reporter construct. Stop-and-Glo reagent (50µl) 
was then added, pipetted up and down 10 times, and the renilla 
luminescence measured.  
e. The relative luminescence was then calculated to control for cell number 
and transfection efficiency. The ratio of luciferase to renilla luminescence 
was first calculated for each well, and then divided by the mean 
luciferase:renilla value of the three wells transfected with empty plasmid.  
 
5.3.9 Lentiviral transduction of ALL-SIL cells and proliferation assays 
ALL-SIL cells were obtained from DSMZ (Leibniz Institute, Germany) and grown in 
RPMI containing 10% FCS and penicillin-streptomycin (R10). Lentiviral supernatants 
were produced as described in Chapter 2, section 2.2. The cells were incubated overnight 
at 37°C in 5% CO2 in a 12-well plate at a density of 1x105/ml with 2mls of R10 per well. 
Cells were transduced by spinoculation at 400g for 60 minutes, a method that has been 
shown previously to enhance infectivity of lentiviral vectors by 40 fold (O'Doherty et al, 
2000), with lentiviral particles expressing either GFP, FLAG-CSL-WT or FLAG-CSL-
TREX at a multiplicity of infection (MOI) of 1 viral particle per cell. Such an MOI has 
relatively low efficiency but is unlikely to lead to cells with multiple viral integrations 
and exceptionally high transgene expression. The plates were then incubated at 37oC in 
5% CO2 and after 24 hours the cells were washed, re-suspended in fresh R10 and 
returned to the incubator. At 48 hours from transduction, cells with equivalent GFP-
positivity were selected by FACS and protein expression was determined by intracellular 
flow as described below in section 5.3.10. For proliferation assays, GFP-positive 
transduced cells were seeded at 1x105/ml in triplicate in 96-well plate format. For ALL-
SIL-GFP control cells, the GSI L685,458 (Sigma) was used at 1µM compared to DMSO 
control treated cells. Over a 7 day period, cell number was counted using an MTS assay: 
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20µl MTS tetrazolium compound (Promega, Southampton, UK) was added to each well, 
the plates were then incubated at 37oC in 5% CO2 and after 4 hours the absorbance at 
490nm was read.  
 
5.3.10 Intracellular flow for anti-FLAG 
To assess expression of the FLAG-tagged CSL-WT or CSL-TREX proteins, 2x105 
transduced and GFP-sorted ALL-SIL cells, as described in section 5.3.9, were spun 
down at 400g for 5 minutes, resuspended in 100µl fix-perm solution (BD Bioscience 
Intracellular flow kit), left for 15 minutes on ice, then pelleted and washed once in perm-
wash (supplied in the kit). The cells were resuspended in 50µl perm-wash containing a 
1:200 dilution of anti-FLAG M2 antibody (Sigma Aldrich), left for 30 minutes on ice, 
washed once in perm-wash and resuspended in 50µl perm-wash containing a 1:200 
dilution of APC-anti-mouse secondary antibody. As negative controls, FLAG-CSL-WT 
and FLAG-CSL-TREX transduced cells were stained with primary antibody only, or 
secondary anti-mouse APC antibody without primary antibody. Samples were then 
analysed on a flow cytometer APC expression. 
 
5.3.11 CD34+ cell selection and transduction 
The use of surplus CD34+ cells from G-CSF-mobilised donors was approved by the 
Joint UCL/UCLH Ethics Committee on Human Research, REC study number 
97/0282/amended. All donors had signed a consent form for the anonymous use of their 
cells in research. Magnetic cell selection of G-CSF-mobilised haematopoietic progenitor 
cells was performed using anti-CD34+ magnetic beads and MACS® cell separation 
columns and reagents (Miltenyi Biotec) according to the manufacturer’s guidelines. In 
brief, cells were incubated with anti-CD34+ beads, loaded onto a MACS® cell 
separation column, washed and eluted. Following selection, a small aliquot of cells was 
tested for purity by flow cytometry using an anti-CD34-APC antibody (BD Pharmingen). 
If the cells were <95% CD34-positive, they were put through a second round of magnetic 
selection. The purified cells were washed in PBS and resuspended in Stem Pro-34 
serum-free medium (SFM) containing 20ng/ml stem cell factor (SCF), 20ng/ml FLT3-
ligand (FL), 45ng/ml thrombopoietin (TPO) at 1x106/ml/well in a 24-well plate and 
incubated for 12 hours at 37°C in 5% CO2 prior to lentiviral transduction.  
 
Lentiviral supernatants (see section 2.2) were thawed on ice and added to the prepared 
cells at an MOI of 40. One non-transduced well was left as a control. The plates were 
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spinoculated at 400g for 60 minutes at room temperature then incubated at 37°C in 5% 
CO2 in the above cytokine mix for 48 hours prior to assessment of transduction 
efficiency by flow cytometry for GFP.  
 
5.3.12 Clonogenic assays of transduced CD34+ cells 
To assess the consequences of CSL-WT or CSL-TREX overexpression on the 
clonogenic potential of CD34+ cells, purified CD34+ cells were transduced with a GFP, 
CSL-WT or CSL-TREX-expressing lentivirus as described in section 5.3.11. At 48 hours 
after transduction, the cells were sorted for GFP by FACS, counted and seeded into 12-
well plates at 100 cells per well in 2mls methocellulose containing 10ng/ml SCF, 
25ng/ml GM-CSF, 25ng/ml G-CSF, 30ng/ml interleukin-3 (IL-3), and 3U/ml 
erythropoietin (EPO). White cell colonies were counted after 2 weeks incubation at 37°C 
in 5% CO2. The experiment was repeated 4 times using 4 separate donors and at least 12 
wells were counted per vector. 
 
 
5.4 RESULTS 
 
5.4.1 Identification of a novel alternatively spliced isoform of CSL 
By RT-PCR of the region spanning exons 9-12, CSL was expressed in haematologically 
normal T-cells (n=6), neutrophils (n=6), and CD34+ cells (n=9), as well as in all primary 
AML samples tested (n=278). While a single band was visualised in the neutrophils and 
T-cells, an unexpected smaller band was present in the majority of AML patients, often 
as the more abundant product (Figure 5.5A). By TOPO cloning and sequencing, the 
smaller band was identified as an alternatively spliced transcript containing a 78bp 
deletion of the C-terminus of exon 10, originating from a cryptic 5’ donor splice site 
within the coding region of exon 10 that spliced in-frame to the start of exon 11 (Figure 
5.5B). Unusually, the donor splice site originates at a GC, rather than a GT, donor site. 
This alternatively spliced transcript was termed CSL-TREX for Truncated Exon X. The  
deleted amino acids are part of a highly conserved region (Figure 5.5C). The observed 
deletion was modelled on the crystal structure of full-length wild-type CSL (CSL-WT) 
by Dr Steven Blacklow of Brigham and Women’s Hospital, Boston, USA, and this 
indicated that it would delete the conserved bridge strand connecting the beta-trefoil 
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Figure 5.5 CSL is alternatively spliced at a cryptic donor site within  
exon 10 in samples from AML patients. (A) Agarose gel electrophoresis of RT-PCR 
products spanning CSL exons 9-12 from normal neutrophils (N) and 8 primary AML patient 
samples. CSL-WT product 304bp, CSL-TREX 226bp. L, Hyperladder IV. (B) Schematic showing 
splicing patterns at the 3’ end of CSL. CSL-TREX splices in-frame from the cryptic donor site in 
exon 10 (downward arrow) to the start of exon 11.  (C) The deleted amino acids of the CSL-
TREX isoform are shown as the shaded region, as compared to the orthologous protein sequences 
from different species. 
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Figure 5.6 Modelling the CSL-TREX deletion on the crystal structure of the CSL-
Notch-MAML1-DNA activation complex. Crystal structure modelling of the CSL-ICN-
MAML-DNA activation complex showing MAML1 (yellow), CSL (green), DNA (orange) and 
ICN (purple). The spliced out portion of CSL is shown in red. Images were created by Dr Steven 
Blacklow from published crystallography data (Nam et al., 2006; Wilson and Kovall, 2006). 
RHR-N, Rel-homology region N-terminal; BTD, beta-trefoil domain; ANK, ankyrin repeat 
domain of Notch; RAM, RBPJ-associated molecule domain 
 
 
 
domain to the C-terminal Rel homology region, and would be likely to interfere with the  
structural integrity of the protein (Figure 5.6) (Nam et al, 2006; Wilson & Kovall, 2006).  
 
5.4.2 Relative quantification of CSL-TREX 
The ratio of CSL-TREX to CSL-WT transcripts was quantified using the same exon 9-12 
PCR as above but with a fluorescently labelled primer. The products were analysed by 
fragment analysis, with peaks for CSL-WT of 304bp and CSL-TREX of 226bp, as 
depicted in Figure 5.7A. Results were expressed as the percentage of CSL-TREX alleles 
as a proportion of total CSL alleles. The assay was highly reproducible. Repeated testing 
of two cDNA samples gave results of 64.1% ± 2.1% (n=12) and 73.1% ± 1.8% (n=7) 
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(mean ± 1 standard deviation) respectively (Figure 5.7B). As some of the AML trial 
samples can take up to 3 days to arrive in the laboratory from the time of bone marrow 
aspiration or phlebotomy, stability of the relative proportion of CSL-TREX transcripts 
was assessed in two fresh samples over time. RNA was made from half the sample 
within 6 hours of bone marrow aspiration, and the other half was left at room 
temperature for 72 hours before RNA extraction. There was no difference in the relative 
levels of CSL-TREX over the three day period, as shown in Figure 5.7C. 
 
 
 
Figure 5.7 Quantification of CSL-TREX by fluorescently labelled PCR  
and fragment analysis.  (A) Fragment analysis traces showing presence of the CSL-WT 
peak at 304bp and CSL-TREX peak at 226bp in a representative example from a normal  
neutrophil sample and an AML patient. (B) Reproducibility of the assay using two 
AML samples. (C) Stability of the relative proportion of the CSL-TREX isoform in two AML 
samples where RNA was prepared within 6 hrs or 72 hrs after sampling from the patient. 
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5.4.3 CSL-TREX is the predominant CSL isoform in many AML patients and is 
present in normal undifferentiated haematopoietic cells 
Using fragment analysis, relative CSL-TREX mRNA levels were quantified in diagnostic 
samples from 278 young adult AML patients. Most patients expressed the CSL-TREX 
isoform, and in the majority it predominated over the CSL-WT isoform (median 57% 
CSL-TREX as a proportion of total CSL transcripts, range 0-100%) (Figure 5.8A). 
Normal terminally differentiated haematopoietic cells expressed low CSL-TREX levels 
(neutrophils (n=6), median 3%, range 0-8%; T-cells (n=6) median 0%, range 0-4%), 
whereas normal CD34+ selected haematopoietic cells expressed substantial levels (n=9, 
median 22%, range 4-41%) (Figure 5.8A), although they were significantly lower than in 
AML patient samples (P <0.001). CSL-TREX levels were less than 10% in RNA 
analysed from 20 different normal tissues from the Ambion RNA panel, and from 13 cell 
lines (Figure 5.8B). 
 
5.4.4 CSL-TREX levels decrease in AML blasts upon differentiation  
To further explore the relationship of cell differentiation stage and levels of CSL-TREX, 
RNA available from primary AML blasts from six patients pre- and post- in vitro culture 
in the presence of IL-3, G-CSF and GM-CSF to induce myeloid differentiation was 
studied (Gale et al, 1998). At day 10 of culture there was a mean of 87% differentiated 
cells, range 50-98.5%. CSL-TREX levels markedly decreased in all six samples, with a 
mean difference before and after differentiation of 30.0% (P<0.001, paired t-test) (Figure 
5.8C). These results indicate that high levels of CSL-TREX transcripts are a particular 
feature of myeloid leukaemic cells, moderate levels are present in undifferentiated 
haematopoietic cells, and low levels in differentiated T-cells and myeloid cells. 
 
5.4.5 A band corresponding to CSL-TREX is expressed at the protein level in AML 
patients 
To assess if CSL-TREX transcripts produced protein, endogenous CSL was 
immunoblotted from nuclear lysates obtained from six different leukaemia cell lines and 
13 primary AML samples. Lysates from HEK-293T cells transfected with MSCV-CSL-
WT were used as a size control. Only a single band corresponding to the expected size 
for CSL-WT was detected in the cell lines (Figure 5.9A), which had  <10% CSL-TREX 
transcripts (Figure 5.8B). A smaller band corresponding to the predicted size of the CSL
-  
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Figure 5.8 Quantification of CSL-TREX by fragment analysis in AML  
patients as compared to normal haematopoietic cells and tissues.  (A) Scatter plot 
showing the relative percentage of CSL-TREX transcripts in samples from young adult AML 
patients, normal CD34+ cells, neutrophils and T-cells. Horizontal bars represent median levels. 
(B) Median percentage of CSL-TREX transcript levels from normal human tissues (each RNA 
sample pooled from 3 different individuals), normal CD34+ cells (n=9) and a variety of cell 
lines, as quantified by fragment analysis. (C) Percentage of CSL-TREX transcripts in primary 
AML blasts before and after in vitro differentiation with IL-3, GM-CSF and G-CSF. Data is 
shown for 6 independent samples.  
 179 
 
 
Figure 5.9 CSL-TREX protein expression in cell lines and primary AML samples.  
(A) Western blots of CSL in nuclear lysates from a variety of cell lines and (B) from primary 
AML cells (lanes 1-6). A whole cell lysate from MSCV-CSL-WT transfected 293T cells was 
included for size comparison (lane 7). The relative percentage of CSL-TREX protein (from 
densitometry) and cDNA (from fragment analysis) is shown below each lane. (C) Correlation of 
relative CSL-TREX transcripts with protein levels in 13 AML samples.
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TREX isoform was also observed in 9 of the 13 primary AML samples studied, in one 
case as the only product (Figure 5.9B, lane 5). The relative amount of CSL-TREX 
isoform as a proportion of total CSL protein was quantified by densitometry and showed 
a significant correlation with transcript levels (n=13, r2=0.72, P= 0.0002) (Figure 5.9C).  
 
5.4.6 CSL-TREX levels have prognostic significance in AML 
In order to assess biological relevance, the clinical features and outcome of the 278 
young adult AML patients were analysed according to levels of CSL-TREX. There were 
no obvious cut off values (Figure 5.10A); the data was therefore analysed for groups 
divided into quartiles (Q1, CSL-TREX 0-28%; Q2, 29-57%; Q3 58-73%; Q4 74-100%). 
There was no association between CSL-TREX level and AML FAB subtype, age or sex, 
but higher levels were significantly correlated with a lower presenting white cell count 
(WCC, P=0.02, Pearson test for correlation) (Table 5.2). CSL-TREX was not associated 
with a particular cytogenetic subgroups, including APML. There was no association 
between CSL-TREX levels and rates of CR (odds ratio [OR] per quartile 0.79, 95% 
confidence intervals [CI] 0.57-1.09, P=0.14), resistant disease (OR per quartile 0.80, CI 
0.55-1.16, P=0.20), or induction death (OR per quartile 0.79, CI 0.44-1.42, P=0.40), 
(Table 5.3). Patients with higher CSL-TREX levels had lower rates of relapse (CIR 31% 
vs 51% for highest [Q4] vs lowest [Q1] quartiles respectively at 5 years, hazard ratio 
[HR] 0.82, CI 0.68-0.99, P=0.04) (Figure 5.10B), improved DFS (63% vs 51% at 5 
years, HR per quartile 0.77, CI 0.62-0.96, P=0.02), and improved OS  (66% vs 45%, HR 
0.82, CI 0.69-0.96, P=0.01) (Figure 5.10C, Table 5.3). Overall, 24% of patients (65 of 
271 tested) had a FLT3-ITD, 10% (28 of 266 tested) a FLT3-TKD mutation and 34% (85 
of 247 tested) an NPM1 mutation. There was no association between CSL-TREX levels 
and genotype for FLT3-ITD (mean CSL-TREX levels in FLT3-ITD+ vs FLT3-ITD- 
samples, 52% vs 50%, P=0.54), FLT3-TKD (42% vs 52%, P=0.07) or NPM1 (55% vs 
48%, P=0.09) that might account for the differences observed in survival according to 
CSL-TREX levels.  
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Table 5.2 Clinical and demographic characteristics of patients in the total AML 
cohort with follow up. 
Demographic Total 
(%) 
Lowest 
quartile 
Quartile 
2 
Quartile 
3 
Highest 
quartile 
p-
value 
for 
trend 
% TREX  0-28% 29-57% 58-73% 74-100%  
Total per 
quartile 
 
278 
 
70 
 
70 
 
74 
 
64 
 
Age 
<15 
15-29 
30-39 
40-49 
50-59 
60+ 
 
3 (1%) 
38 (14%) 
38 (14%) 
86 (31%) 
86 (31%) 
27 (9%) 
 
1 (1%) 
12 (17%) 
7 (10%) 
19 (27%) 
25 (36%) 
6 (9%) 
 
0 (0%) 
7 (10%) 
11 (16%) 
26 (37%) 
17 (24%) 
9 (13%) 
 
2 (3%) 
12 (16%) 
11 (15%) 
19 (26%) 
23 (31%) 
7 (9%) 
 
0 (0%) 
7 (11%) 
9 (14%) 
22 (34%) 
21 (33%) 
5 (8%) 
0.9 
Sex 
Female 
Male 
 
138 (50%) 
140 (50%) 
 
36 (51%) 
34 (49%) 
 
32 (46%) 
38 (54%) 
 
38 (51%) 
36 (49%) 
 
32 (50%) 
32 (50%) 
0.9 
Secondary 
No 
Yes 
 
259 (93%) 
19 (7%) 
 
66 (94%) 
4 (6%) 
 
63 (86%) 
7 (14%) 
 
69 (93%) 
5 (7%) 
 
61 (95%) 
3 (5%) 
0.6 
Performance 
Status 
WHO 0 
WHO 1 
WHO 2 
WHO 3 
WHO 4 
 
 
165 (59%) 
89 (32%) 
14 (5%) 
7 (3%) 
3 (1%) 
 
 
37 (53%) 
24 (34%) 
3 (4%) 
4 (6%) 
2 (3%) 
 
 
40 (57%) 
25 (36%) 
5 (7%) 
0 (0%) 
0 (0%) 
 
 
51 (69%) 
16 (22%) 
4 (5%) 
2 (3%) 
1 (1%) 
 
 
37 (58%) 
24 (38%) 
2 (3%) 
1 (1%) 
0 (0%) 
0.08 
WCC,  
<10 
10-19.9 
20-49.9 
50-99.9 
100+ 
 
119 (45%) 
31 (13%) 
50 (18%) 
33 (12%) 
33 (12%) 
 
28 (40%) 
10 (14%) 
9 (13%) 
6 (10%) 
16 (23%) 
 
30 (43%) 
9 (13%) 
12 (17%) 
8 (11%) 
11 (16%) 
 
34(46%) 
7 (9%) 
16 (22%) 
12 (16%) 
5 (7%) 
 
27 (43%) 
15 (24%) 
13 (21%) 
7 (11%) 
1 (1%) 
0.02 
Cytogenetics 
Favourable 
Intermediate 
Adverse 
 
69 (28%) 
153 (62%) 
23 (10%) 
 
21(33%) 
40 (62%) 
3 (5%) 
 
16 (25%) 
36 (58%) 
11 (17%) 
 
17 (27%) 
38 (61%) 
7 (12%) 
 
15 (27%) 
39 (70%) 
2 (3%) 
0.8 
APL 
No  
Yes 
 
246 (88%) 
32 (12%) 
 
61 (87%) 
9 (13%) 
 
63 (90%) 
7 (10%) 
 
64 (86%) 
10 (14%) 
 
58 (91%) 
6 (9%) 
0.7 
WCC x109/L
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Figure 5.10 Prognostic outcome according to CSL-TREX levels in AML patients 
treated on the AML MRC trials. (A) Centile chart showing distribution of CSL-TREX 
levels as a proportion of total CSL transcripts in the 278 AML patient samples as quantified by 
fragment analysis.  (B) Relapse rate and (C) Overall survival of young adult AML patients 
treated on the AML MRC trials stratified according to quartile levels of CSL-TREX
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Table 5.3 Outcome of AML patients according to CSL-TREX levels 
Outcome Lowest 
quartile 
Q2 Q3 Highest 
quartile 
 Unadjusted OR per 
quartile (CI) 
Adjusted OR per 
quartile (CI) 
CR/CRi 84% 84% 88% 92% 0.79 (0.57-1.09) p=0.14 0.76 (0.53-1.11) p=0.16 
RD 11% 11% 8% 6% 0.80 (0.55-1.16) p=0.2 0.70 (0.44-1.12) p=0.14 
ID 4% 4% 4% 2% 0.79 (0.44-1.42) p=0.4 0.98 (0.53-1.81) p=0.9 
DFS (5yrs) 51% 43% 63% 63% 0.77, (0.62-0.96) p=0.02 0.79 (0.61-1.04) p=0.09 
OS (5yrs) 45% 48% 55% 66% 0.82 (0.69-0.96) p=0.01 0.83 (0.69-1.00) p=0.05 
CIR (5yrs) 51% 40% 31% 31% 0.82 (0.68-0.99) p=0.04 0.90 (0.72-1.13) p=0.4 
Adjusted analyses use level as quartile and are adjusted for age, secondary disease, performance status, WCC and 
cytogenetics. CR Complete remission; Cri Complete remission with incomplete blood count recovery; RD Resistant 
disease; ID Induction Death; DFS Disease free survival; OS Overall survival; CIR Cumulative incidence of relapse. CI 
Confidence intervals 
 
 
 
 
Figure 5.11 CSL-TREX cannot bind to ICN-1. Western blots of lysates (lanes 1-3) or 
anti-FLAG immunoprecipitates (lanes 4-6) of HEK-293T cells transfected with FLAG-tagged 
CSL constructs were probed with an anti-Notch-1 antibody (N6786, upper panel) or anti-CSL 
antibody (T6719, lower panel). HC, Heavy chain. The experiment was performed twice. 
 
 
 
 
5.4.7 CSL-TREX is unable to bind NOTCH-1  
To investigate the biological function of CSL, full-length isoform 2 (the predominant 
form expressed in haematopoietic cells) (Figure 5.1) was cloned into an MSCV retroviral 
vector. To assess whether CSL-TREX retained the capacity to bind to ICN-1, a co-
immunoprecipitation experiment was performed in HEK-293T cells (Figure 5.11). The 
lower panel shows expression of the transfected CSL constructs using the anti-CSL 
antibody. The upper left panel shows a Western blot using a NOTCH-1 antibody and 
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indicates that the ICN-1 plasmid was equally transfected and expressed in all three cell 
lysates. The upper right panel (for FLAG-immunoprecipitated proteins) shows a strong 
ICN-1 band co-immunoprecipitating with FLAG-CSL-WT but not with FLAG-CSL-
TREX. There was no apparent binding with non-FLAG-tagged CSL-WT. This is 
consistent with the findings from the crystal structure modelling that suggested CSL-
TREX would lose structural integrity.  
 
5.4.8 CSL-TREX does not have dominant-negative activity 
In order to explore the possibility that the CSL-TREX isoform can activate Notch 
signalling in the absence of ICN, CSL constructs were expressed in U2OS cells (which 
have low endogenous Notch signalling) together with a luciferase reporter construct 
containing 10 CSL-binding sites. Neither CSL-WT nor CSL-TREX alone were able to 
significantly activate the reporter (Figure 5.12). To assess whether CSL-TREX could 
exert a dominant-negative effect on Notch signalling, CSL-WT or CSL-TREX were co-
expressed with ICN-1 in the same assay. ICN-1 markedly activated luciferase activity on 
its own, and co-expression of CSL-TREX had no effect on the reporter activity induced 
by ICN-1, suggesting it does not exert a dominant-negative effect on Notch signalling 
(Figure 5.12). Of note, there was no interaction between CSL-WT and ICN-1 in these 
assays, suggesting that endogenous CSL abundance was not dose-limiting. 
 
 
Figure 5.12 CSL-TREX does not show dominant-negative activity. Luciferase reporter 
assay of Notch activation in U2OS cells transfected with vector  (MSCV-GFP), CSL and ICN-1 
constructs. Data is shown for three independent experiments performed in triplicate and analysed 
by Student’s t-test.
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Figure 5.13 CSL-TREX does not show dominant-negative activity on growth of the 
Notch dependent T-ALL cell line ALL-SIL. (A) Intracellular flow cytometry of ALL-SIL 
cells transduced with GFP vector alone, FLAG-CSL-WT, FLAG-CSL-TREX, or non-transduced 
(NT) and stained with anti-FLAG primary (1o) and APC-anti-mouse secondary (2o) antibodies. 
Negative control cells were transduced with FLAG-CSL-WT and stained with primary but not 
secondary, or secondary but not primary antibody. Intensity of APC on X-axis versus cell count 
on the Y-axis.  (B) Proliferation of transduced ALL-SIL cells after FACS sorting for GFP and 
then treated with vehicle (DMSO) or the γ-secretase inhibitor (GSI) L685,458 at 1µM. Cell 
numbers shown as percentage of cells at day 0.  
 
This finding was corroborated by proliferation experiments in the T-ALL cell line ALL-
SIL, which has activating mutations in NOTCH-1 (L1575P in the HD-N domain, 2478X 
in the PEST domain) and requires sustained NOTCH-1 activity for optimal growth 
(Weng et al, 2004). ALL-SIL cells were stably transduced with a lentiviral vector 
expressing either GFP vector alone, FLAG-CSL-WT or FLAG-CSL-TREX, and cells of 
equal GFP intensity were selected by FACS 48 hours after transduction. Expression of 
FLAG, as assessed by intracellular flow cytometry, showed equivalent protein 
expression in FLAG-CSL-WT and FLAG-CSL-TREX transduced cells (Figure 5.13A). 
The rate of proliferation was not significantly affected by stable expression of either 
CSL-WT (mean fold increase in cell number at day 7 was 11.9±0.8 [mean ± 1SD]) or 
CSL-TREX (10.5±0.2) compared to GFP transduced cells (11.6±0.5, P=0.81 and 0.18 
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respectively), whereas treatment of GFP-transduced ALL-SIL cells with a GSI 
significantly retarded growth (5.8±0.3, P=0.002) (Figure 5.13B). This indicates that 
CSL-TREX does not exert a dominant-negative effect on the endogenous CSL-WT 
isoform /Notch signalling interaction.  
 
5.4.9 CSL-WT, but not CSL-TREX, inhibits clonogenic potential of CD34+ cells  
To assess whether CSL-TREX has an impact on the clonogenic potential of CD34+ cells 
that could be relevant to AML pathogenesis, normal CD34+ cells were transduced with 
lentivirus expressing GFP vector control, CSL-WT, or CSL-TREX, FACS sorted 48 
hours later and seeded at 100 cells per well into methocellulose containing IL-3, G-CSF, 
GM-CSF, TPO, and EPO. The mean infection efficiency (± SD), calculated as the 
percentage of cells expressing GFP 48 hours after transduction was 50.4% (± 18.1%), 
8.4% (± 5.2%) and 10.6% (± 6.4%) for GFP, CSL-WT and CSL-TREX infected CD34+ 
cells respectively (Figure 5.14A). In an attempt to obtain cells with equal transgene 
expression, cells of equivalent GFP fluorescent intensity were selected by FACS. The 
cells were left at 37°C for 2 weeks then colony-forming units (CFUs) were counted by 
light microscopy. The experiment was performed four times from four separate donors 
with a minimum of 12-wells per condition. The cell number required in these assays 
limited the ability to assess protein expression of the transgene, therefore 10,000 of the 
sorted cells were harvested for RNA and expression of the appropriate transduced gene 
confirmed by fragment analysis (Figure 5.14B). The presence of a CSL-WT peak in the 
GFP control was due to endogenous CSL, and the particular example shown had levels 
of CSL-TREX below the level of detection. Transduction with CSL-WT led to a marked 
and consistent reduction in CFUs compared to GFP control (mean 3.1 colonies/100 
CD34+ cells for CSL-WT versus 10.6 for GFP control, P<0.0001) and CSL-TREX (8.5, 
P=0.001), while no significant difference was observed for cells transduced with CSL-
TREX compared to GFP control (8.5, P=0.31) (Figure 5.14C). Furthermore, colonies 
from CSL-WT transduced CD34+ cells appeared smaller than control or CSL-TREX 
transduced cells, although this was not formally quantified (Figure 5.14D). This suggests 
that the CSL-WT isoform has a negative impact on the cell growth of haematopoietic 
progenitors, and raises the possibility that alternative splicing to a loss-of-function 
isoform may be a means of reducing CSL dosage in these cells. 
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Figure 5.14 CSL-WT, but not CSL-TREX, markedly inhibits the clonogenic 
potential of CD34+ cells. (A) Transduction efficiency of CD34+ transduced cells as measured 
by flow cytometry. Data represents the mean ±SEM from 4 different donors (B) Expression of 
CSL isoforms in RNA from GFP-sorted CD34+ cells after lentiviral transduction with GFP 
vector only (upper panel), CSL-WT (middle panel), or CSL-TREX (lower panel) (C) Number of 
white cell colony forming units (CFUs) obtained from purified CD34+ cells, FACS sorted for 
GFP and cultured for 2 weeks in methocellulose and cytokines. Data is from 4 different CD34+ 
donor samples and was analysed by Student’s t-test. (D) Representative images of individual 
colonies visualised by fluorescent microscopy at 2 weeks. 
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5.5 DISCUSSION 
The analysis of CSL expression in AML by RT-PCR led to the serendipitous discovery 
of a smaller band in the majority of AML patient samples that was not present in 
differentiated haematopoietic cells (Figure 5.5).  Further analysis identified the smaller 
band as an alternatively spliced transcript of CSL that deleted the last 78bp of exon 10, 
that was termed CSL-TREX (Figure 5.5). Fragment analysis and Western blotting showed 
a correlation between the CSL-TREX isoform at the RNA and protein level (Figure 5.9), 
suggesting that despite the predicted loss of structural integrity, CSL-TREX forms a 
stable protein. Although transcript artefacts can be created by strand skipping during 
reverse transcription as a result of RNA secondary structure, often occurring due to high 
GC content within the gene (Prasov et al, 2010), the presence of a protein band of the 
expected size and correlating in intensity to that seen at the cDNA level argues against 
this possibility for CSL.  
 
The CSL-TREX isoform has not been previously reported and is not included as an 
alternatively spliced isoform on the Ensembl database, most likely because fragment 
analysis showed it is a rare transcript in a library of normal tissues (Figure 5.8), and 
databases such as Ensembl are created from such material (Flicek et al, 2012). Analysis 
of the CSL-TREX RNA and protein sequence using a basic local alignment search tool 
(BLAST) failed to identify matching sequences, so it is unlikely that this transcript 
results from a pseudogene (Altschul et al, 1997). The cryptic exon 10 donor splice site 
occurs at an AG-GC sequence; such sites are unusual in normal splicing (0.6% of donor 
sites), but are over-represented in transcripts occurring through alternative splicing and 
occur particularly at sites that create cryptic introns from exonic sequence, as found in 
this case (Burset et al, 2000; Thanaraj & Clark, 2001). 
 
Co-immunoprecipitation studies showed that CSL-TREX does not form a complex with 
ICN-1 (Figure 5.11), but this does not exclude the possibility that it is able to bind other 
Notch family members, MAML1 or DNA, that were not tested in these studies. 
Predictions from crystallography data of the ICN-MAML1-CSL-DNA quaternary 
complex performed by Dr Steven Blacklow suggest that CSL would not maintain 
sufficient structural integrity to enable binding to either Notch or MAML1. To further 
test the possibility that the DNA-binding domain remained in tact, a collaboration was 
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established with Dr Jon Aster of Brigham and Women’s Hospital, Boston, USA, who 
performed Electrophoretic Mobility Shift Assays using the constructs prepared in this 
thesis to investigate the interaction of CSL-WT and CSL-TREX with a radioactively 
labelled probe of the HES-1 promoter. Whilst there was significant gel shift with the 
CSL-WT isoform to both anti-CSL and anti-FLAG antibodies, CSL-TREX did not 
display evidence of HES-1 promoter binding (data not shown), which suggests that CSL-
TREX is also unable to bind DNA, at least at canonical target sequences.  
 
To test the possibility that CSL-TREX retained binding activity at other promoters and 
acted as a dominant-negative factor with regards to Notch signalling, CSL-TREX was 
expressed in ALL-SIL cells, a T-ALL cell line that is dependent on maintained Notch 
signalling for optimal growth. CSL-TREX did not alter the growth of these cells (Figure 
5.13), suggesting that this isoform does not compete for DNA-binding with the CSL-WT 
isoform in a dominant-negative fashion. Nor did CSL-TREX appear to have Notch-
independent constitutive activity at promoter sites because CSL-TREX alone did not 
significantly activate a CSL-luciferase reporter construct in U2OS cells (Figure 5.12). 
The most striking phenotype seen in a functional assay was the marked inhibition of the 
size and number of CFUs in in vitro culture after transduction of purified CD34+ cells 
with CSL-WT, which was not seen in cells transduced with CSL-TREX (Figure 5.14). 
One possible interpretation of these findings is that CSL-WT has an inhibitory effect on 
the proliferation of haematopoietic progenitors, and therefore the high levels of CSL-
TREX observed in AML occur as a consequence of positive selection and outgrowth of 
cells bearing the highest levels of CSL-TREX. Thus, taken together, the data supports 
CSL-TREX as a loss-of-function isoform in regards to Notch signalling. Further studies 
are required to address whether AML patients with higher levels of CSL-TREX have 
lower levels of downstream Notch targets, such as HES-1 and DELTEX.   
 
There is an emerging role for a tumour suppressor function for the Notch pathway in 
myeloid malignancy. Not only does inactivation of Notch signalling in the 
haematopoietic compartment of mice lead to a CMML-like disease (Klinakis et al, 
2011), but exon sequencing has also identified loss-of-function mutations in 12% of 
patients with CMML in a variety of components of the Notch pathway (NCSTN, APH1, 
MAML1 and NOTCH2) in 12% of patients with CMML (Klinakis et al, 2011). Whether 
such mutations also exist in AML has not yet been reported. However, activation of 
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Notch signalling using a Jagged-1 peptide has been shown to induce apoptosis in AML 
cell lines, suggesting that Notch signalling may also have a tumour suppressor role in 
AML (Sutphin et al, 2006). 
 
The association between high levels of CSL-TREX and improved prognosis was 
independent of FLT3-ITD and NPM1 mutation status, and suggests that this isoform has 
clinico-biological relevance. Whether this association is direct (for instance, the 
chemosensitivity of AML blasts is influenced by presence of the CSL-TREX isoform 
itself) or indirect (for instance, presence of CSL-TREX reflects disordered AS on a wider 
scale, and it is this that influences chemosensitivity) remains to be determined. In support 
of the former hypothesis, AML blasts cultured on bone marrow stroma cells that express 
high levels of Jagged-1 and -2 exhibit marked chemoresistance in vitro (Nefedova et al, 
2008), and a recent study demonstrated that AML patients with high mRNA expression 
of NOTCH-1, JAGGED-1 and DELTA-1 have a poorer prognosis (Xu et al, 2011). Thus 
it is possible that the activation of the Notch pathway that occurs through stromal 
interaction or cell-to-cell contact is abrogated in AML blasts that express a high 
proportion of CSL-TREX, which leads to lower levels of chemoresistance and is 
reflected in an improved prognosis.  
 
Since completion of this work, mutations in the spliceosome machinery have been 
described as frequent somatic events in myelodysplastic syndromes (MDS). Thus far the 
genes affected are: 
1. U2AF1. Mutations in exons 2 and 6 affect the two zinc finger domains of this 
protein, with the two most frequent mutations being S34F and Q157P (Graubert 
et al, 2012; Makishima et al, 2012). These have been found in 8-10% of patients 
with MDS, and are associated with a poor prognosis (Graubert et al, 2012; 
Makishima et al, 2012).  
2. SF3B1. These mutations are most commonly found in exons 14 or 15, with the 
K700E mutation being the most recurrent (Makishima et al, 2012; Papaemmanuil 
et al, 2011). They have been detected in approximately 20% of MDS patients and 
at highest incidence (65%) in MDS-RARS (MDS refractory anaemia with ringed 
sideroblasts), a subtype of MDS with the best prognosis. In AML they occur in 
5% or fewer of patients, and are typically found in patients who have transformed 
from MDS.   
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3. SRSF2. Almost all mutations are found at position P95 (in order of frequency: 
P95H, P95L, P95R). They are not associated with a particular MDS subgroup and 
are not associated with prognostic outcome. They are also found in CMML.  
4. Rare mutations affecting <2% of MDS patients have also been found in other 
genes that are involved in splicing including PRPF8, LUC7L2, ZRSR2, HCFC1, 
SAP130, SRSF6, SON and U2AF26.  
 
The functional consequences of mutations in the spliceosome machinery await to be 
determined. Although SF3B1 mutations are associated with downregulation of genes 
associated with mitochondrial electron transport, specific splicing defects in this pathway 
have not been identified (Papaemmanuil et al, 2011). RNA-Seq data suggests that 
mutations in SF3B1, U2AF and SRSF2 are not associated with widespread AS, but rather 
alter splicing at specific genes. For instance, U2AF1 mutations result in retention of 
intron 5 of the TET2 gene and intron 6 of the RUNX1 gene (Makishima et al, 2012).  
 
What is the mechanism of AS in AML, considering mutations affecting the spliceosome 
machinery are relatively rare in this disease? One possibility is that mutations affecting 
one or more of the splicing regulators exist but have yet to be discovered. Since 
chromatin and histone modifications have been shown to regulate AS (Luco et al, 2010), 
and a recent study has linked exonic methylation with increases in AS (Flores et al, 
2012), a second hypothesis is that the presence of AS occurs secondary to widespread 
alterations of the methylation marks and histone/chromatin state that occurs in AML 
(Ameyar-Zazoua et al, 2012). Analysis of the methylation status of the CpG dinucleotide 
in exon 10 or nearby introns of CSL therefore warrants further study.  
 
It is possible that transcripts generated through AS have neomorphic functions (i.e. a 
novel function outside of their canonical signalling pathway); determining whether CSL-
TREX has functional consequences outside of the Notch pathway would therefore be of 
interest. Future studies could address whether CSL-TREX has novel protein binding 
partners, for instance, by pull-down mass spectrometry, or altered transcriptional 
activity, for instance, by chromatin immunoprecipitation coupled to massively parallel 
DNA sequencing, as compared to the CSL-WT form. 
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In conclusion, a novel alternatively spliced isoform of CSL occurring through a cryptic 
donor splice site within exon 10 was identified that is the predominant isoform in many 
patients with AML at both the mRNA and protein level. CSL-TREX has clinico-
biological relevance given that it has prognostic significance in AML. Biochemical and 
in vitro studies all support CSL-TREX as a loss-of-function variant as regards Notch 
signalling, although a neomorphic function relevant to AML cannot be excluded. The 
presence of CSL-TREX in normal CD34+ cells, together with the negative impact on the 
clonogenic potential observed with in vitro overexpression of CSL-WT, support a model 
in which CSL dosage is controlled through alternative splicing, and the high CSL-TREX 
levels observed in AML occur as a result of selection against the CSL-WT isoform or 
proliferative outgrowth of high CSL-TREX expressing cells. While somatic mutations in 
the splicing machinery are frequent in MDS, these mutations are uncommon in de novo 
AML (Hahn & Scott, 2012) and so are unlikely to account for the high prevalence of 
CSL-TREX identified here. Predominance of the CSL-TREX variant isoform in AML 
patients together with its inability to support canonical Notch signalling support a tumour 
suppressor function for the Notch pathway in AML, although further experiments are 
clearly required to determine this definitively.  
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CHAPTER 6. CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
This thesis set out to investigate the role of the Notch signalling pathway in acute 
leukaemia, focusing initially on the incidence, characteristics, and prognostic 
significance of activating mutations of NOTCH-1 in adult T-ALL. Whether NOTCH-1 
mutations occur as primary initiating events or as late secondary events was studied by 
analysing mutation level, together with NOTCH-1 mutation status in paired presentation-
relapse samples. Finally, the functional and clinical significance of a novel isoform of 
CSL was investigated in AML.  
 
6.1 NOTCH-1 and FBXW7 mutations, and their prognostic implications 
There has been a steady improvement in the outcome of paediatric ALL over the past 
forty years, so what was once a terminal disease treated only with palliation is now 
curable in over 85% of cases (Pui & Evans, 1998, 2006). However, the outcome of adult 
ALL is still poor, with only 35-50% of adult patients achieving long-term remission 
(Goldstone et al, 2008; Hann et al, 2000; Larson, 2005). In B-ALL, this disparity in 
outcome can be partly explained by differences in the frequency of cytogenetic 
abnormalities that occur with age. For instance, Philadelphia-positive (Ph+) ALL, which 
is associated with poor outcome, occurs in only 2-3% of children, but 20-30% of adults 
(Jones & Saha, 2005; Moorman et al, 2007). The introduction of tyrosine kinase 
inhibitors for Ph+ ALL appears to be making significant improvements in outcome 
(Fielding, 2010), serving as a useful example that targeting high–risk molecular lesions 
has the potential to reduce the disparity in survival associated with age. In T-ALL, 
however, differences in the frequency of cytogenetic or molecular abnormalities between 
age groups that could explain the divergence in prognosis have not been clearly 
identified. Thus, after the description of activating mutations in NOTCH-1 in paediatric 
T-ALL (Weng et al, 2004), it was important to assess the frequency and characteristics 
of NOTCH-1 mutations in adult patients. In the cohort of 60 adult patients analysed in 
the studies presented in this thesis, 38 patients (63%) had at least one NOTCH-1 
mutation, (Chapter 3), which was very similar to the incidence of NOTCH-1 mutations 
(56%) reported in paediatric T-ALL. Furthermore, the characteristics of the NOTCH-1 
mutations themselves were comparable between adult and paediatric patients, with 
similar frequencies of point mutations and insertions and/or deletions in the HD-N, HD-
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C, TAD and PEST domains. Nor was there a difference in the incidence of FBXW7 
mutations in the adult cohort, with 11 of 60 patients (18%) affected, compared to 14-
18% of paediatric T-ALL	  (Jenkinson et al, 2012; Kox et al, 2010; Park et al, 2009; 
Zuurbier et al, 2010). These results indicate that the difference in curability between the 
two groups is not related to a differing frequency or characteristics of NOTCH-1/FBXW7 
mutations. 
 
This majority of paediatric studies have shown improved outcome associated with 
NOTCH-1 and/or FBXW7 mutations (Table 3.9). To directly assess whether this is the 
case in adult patients, the outcome of a combined cohort of 88 patients treated on the 
ECOG2993/UKALLXII trials was analysed. The 5 year EFS was 51% vs. 27% (P=.10) 
in NOTCH-1 and/or FBXW7 mutant-positive and WT patients respectively (Figure 3.6). 
The trend towards improved EFS in patients with a Notch pathway mutation on this trial 
was not of sufficient magnitude to warrant the recommendation of treatment reduction 
(for instance, avoidance of allogeneic transplant in first CR), as had been suggested by 
other groups (Asnafi et al, 2009).  
 
An important issue, therefore, is whether there is a subgroup of T-ALL patients where a 
Notch pathway mutation could inform clinical decision-making. In adult patients, based 
on current data, the answer would appear to be no. Although NOTCH-1/FBXW7 
mutation status was an independent prognostic factor on the adult French LALA-94 and 
GRAALL-2003 trials (median EFS of 36 vs. 17 months, P = .01, in patients with 
NOTCH1 and/or FBXW7 mutations versus WT patients) (Asnafi et al, 2009), reducing 
treatment intensity for the mutant-positive group has to balanced against the extremely 
poor salvage rates of adult ALL at relapse (7% are long-term survivors after relapse). In 
paediatric patients, recent data from the UKALL2003 trial has shown a 100% OS for 
patients with double mutations (defined as either HD plus PEST mutations of NOTCH-1 
or both NOTCH-1 and FBXW7 mutations) (Jenkinson et al, 2012). Because 84% of the 
double mutation subgroup was considered high-risk (by virtue of slow early treatment 
response and/or MRD positivity), yet all survived, a possible question on future studies is 
whether this group truly requires treatment intensification. However, large numbers of 
patients will be required to test this definitively.  
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Due to its rarity, T-ALL does not have the luxury of large patient cohorts to sufficiently 
power studies to detect small effects on prognosis. A recent meta-analysis of published 
data from six paediatric (n=711) and three adult trials (n=253), which included the data 
presented in Chapter 3, failed to show a prognostic significance for NOTCH-1 mutations 
in either age group (Ma & Wu, 2012). It should be noted that FBXW7 mutation status 
and other possible confounders, such as rates of transplantation, were not included in this 
analysis. Whether the differences in prognostic impact of NOTCH-1 mutation status 
observed between studies relates to differences in therapy or protocol design await to be 
determined.  
 
There are a number of variables that need to be addressed in future studies. Firstly, no 
study has yet addressed the prognostic implication of NOTCH-1/FBXW7 mutation status 
taking into account ETP disease. As discussed in Chapter 1, such patients fare 
particularly poorly and have a relatively low incidence of NOTCH-1 (19%) and FBXW7 
mutations (6%) (Zhang et al, 2012). This means that in prognostic studies a higher 
proportion of patients with ETP will be represented in the WT group compared to the 
NOTCH-1/FBXW7 mutated group, which could confound the outcome data, particularly 
in paediatric studies where the number of relapse events or induction failures is low. 
Secondly, activating mutations in JAK1 have recently been identified in 21% of adult 
patients with T-ALL and are also associated with very poor outcome (Flex et al, 2008). 
All the JAK1 mutated patients had NOTCH-1 mutations, suggesting that there may be a 
group of NOTCH-1 mutant JAK1 WT patients that actually fare particularly well. 
Interestingly, JAK1 mutations were found in only 1% of paediatric patients in this study, 
which raises the possibility that they may account for the difference in outcome seen 
between adult and paediatric disease generally, and perhaps explain the lack of 
association of NOTCH-1 mutation status and outcome seen on some adult trials, 
including the data presented here, suggesting that JAK1 mutation status may be an 
important prognostic variable that should be considered in future adult studies.  
 
Whether the Notch pathway is activated by alternative mechanisms in those T-ALL 
patients without NOTCH-1 or FBXW7 mutations, would be an interesting area for future 
study. Only a weak correlation between NOTCH-1/FBXW7 mutation status and 
activation of the downstream target gene HES-1 was found by qPCR, with many WT 
patients having significantly higher HES-1 transcript levels than mutant-positive patients 
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(Larson Gedman et al, 2009). Other possible mechanisms of activation include 
overexpression of one or more Notch ligands, inactivation of other negative regulators of 
the Notch pathway such as Numb, as has been reported in lung cancer (Westhoff et al, 
2009), alternative mutational hotspots in NOTCH-1, or mutational activation of other 
NOTCH family members. With regards to the latter possibility, ICN-3 is able to initiate 
T-ALL in mice and NOTCH-3 is overexpressed in human T-ALL (Bellavia et al, 2000; 
Bellavia et al, 2002), and therefore NOTCH-3 was thought to be a good candidate for 
mutational screening. However, analysis of the HD, TAD and PEST domains of 
NOTCH-3 in 38 adult T-ALL patients did not identify the presence of activating 
mutations (Chapter 3). A novel mutation of the NOTCH-1 LNR domain (H1545P) was 
identified in a T-ALL patient who had a co-existing PEST domain mutation (Chapter 3), 
which was subsequently shown to be activating in functional studies performed by Jon 
Aster’s group (Gordon et al, 2009). Mutations in this domain do not appear to be 
recurrent in other T-ALL cohorts that have since been analysed, although another LNR 
domain mutation (C1528R) was recently identified in a paediatric patient (Jenkinson et 
al, 2012). 
 
Mutational analysis of samples from 157 AML and 30 infant leukaemia patients failed to 
identify somatic NOTCH-1 or FBXW7 mutations (Chapter 3). This indicates that Notch 
pathway activation through somatically acquired mutations is not responsible for the 
high incidence of aberrant expression of T-cell markers in these two groups of patients, 
but it does not exclude the possibility that Notch pathway activation by an alternative 
mechanism, such as through ligand activation, plays a role in these aberrant 
immunophenotypes.  
 
 
6.2 NOTCH-1 mutations as secondary events in T-ALL 
In murine models of T-ALL, aberrant Notch activation can directly induce leukaemia or 
collaborate as a secondary event on other transgenic backgrounds (Lin et al, 2006; 
O'Neil et al, 2006; Pear et al, 1996; van den Brandt et al, 2006). Three lines of evidence, 
as presented in Chapter 4, support a model in which NOTCH-1 mutations can occur as 
late secondary events in human T-ALL: 
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1. The NOTCH-1 mutation level was <10% in nearly 20% of patients tested, 
suggesting that they often occurred in subclones. 
 
2. Several patients with paired presentation-relapse samples showed a change in 
NOTCH-1 mutation status at relapse, despite relapsing with a clone with the 
same TCR rearrangement. 
 
 
3. A SCID-X1 patient who developed T-ALL after gene therapy due to viral 
integration and activation of LMO2, had acquired a NOTCH-1 mutation by 
the time of overt disease. 
 
The results of the studies of NOTCH-1 mutations in T-ALL presented in Chapter 4 are 
consistent with the highly heterogeneous and complex clonal architecture of ALL that 
has since been described by others (Anderson et al, 2011; Mullighan et al, 2008). This 
data has two clinical implications. Firstly, given the lack of mutation stability at relapse, 
it limits the utility of using NOTCH-1 mutations as markers for MRD analysis. Secondly, 
it has potential implications for the use of Notch pathway inhibitors that are currently in 
clinical trials as they may only target NOTCH-1 mutant subclones and give a selection 
advantage to the remaining leukaemic NOTCH-1 WT cells.  
 
6.3 Notch pathway inhibitors for the treatment of T-ALL 
Because HD and PEST-mutated NOTCH-1 receptors are still dependent on cleavage by 
the γ-secretase complex for activation, there is the potential to use GSIs to inhibit the 
Notch pathway in T-ALL. There has been long-standing interest from large 
pharmaceutical companies in the development of GSIs for the treatment of Alzheimer’s 
disease, because amyloid precursor protein (APP) is cleaved to β-amyloid peptide (the 
major constituent of amyloid plaques responsible for disease) by a γ-secretase-dependent 
complex (Miyazaki et al, 1993). A Phase II study using an orally available GSI was 
already underway for Alzheimer’s disease by the time NOTCH-1 mutations were 
discovered in T-ALL (Barten et al, 2006). A phase II trial of the Merck compound MK-
0752 was rapidly expedited at Dana-Farber Cancer Institute (DFCI 04-390 trial), and 
recruited eight patients that included seven patients with T-ALL and one patient with 
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AML (Deangelo, 2006). Although the first T-ALL patient to receive this drug had a 
transient response, there were no other responders. It should be noted that only four 
patients actually had a NOTCH-1 mutation (one of which was the responder), and there 
were no studies performed to show efficacy of on-target effect such as a reduction in 
downstream Notch signalling or decreased ICN-1 protein in blast cells. There was also 
significant dose-limiting toxicity in the form of either grade III/IV diarrhoea and/or 
extreme fatigue, and the drug had to be discontinued in the majority of patients. 
Nonetheless, there are currently over ten ongoing trials assessing the safety and efficacy 
of GSIs in phase II trials, mostly of the drug RO4929097, recruiting patients with a wide 
range of tumours including osteosarcoma, melanoma, lymphoma, T-ALL, as well as 
breast, lung, and pancreatic cancer (www.clinicaltrials.gov).  
 
There are a number of possible molecular reasons for the lack of efficacy of GSIs in T-
ALL. The presence of PTEN deletions, present in 10-20% of T-ALL cases, has been 
associated with GSI-resistance, due to upregulation of the PI3K pathway (Palomero et al, 
2007). FBXW7 mutations have also been shown to cause resistance to GSI treatment 
through their impact on the oncogene c-MYC (O'Neil et al, 2007). T-ALL cells are 
dependent on c-MYC, which is transcriptionally activated by ICN and then targeted for 
degradation by FBXW7. Notch inhibition by GSIs results in a reduction in c-MYC, 
except in the presence of an inactivating FBXW7 mutation, where c-MYC is stabilised at 
the protein level as a consequence of the loss of FBXW7 function.  
 
Unfortunately, there is clear evidence that the gastro-intestinal toxicity of GSIs is an on-
target rather than off-target effect of Notch inhibition, so developing increasingly potent 
drugs to achieve efficacy is unlikely to be a fruitful approach. Notch signalling regulates 
the cell fate of intestinal progenitor cells, such that active Notch signalling leads to 
differentiation towards the enterocyte lineage, whilst low Notch signals favours a goblet 
cell fate (Stanger et al, 2005). Prolonged treatment with GSIs increases goblet cell 
numbers (i.e. the mucous secreting cells) and disrupts villous architecture, leading to 
severe diarrhoea (van Es et al, 2005). Thus, although the DFCI 04-390 trial did not show 
evidence for Notch pathway inhibition in leukaemia cells, the development of diarrhoea 
in most patients suggests that adequate on-target effect was achieved, at least in the gut, 
which, together with the lack of clinical responses, has tempered excitement about the 
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future of such drugs. However, there has been recent development of three major 
strategies for overcoming gut toxicity in vivo:  
 
1. Steroids - when steroids are used in combination with GSIs in mouse models, 
there is almost complete abrogation of GSI-induced gut toxicity (Real et al, 
2009). Furthermore, GSIs have efficacy in overcoming steroid-resistance in T-
ALL, and current trials of GSIs in T-ALL include the addition of dexamethasone 
(NCT01088763; www.clinicaltrials.gov). 
 
2. Dosing schedules - use of short drug-holidays (for instance, a three-day-on, four-
day-off schedule) avoids gut toxicity but retains efficacy in murine xenograft 
models of T-ALL (Tammam et al, 2009), and such dosing schedules have been 
used safely in phase I trials (Tolcher et al, 2012). 
 
 
3. Specific targeting of NOTCH-1 – GSIs inhibit activation of all four NOTCH 
family members, and gut toxicity occurs when both NOTCH-1 and -2 are 
inhibited concurrently, but not if they are inhibited individually (Riccio et al, 
2008; Wu et al, 2010).  Thus specific targeting of NOTCH-1 has the potential of 
targeting leukaemic cells without affecting gut homeostasis. A synthetic 
stabilised alpha-helical peptide (known as SAHM1) that acts to inhibit the 
interaction of MAML-1 with ICN-1 has shown efficacy in vivo in murine T-ALL 
xenograft models without causing gut toxicity (Moellering et al, 2009). 
Monoclonal antibodies that bind to and stabilise the LNR domain, and thereby 
inhibit activation of specific NOTCH receptors, have also shown promise in pre-
clinical models of T-ALL without producing gastro-intestinal side effects (Wu et 
al, 2010). 
 
NOTCH-1 has a tumour suppressor role in several cellular contexts. Mice chronically 
treated with GSIs are highly prone to skin malignancies (Nicolas et al, 2003) and, given 
a potential tumour suppressor role for the Notch pathway in the liver, lung and myeloid 
compartment, prolonged use of Notch pathway inhibitors must be approached with some 
caution. However, this is likely to be more relevant to long-term chronic use of such 
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drugs, for instance in Alzheimer’s disease, rather than short-term intermittent use for T-
ALL. 
 
6.4 Alternative splicing of CSL in AML 
As discussed in Chapter 5, the issue of whether Notch acts as an oncogene or tumour 
suppressor in AML remains contentious. Inactivation of Notch-1 and -2 in the 
haematopoietic compartment of mice leads to a myeloproliferative disease, and 
activation of Notch signalling using a Jagged-1 peptide has been shown to induce 
apoptosis in AML cell lines (Klinakis et al, 2011; Sutphin et al, 2007). Two very recent 
papers support a tumour suppressor function for Notch signalling in AML. The first 
identified low levels of HES-1 in AML samples, despite high expression of NOTCH-1 
and -2, and showed that activation of the Notch pathway through expression of ICN-1, 
ICN-2, HES-1 or with a DLL1 peptide, induced apoptosis in AML cells in vitro and in 
vivo (Kannan et al, 2013).  The second paper recapitulated many of these findings, and 
also showed that overexpression of ICN-1 in an MLL-AF9 murine model of AML 
significantly delayed tumour onset (Lobry et al, 2013). Furthermore, mice with 
homozygous compound deletion of Tet2 and Ncstn, leads to a fully penetrant 
transplantable AML-like disease. 
 
The data presented in Chapter 5 is consistent with expression of a loss-of-function 
isoform of CSL in AML patients, in the majority of cases as the major isoform. CSL-
TREX was unable to bind NOTCH-1 and did not have dominant-negative activity in 
reporter or biological assays. However, expression of CSL-WT in CD34+ cells 
profoundly inhibited in vitro cell growth, while expression of CSL-TREX did not, 
suggesting that splicing to CSL-TREX may be a means of regulating or fine-tuning 
Notch signalling. Further studies are required to demonstrate that this is a NOTCH-
dependent mechanism. Whether expression of CSL-TREX functionally impacts on 
downstream signalling in AML, which could be assessed by analysis of HES-1 and other 
downstream targets by qRT-PCR, is also worthy of further study. 
 
Since moving to the Dana-Farber Cancer Institute, in the laboratory of Dr Tom Look, I 
have been able to continue some functional studies into CSL-TREX. With assistance from 
Dr Evisa Gjini, I have used a zebrafish model to examine whether CSL-TREX can rescue 
the phenotype of CSL-WT depletion. Notch signaling and csl expression are required for 
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normal vessel formation during early embryonic development (Siekmann & Lawson, 
2007), therefore early embryogenesis offers an effective means to test CSL-TREX in 
vivo. Depletion of endogenous csl through morpholino injection at the single-cell stage 
of zebrafish embryogenesis causes a marked vessel defect, with characteristic alterations 
consisting of increased tortuosity and abnormal sprouting of the inter-segmental vessels 
(ISVs), and disrupted formation of the dorsal longitudinal anastomotic vessels (DLAV) 
(Siekmann and Lawson, 2007). Conversely, notch activation causes a global suppression 
of angiogenesis (Siekmann and Lawson, 2007). These features can be clearly visualised 
in the Tg(fli:EGFP) reporter zebrafish model and, given the high degree of conservation 
of the Notch pathway between humans and zebrafish, make it an ideal model in which to 
test CSL variants (Lawson & Weinstein, 2002; Siekmann & Lawson, 2007). No vessel 
defects were observed when CSL-WT or CSL-TREX cRNA were injected into Tg(fli-
EGFP) embryos, showing that they do not have gain-of-function or dominant-negative 
activity (Figure 6.1 A, B and C). Use of the anti-csl morpholino, that specifically targets 
endogenous but not human CSL, resulted in characteristic vessel defects in an average of 
76% of embryos injected, with increased tortuosity and abnormal sprouting of the ISVs 
and disrupted formation of the DLAV (Figure 6.1 D and H). Co-injection of human CSL-
WT cRNA with the morpholino rescued the vessel phenotype in approximately half of 
the embryos (Figure 6.1 E and H; mean 38% of embryos with the phenotype, P=0.005 
versus morpholino alone), whereas co-expression of CSL-TREX cRNA did not abrogate 
the effect of the morpholino (Figure 6.1 F and H; mean 69% of embryos with the 
phenotype, P=0.26 versus morpholino alone). These results indicate that CSL-TREX does 
not have dominant-negative activity and cannot compensate for the loss of endogenous 
csl, which strongly supports CSL-TREX as a loss-of-function variant. 
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Figure 6.1  Knockdown of endogenous zebrafish csl induces a severe vessel deformity that can be rescued by human wild-type 
CSL cRNA but not CSL-TREX. (A-F) Transgenic fli1-EGFP embryos at 2 days post-fertilization (2dpf) visualised by fluorescent microscopy 
showing the dorsal aorta (DA), posterior cardinal vein (PCV), inter-segmental vessels (ISV) and dorsal longitudinal anastomotic vessels (DLAV). 
(A) Non-injected embryos. (B) Embryos injected with human CSL-WT cRNA. (C) Embryos injected with CSL-TREX cRNA. (D) Embryos 
injected with anti-csl morpholino (MO) that targets endogenous but not human CSL. Vessel deformities are indicated with red arrowheads. (E) 
Embryos injected with anti-csl morpholino and CSL-WT cRNA. (F) Embryos injected with anti-csl  morpholino and CSL-TREX cRNA. (G) Light 
microscopy of a zebrafish embryo at 2dpf. (H) The percentage of injected embryos displaying the normal (blue) or csl loss-of-function vessel 
phenotype (red). Error bars represent standard error of the mean for 3 independent experiments, with the total embryo count given above the bars.  
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6.5 CONCLUSION 
The Notch pathway plays a well-defined role in early definitive haematopoiesis and 
during lineage commitment of early haematopoietic cells. Activation of Notch signalling 
occurs in the majority of cases of T-ALL, and has more recently been implicated in other 
haematological malignancies including mantle cell lymphoma and CLL (Kridel et al, 
2012; Puente et al, 2011).  Notch also plays a tumour suppressor role in other 
malignancies, such as squamous cell carcinomas, and myeloid malignancies, including 
CMML and AML, highlighting the importance of cell context to the outcome of Notch 
pathway dysregulation. 
 
A summary of the major findings in this thesis are listed below: 
 
• NOTCH-1 mutations are frequent in adult T-ALL, affecting over 50% of patients 
• The characteristics and frequency of NOTCH-1 mutations are similar in adult and 
paediatric T-ALL, and thus do not explain the difference in prognosis between 
these two groups of patients 
• NOTCH-1 and FBXW7 mutation status are associated with a trend towards 
improved outcome in adult T-ALL, but not of significant magnitude to inform 
clinical decision-making 
• NOTCH-1 mutations are not a common feature of infant leukaemia or adult 
AML, and so do not account for the aberrant expression of T-cell markers 
frequently seen in these diseases 
• A novel activating mutation of the LNR domain of NOTCH-1 was identified in a 
single T-ALL patient 
• No mutations were identified in NOTCH-3 in T-ALL 
• NOTCH-1 mutations occur as late secondary events in a significant proportion of 
patients, often occurring in minor leukaemic subclones  
• NOTCH-1 mutations often show instability between presentation and relapse, 
suggesting they are not always the primary initiating event. This has potential 
implications for Notch targeted therapy, as well as the application of NOTCH-1 
mutations as markers for MRD analysis. 
• In the majority of patients with AML, CSL is aberrantly spliced to an isoform 
lacking the last 78bp of exon 10 (termed CSL-TREX), which encodes a bridge-
strand of the BTD, that is likely to result in loss of functional integrity 
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• The CSL-TREX isoform is also present at moderate levels in normal CD34+ cells, 
but not in differentiated T-cells, neutrophils or other normal tissues 
• CSL-TREX levels decrease on differentiation of AML blasts in vitro 
• CSL-TREX does not have dominant-negative activity  
• Wild-type CSL markedly inhibits the clonogenic potential of CD34+ cells 
• Together, this suggests splicing to CSL-TREX may be a means of fine-tuning 
CSL levels in haematopoietic cells, and supports a tumour suppressor function 
for the Notch pathway in AML. 
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APPENDIX TABLE 1 NOTCH-1/FBXW7 mutational status of adult T-ALL patients treated on ECOG2993 (data from of A. Ferrando)  
Case# UKALLXII/ 
ECOG  
TRIAL NO. 
NOTCH-1 
mutation  
status 
FBXW7 
mutation 
status 
NOTCH-1 
Mutation (nucleotide) 
NOTCH-1 
Mutation (amino acid) 
FBXW7 
Mutation 
(nucleotide) 
FBXW7 
Mutation (amino 
acid) 
E1 ECOG13032 WT WT     
E2 ECOG15451 HD-N MUT WT 4799T>A  L1601Q   
E3 ECOG18654 TAD MUT  WT 7004-7005insGAGCACACAGGCCCCCT  fs@2336, STOP@2364   
E4 ECOG12535 HD-N MUT WT 4778insACCATAACC  L1594H+insHNL   
E5 ECOG10726 HD-C MUT WT 5045A>T N1683I   
E6 ECOG12107 WT WT     
E7 ECOG18774 WT WT     
E8 ECOG13205 HD-N MUT WT 4776insGGGCTC  F1573L+insGS   
E9 ECOG10614 WT MUT   1436G>A R479Q 
E10 ECOG18296 WT WT     
E11 ECOG16185 HD-N MUT WT 4747-4748insCCG  1583-1584insP   
E12 ECOG12894 HD-N MUT MUT 4793G>C  R1599P 1513C>T R505C 
E13 ECOG18849 HD-N MUT WT 4721T>C  L1575P   
E14 ECOG18250 WT WT     
E15 ECOG15445 HD-N MUT WT 4823G>A  R1609Q   
E16 ECOG11496 HD-N MUT WT T4775T>C F1593S   
E17 ECOG10496 WT WT     
E18 ECOG11006 WT WT     
E19 ECOG12004 WT MUT   1436G>A R479Q 
E20 ECOG12874 HD-N MUT WT 4747-4748insCCTTCT  1583-1584insPS   
E21 ECOG13684 HD-N MUT MUT 4741-4742delC+insAGGGAAGAGAGGGCCA 1581-1582insREERA+P1582T 1513C>T R505C 
E22 ECOG13964 HD-N+ 
PEST MUT 
WT 4757G>C 
7021delTinsCC 
R1587P 
fs@2342, stop@2354 
  
E23 ECOG14383 HD-N MUT WT 4818delCinsACTTAATCCG  F1607L+1607-1608insLNP   
E24 ECOG17534 PEST MUT WT 7367insGT fs@2457, STOP@2478   
E25 ECOG8222 PEST MUT WT G7387T A2465T   
E26 ECOG10766 HD-N MUT WT 4813-4delGTinsCTCCCCCCTCCGGC  V1606L+insPPPA   
E27 ECOG11769 PEST MUT WT 7541-7542delCT fs@2515, STOP at 2518   
E28 ECOG12290 JME MUT WT 5303-5371 duplication 69 bases  23 aa tandem duplication 1769-1792   
E29 ECOG10438 WT WT     
E30 ECOG12487 WT MUT   1394G>A R465H 
E31 ECOG15522 HD-N MUT WT 4774-4775insGAG  1592-1593insE   
E32 ECOG13564 WT MUT   1513C>T R505C 
E33 ECOG16911 HD-N MUT WT 4754T>C  L1586P   
E34 ECOG11593 WT WT     
E# local patient  case number, WCC white cell count, MUT mutant, WT wild type, ins insertion, del deletion, SNP single nucleotide polymorphism, HD-N N-terminal 
heterodimerisation domain, HD-C C-terminal heterodimerisation domain, JME juxtamembrane expansion mutation, fs frameshift, X stop codon 
